STOCK PURCHASE AGREEMENT by and among PDF SOLUTIONS, INC., THE SELLING STOCKHOLDERS OF SI AUTOMATION S.A. and SOCIÉTÉ GÉNÉRALE ASSET MANAGEMENT ALTERNATIVE INVESTMENTS, as the Stockholders’ Representative October 25, 2006
Exhibit 2.01
by and among
PDF SOLUTIONS, INC.,
THE SELLING STOCKHOLDERS OF
SI AUTOMATION S.A.
SI AUTOMATION S.A.
and
SOCIÉTÉ GÉNÉRALE ASSET MANAGEMENT
ALTERNATIVE INVESTMENTS, as
the Stockholders’ Representative
ALTERNATIVE INVESTMENTS, as
the Stockholders’ Representative
October 25, 2006
TABLE OF CONTENTS
Page | ||||||||||
SECTION ONE | ||||||||||
1. | The Purchase | 1 | ||||||||
1.1 | Purchase and Sale of the Shares | 1 | ||||||||
1.2 | Purchase Price | 2 | ||||||||
1.3 | Purchase Price Adjustment | 2 | ||||||||
1.4 | Closing | 5 | ||||||||
1.5 | Actions at the Closing | 5 | ||||||||
1.6 | Payment | 6 | ||||||||
1.7 | Purchase Price True Up | 9 | ||||||||
1.8 | Purchase of Common Stock; Net Exercise of Warrants | 11 | ||||||||
1.9 | Securities Act Exemption | 12 | ||||||||
1.10 | Stock Restrictions | 12 | ||||||||
1.11 | Withholding | 12 | ||||||||
SECTION TWO | ||||||||||
2. | Representations and Warranties Relating to the Company | 12 | ||||||||
2.1 | Organization; Subsidiaries; Officers, Directors, Members of the Management Board and Members of the Supervisory Board | 13 | ||||||||
2.2 | Applicable Organizational Documents | 14 | ||||||||
2.3 | Capital Structure | 14 | ||||||||
2.4 | Authority | 15 | ||||||||
2.5 | No Conflicts; Required Filings and Consents | 15 | ||||||||
2.6 | Financial Statements | 16 | ||||||||
2.7 | Absence of Undisclosed Liabilities | 16 | ||||||||
2.8 | Absence of Certain Changes | 16 | ||||||||
2.9 | Litigation | 18 | ||||||||
2.10 | Restrictions on Business Activities | 19 | ||||||||
2.11 | Permits; Company Products; Regulation | 19 | ||||||||
2.12 | Title to Property | 20 | ||||||||
2.13 | Intellectual Property | 21 | ||||||||
2.14 | Environmental Matters | 24 |
-i-
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||||||||
2.15 | Taxes | 25 | ||||||||
2.16 | Employee Benefit Plans | 28 | ||||||||
2.17 | Certain Agreements Affected by the Purchase | 29 | ||||||||
2.18 | Employee Matters | 29 | ||||||||
2.19 | Material Contracts | 31 | ||||||||
2.20 | Interested Party Transactions | 33 | ||||||||
2.21 | Insurance | 34 | ||||||||
2.22 | Compliance With Laws | 34 | ||||||||
2.23 | Minute Books | 34 | ||||||||
2.24 | Complete Copies of Materials | 34 | ||||||||
2.25 | Brokers’ and Finders’ Fees | 34 | ||||||||
2.26 | Inventory | 34 | ||||||||
2.27 | Accounts Receivable | 35 | ||||||||
2.28 | Customers and Suppliers | 35 | ||||||||
2.29 | No Commitments Regarding Future Products | 36 | ||||||||
2.30 | Forecasts | 36 | ||||||||
2.31 | Representations Complete | 36 | ||||||||
2.32 | No Other Representations and Warranties Relating to the Company | 36 | ||||||||
2.33 | Fraud and Intentional Misrepresentation | 36 | ||||||||
SECTION THREE | ||||||||||
3. | Representations and Warranties of Selling Stockholders | 37 | ||||||||
3.1 | Power, Authorization and Validity | 37 | ||||||||
3.2 | Title to Stock | 37 | ||||||||
3.3 | No Violation | 37 | ||||||||
3.4 | Acknowledgment | 38 | ||||||||
3.5 | Investment Representations | 38 | ||||||||
SECTION FOUR | ||||||||||
4. | Representations and Warranties of Acquiror | 39 | ||||||||
4.1 | Organization, Standing and Power | 39 | ||||||||
4.2 | Capital Structure | 40 |
-ii-
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||||||||
4.3 | Authority | 40 | ||||||||
4.4 | No Conflict; Required Filings and Consents | 40 | ||||||||
4.5 | SEC Documents | 41 | ||||||||
4.6 | Brokers’ and Finders’ Fees | 41 | ||||||||
4.7 | Financial Statements | 41 | ||||||||
4.8 | Internal Controls | 41 | ||||||||
4.9 | Changes | 42 | ||||||||
4.10 | Registration Rights | 42 | ||||||||
4.11 | Registration of Common Stock | 42 | ||||||||
SECTION FIVE | ||||||||||
5. | Conduct Prior to the Closing | 43 | ||||||||
5.1 | Conduct of Business of Company | 43 | ||||||||
5.2 | No Shop | 45 | ||||||||
SECTION SIX | ||||||||||
6. | Additional Agreements | 47 | ||||||||
6.1 | Commercially Reasonable Efforts and Further Assurances | 47 | ||||||||
6.2 | Consents; Cooperation | 47 | ||||||||
6.3 | Access to Information | 48 | ||||||||
6.4 | Confidentiality | 49 | ||||||||
6.5 | Public Disclosure | 49 | ||||||||
6.6 | Escrow Agreement | 49 | ||||||||
6.7 | Blue Sky Laws | 49 | ||||||||
6.8 | Employment Agreements | 49 | ||||||||
6.9 | Spreadsheet | 49 | ||||||||
6.10 | Non-Competition; Non-Solicitation; Confidentiality | 50 | ||||||||
6.11 | Company Transaction Expenses | 51 | ||||||||
6.12 | Notification of Certain Matters | 52 | ||||||||
6.13 | Release | 52 | ||||||||
6.14 | Resignation of Officers, Directors, Members of the Management Board and Members of the Supervisory Board | 53 |
-iii-
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||||||||
6.15 | Preemptive Right | 53 | ||||||||
6.16 | Transfer Restrictions for Top Management | 53 | ||||||||
6.17 | Registration Statement on Form S-3 | 54 | ||||||||
6.18 | Registration with French Tax Authority | 55 | ||||||||
6.19 | Selling Stockholders Advisors Fees | 55 | ||||||||
SECTION SEVEN | ||||||||||
7. | Conditions to the Purchase | 57 | ||||||||
7.1 | Conditions to Obligations of Each Party to Effect the Purchase | 57 | ||||||||
7.2 | Additional Conditions to Obligations of Selling Stockholders | 57 | ||||||||
7.3 | Additional Conditions to the Obligations of Acquiror | 58 | ||||||||
SECTION EIGHT | ||||||||||
8. | Termination, Amendment and Waiver | 60 | ||||||||
8.1 | Termination | 60 | ||||||||
8.2 | Effect of Termination | 61 | ||||||||
8.3 | Fees and Expenses | 61 | ||||||||
8.4 | Amendment | 61 | ||||||||
8.5 | Extension; Waiver | 61 | ||||||||
SECTION NINE | ||||||||||
9. | Escrow and Indemnification | 62 | ||||||||
9.1 | Survival of Representations and Warranties | 62 | ||||||||
9.2 | Warranty Escrow Fund | 62 | ||||||||
9.3 | Indemnification | 62 | ||||||||
9.4 | SGAM AI Special Earnout | 64 | ||||||||
9.5 | Escrow Period | 65 | ||||||||
9.6 | Distributions; Voting | 65 | ||||||||
9.7 | Method of Asserting Claims | 66 | ||||||||
9.8 | Tax Characterization of Indemnification Payments | 66 | ||||||||
9.9 | Representative of the Stockholders; Power of Attorney | 66 | ||||||||
SECTION TEN | ||||||||||
10. | General Provisions | 68 |
-iv
TABLE OF CONTENTS
(continued)
(continued)
Page | ||||||||||
10.1 | Notices | 68 | ||||||||
10.2 | Interpretation | 69 | ||||||||
10.3 | Counterparts | 70 | ||||||||
10.4 | Entire Agreement; Nonassignability; Parties in Interest | 70 | ||||||||
10.5 | Severability | 70 | ||||||||
10.6 | Remedies Cumulative | 70 | ||||||||
10.7 | Governing Law; Venue; English Language | 70 | ||||||||
10.8 | Rules of Construction | 70 | ||||||||
10.9 | Amendments and Waivers | 71 | ||||||||
10.10 | Attorneys’ Fees | 71 |
-v-
THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the
25th day of October, 2006, by and among PDF Solutions, Inc., a Delaware corporation (the
“Acquiror”), all of the stockholders and holders of warrants to purchase the stock of Si
Automation S.A., a company organized under the laws of France (the “Company”), as well as
certain persons having a right to receive stock of the Company, all of which are listed on
Exhibit A (the “Selling Stockholders”) acting severally but not jointly, and
Société Générale Asset Management Alternative Investments (the “Stockholders’
Representative”).
RECITALS
WHEREAS, the Selling Stockholders own or have warrants to purchase an aggregate of 1,886,906
shares of the Company, which amount includes the ordinary shares to be issued upon the net exercise
of Company Warrants (as defined below) at the Closing (the “Shares”), divided into
1,886,906 ordinary shares, €1.00 par value per share, which constitute 100% of the issued and
outstanding shares of capital stock of the Company together with all of the Shares subject to
outstanding warrants or other rights to purchase shares of capital stock of the Company, in each
case at the date hereof (excluding any ordinary shares of the Company held by the Company).
WHEREAS, the persons designated on Exhibit A as “Warrant Holders” (the “Warrant
Holders”) are the beneficial and record owners of 100% of the outstanding warrants to purchase
capital stock of the Company issued by the Company (the “Company Warrants”) in the
proportions as set forth on Exhibit A.
WHEREAS, as a result of the exercise of the Company Warrants, a maximum of 1,000 new shares
may be issued at or prior to Closing.
WHEREAS, the Selling Stockholders desire to sell to the Acquiror, and the Acquiror wishes to
purchase from the Selling Stockholders, all Shares held by the Selling Stockholders for the
purchase price and upon the terms and conditions set forth herein (the “Purchase”).
WHEREAS, in connection with the Purchase, the Acquiror and certain employees of the Company,
namely Xxxxxxx Moustiés, Xxxxxxx Xxxxxxx, Xxxx Xxxxxx and Xxxxxxx Xxxxxx (the “Designated
Employees”) desire to enter or amend certain agreements.
AGREEMENT
NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements
hereinafter contained, the parties, intending to be legally bound hereby agree as follows:
SECTION ONE
1. The Purchase.
1.1 Purchase and Sale of the Shares. Upon the terms and subject to the conditions of
this Agreement, at the Closing (as defined below) each Selling Stockholder, acting
severally and not jointly, shall sell to the Acquiror or a wholly owned subsidiary of the
Acquiror, free and clear of any and all liens, and the Acquiror or a wholly owned subsidiary of the
Acquiror shall purchase from each Selling Stockholder, the Shares owned (or issuable upon the net
exercise of Company Warrants as provided herein) by such Selling Stockholder set forth opposite
such Selling Stockholder’s name on Exhibit A.
1.2 Purchase Price. The aggregate purchase price to be paid by the Acquiror for the
Shares shall be an amount equal to US$30,000,000, as adjusted by the Purchase Price Adjustment (as
defined below) (as so adjusted, the “Purchase Price”), to be comprised of the following:
(a) US$30,000,000 (the “Enterprise Value”) to be paid at Closing as follows:
(i) 70% of the Enterprise Value shall be paid in cash in U.S. dollars (together with the
adjusted Net Cash amount to be paid pursuant to clause (b) immediately below, the “Closing Cash
Consideration”); and
(ii) 30% of the Enterprise Value shall be paid in shares of common stock of the Acquiror, par
value $0.001 per share (the “Acquiror Stock”), based on the average of (1) the average
reported closing price for such securities on the NASDAQ National Market, or any other major
national reporting or quotation system on which the Acquiror Stock may be listed or quoted after
the date of this Agreement (the “NASDAQ”) for the ten (10) trading days ending one (1)
trading day prior to the date of this Agreement and (2) the average reported closing price for such
securities on the NASDAQ for the ten (10) trading days ending one (1) trading day prior to the
Closing Date (such average stock price shall be referred to as the “Closing Average Stock
Price,” such amount of shares shall be referred to as the “Closing Stock
Consideration”); and
(b) An amount equal to the Net Cash (as hereinafter defined) as adjusted by the Working
Capital Adjustment (as hereinafter defined), minus the Company Transaction Expenses incurred or
accrued (whether billed or unbilled) but not paid prior to the Closing Date, and minus the Transfer
Taxes, (each as hereinafter defined), in cash in U.S. dollars (it being understood that to the
extent such adjusted amount is negative, the Closing Cash Consideration will be reduced on a dollar
for dollar basis).
1.3 Purchase Price Adjustment.
(a) The “Purchase Price Adjustment” shall mean the sum of the following amounts: (i)
the Net Cash as adjusted by the Working Capital Adjustment, (ii) less the amount of the Company
Transaction Expenses (as hereinafter defined) incurred or accrued (whether billed or unbilled) but
not paid prior to the Closing Date, and (iii) less the amount of the Transfer Taxes.
(b) The “Working Capital Adjustment” shall mean the adjustment to the Purchase Price
set forth herein as follows: The Purchase Price shall be adjusted downward on a dollar for dollar
basis to the extent the Net Asset Amount (as hereinafter defined) reflected on the unaudited
balance sheet of the Company as of June 30, 2006 prepared by the Company in
-2-
accordance with French generally accepted accounting principles (“French GAAP”) and
reconciled to be in accordance with U.S. generally accepted accounting principles (“U.S.
GAAP”) (the “Reference Balance Sheet”) exceeds the Net Asset Amount reflected on the
unaudited balance sheet of the Company as of the Closing Date, which shall be prepared by the
Acquiror in accordance with this Agreement and reconciled to be in accordance with U.S. GAAP
applied on a basis consistent with reconciliation of the Reference Balance Sheet (the “Closing
Balance Sheet”). The Purchase Price shall be adjusted upward on a dollar for dollar basis to
the extent the Net Asset Amount (as hereinafter defined) reflected on the Reference Balance Sheet
is less than the Net Asset Amount reflected on the Closing Balance Sheet. The “Net Asset
Amount” shall mean the difference between the book value of the Assets (as hereinafter defined)
and Liabilities (as hereinafter defined) of the Company as reflected in the Reference Balance Sheet
or the Closing Balance Sheet, as applicable, which difference shall be stated in U.S. dollars on
the basis of the exchange rate quoted by Citibank in New York at the opening of business on the
date of payment to the Selling Stockholders or the Acquiror of the difference between the Estimated
Adjustment and the Final Adjustment pursuant to this section.
(c) The “Assets” shall mean all of the assets of the Company other than (i) any
components of Net Cash, (ii) any assets that were purchased during the period beginning on June 30,
2006 and ending on July 18, 2006, which are not listed on Schedule 1.3(c) and (iii) any assets that
were purchased during the period beginning on July 18, 2006 and ending on the Closing Date without
the written consent of the Acquiror, unless such assets in the aggregate were purchased for
consideration of €50,000 or less.
(d) The “Liabilities” shall mean all of the liabilities of the Company other than (i)
any components of Net Cash, and (ii) any liabilities for Company Transaction Expenses incurred or
accrued (whether billed or unbilled) but not paid prior to the Closing Date.
(e) “Net Cash” shall mean the Cash (as hereinafter defined) and Cash Equivalents (as
hereinafter defined), plus the amount of the Aggregate Exercise Price (as hereinafter defined),
less Indebtedness (as hereinafter defined) of the Company at the Closing Date, it being understood
that this amount could be a negative number that would result in a decrease to the Purchase Price.
(f) “Cash” shall mean the cash (disponibilités) and bank deposits as reflected in bank
statements and certificates of deposit less escrowed amounts or other restricted cash balances and
less the amounts of any unpaid checks, drafts and wire transfers issued on or prior to the date of
determination, calculated in accordance with French GAAP applied using the same accounting methods,
practices, principles, policies and procedures, with consistent classifications, judgments and
valuation and estimation methodologies that were used in the preparation of the Company’s audited
Financial Statements for the most recent fiscal year end as if such accounts were being prepared
and audited as of a fiscal year end, it being understood that in no event shall shares of the
Company’s capital stock held by the Company be included in Cash, with a reconciliation to be in
accordance with U.S. GAAP. Without limiting the generality of the foregoing, Cash shall include
any cash proceeds from the exercise of Company Warrants on or prior to the Closing.
-3-
(g) “Cash Equivalents” shall mean the consolidated Cash and any short-term, highly
liquid investments and marketable securities that are both readily convertible to known amounts of
cash and having such maturity that they present insignificant risk of changes in value because of
changes in interest rates, such as net VAT credit, Treasury bills, commercial paper, money market
funds, and any other cash equivalents of the Company and its Subsidiaries (such as latent capital
gains estimated as at the Closing Date on the basis of the corresponding stock price of such
investments as at the Closing Date) as of the open of business on the Closing Date and any credit
of the Company against the Acquiror with respect to any Accountant Fees (as hereinafter defined)
pursuant to Section 6.11(c) to the extent already paid by the Company or accounted as Indebtedness,
it being understood that in no event shall shares of the Company’s capital stock held by the
Company be included in Cash Equivalents.
(h) “Indebtedness” of any person shall mean, without duplication, (i) the principal,
accreted value, accrued and unpaid interest, prepayment and redemption premiums or penalties (if
any), unpaid fees or expenses and other monetary obligations in respect of (A) indebtedness of such
person for money borrowed and (B) indebtedness evidenced by notes, debentures, bonds or other
similar instruments for the payment of which such person is responsible or liable; (ii) all
obligations of such person issued or assumed as the deferred purchase price of property (including
shares or Intellectual Property rights), all conditional sale obligations of such person and all
obligations of such person under any title retention agreement (but excluding trade accounts
payable and other accrued current liabilities arising in the ordinary course of business (other
than the current liability portion of any indebtedness for borrowed money)); (iii) all obligations
of such person under leases required to be capitalized in accordance with French GAAP reconciled to
be in accordance with U.S. GAAP; (iv) all obligations of such person for the reimbursement of any
obligor on any letter of credit, banker’s acceptance or similar credit transaction; (v) all
obligations of such person under interest rate or currency swap transactions (valued at the
termination value thereof); (vi) all obligations of the type referred to in clauses (i) through (v)
of any other person for the payment of which such first person is responsible or liable, directly
or indirectly, as obligor, guarantor, surety or otherwise, including guarantees of such
obligations; and (vii) all obligations of the type referred to in clauses (i) through (vi) of any
other persons secured by (or for which the holder of such obligations has an existing right,
contingent or otherwise, to be secured by) any lien on any property or asset of such first person
(whether or not such obligation is assumed by such person). Without limiting the generality of the
foregoing, Indebtedness shall specifically include the amount of any outstanding government
research loans, including the loan from Agence Nationale de Valorisation de la Recherche (ANVAR)
pursuant to the loan agreement number A0405055 J dated 28 September 2004 (the “ANVAR Loan
Agreement” and together with the other outstanding government research loan agreements, the
“Governmental Loan Agreements”), up to the actual amounts paid out to the Company under
such Government Loan Agreements at the date at which such Indebtedness is calculated and to the
extent such amounts are not the subject of a waiver under such Government Loan Agreements
(including clause 3.5 of the ANVAR Loan Agreement).
(i) The “Transfer Taxes” shall mean the amount of transfer Taxes (as hereinafter
defined) and stamp duties payable by the Acquiror as a result of the transfer of the Shares under
this Agreement including those contemplated by Section 6.18.
-4-
1.4 Closing. The closing of the Purchase (the “Closing”) shall take place as
soon as practicable, and in no event later than five (5) business days after the satisfaction or
waiver of each of the conditions set forth in Section 6 or at such other time as the parties agree
(the “Closing Date”). The Closing shall take place at the offices of Xxxxxx, Xxxxxxxxxx &
Xxxxxxxxx LLP, 0000 Xxxxx Xxxx, Xxxxx Xxxx, Xxxxxxxxxx 00000, or at such other location as the
parties agree.
1.5 Actions at the Closing. At the Closing, the Selling Stockholders, acting
severally and not jointly, and the Acquiror shall take such actions and execute and deliver such
agreements and other instruments and documents as necessary or appropriate to effect the
transactions contemplated by this Agreement in accordance with its terms, including without
limitation the following:
(a) Each of the Selling Stockholders shall deliver or cause the Company to deliver, as
applicable, to the Acquiror:
(i) an “ordre de mouvement” (transfer form) for the transfer of such Shares to the Acquiror
free and clear of all liens;
(ii) satisfactory evidence that (A) each Warrant Holder has validly exercised his/her Company
Warrants with effect prior to the Closing or by net exercise at the Closing (as hereinafter
provided), and (B) satisfactory evidence that all options, warrants and other rights to purchase
capital stock granted by the Company other than the Company Warrants have been validly and
irrevocably discharged and/or that any other such rights have been validly waived with effect prior
to the Closing Date and without any penalties or indemnities;
(iii) all statutory registers and other books and records relating to the Company and its
subsidiaries including, but not limited to, the Company’s comptes individuels d’actionnaires and
registre des mouvements de titres;
(iv) a certificate of good standing “certificat de non faillite” issued by the Registre du
Commerce et des Sociétés of Montpellier no more than ten business days before Closing certifying
that the Company is not in an insolvency process;
(v) certificates of good standing for the Subsidiary issued by the Secretary of State of
California and the California Franchise Tax Board no more than ten business days before Closing;
(vi) all instruments and documents necessary to release any and all liens on the assets owned
by the Company other than liens for Taxes (as hereinafter defined) not yet due and payable, and
together with a statement (état des nantissements et privilèges) made by the Registre du Commerce
et des Sociétés of Montpellier issued no later than fifteen business days before Closing confirming
that there is no lien on such assets except those released hereby or mentioned above;
(vii) the Escrow Agreement (as defined in Section 6.6) executed by the Escrow Agent (as
defined in Section 9.2), the Acquiror and the Selling Stockholders;
-5-
(viii) the reiterative deed of sale summarizing the main terms and conditions of this
Agreement in the French language, for Tax registration purposes (the “Reiterative Deed of
Sale”);
(ix) the powers of attorney duly executed by each of the minority Selling Stockholders
designated as “Minority Selling Stockholders” on Exhibit A (the “Minority Selling
Stockholders”);
(x) a completed and executed IRS Form W-8 duly executed by each of the Selling Stockholders,
including the Minority Selling Stockholders; and
(xi) all other documents required of the Selling Stockholders or the Company pursuant to this
Agreement.
(b) The Acquiror will deliver to the Selling Stockholders or to such other delegated agent for
distribution to each of the Selling Stockholders (the “Paying Agent”), on behalf of Selling
Stockholders, (i) by cashier’s check or wire transfer (as directed by each Selling Stockholder) the
Closing Cash Consideration, net of the amounts as set forth in Section 1.6 and (ii) by book entry
for the Closing Stock Consideration, net of the amounts as set forth in Section 1.6 below, and the
Acquiror will deliver all other documents required of the Acquiror pursuant to this Agreement.
(c) The Company and each of the Designated Employees shall enter into an Employment Agreement
(or amended Employment Agreement, as the case may be) in the form attached hereto as Exhibit
B (the “Employment Agreement”).
(d) Originals of the resignation letters of Xxxx-Xxxxxx Xxxxxx, Xxxx Xxxxxxxx, Xxxx Xxxxxx,
Banexi Ventures Partners, Credit Lyonnais Venture Capital and Société Générale Asset Management
Alternative Investments (the “Existing Supervisory Board”) resigning as members of the
Supervisory Board of the Company, effective as of Closing.
(e) A certified copy of the minutes of the Management Board meeting at which resolutions have
been passed to amend the Bylaws of the Company effective as of the Closing to increase the share
capital associated with the Company Warrants being net exercised immediately prior to the Closing.
1.6 Payment. At the Closing, the Acquiror shall pay the Estimated Purchase Price (as
hereinafter defined) as follows:
(a) Holdback. The Acquiror shall retain the Holdback to satisfy the Purchase Price
true up set forth in Section 1.7. The “Holdback” shall mean US$3,000,000 of the Closing
Cash Consideration.
(b) Escrow Amounts. 10% of the Estimated Cash Consideration, 10% of the Estimated
Stock Consideration (rounded to the nearest whole share), $500,000 in cash and US$75,000 in cash,
representing the Selling Stockholders’ portion of the estimated fees and expenses of the Arbiter
(as hereinafter defined) (the “Arbiter Costs”), shall be placed in Escrow as provided in
Section 9 solely for the purpose of satisfying the Selling Stockholders’
-6-
indemnification obligations under Section 9, the payment of any shortfall in the Holdback (as
hereinafter defined) under Section 1.7 and the payment of the Arbiter Costs (the “Warranty
Escrow Fund”).
(c) Closing Payments to Selling Stockholders. Subject to Sections 1.6(d), (e) and
(f), the remaining Estimated Cash Consideration and Estimated Stock Consideration after the
payments set forth in Section 1.6(b) (the “Remaining Cash” and the “Remaining
Stock,” respectively), less the Holdback, less the Selling Stockholders Advisors Fees (as
hereinafter defined) and less the Stockholders’ Representative Expenses Reserve (as hereinafter
defined) shall be paid to the Selling Stockholders as follows: each Selling Stockholder (including
Warrant Holders) shall receive:
(i) an amount of cash, rounded to the nearest fifth decimal, equal to (I) the number of Shares
being delivered by such Selling Stockholder at the Closing (which number shall include any Shares
underlying Company Warrants held by such Selling Stockholder) multiplied by (II) the quotient of
(x) the Remaining Cash, less the cash portion of the Holdback, less the Selling Stockholders
Advisors Fees, less the Stockholders’ Representative Expenses Reserve, divided by (y) the aggregate
number of Shares (including Shares underlying Company Warrants) being purchased by the Acquiror
from all Selling Stockholders (including Warrant Holders) at the Closing, less (III) an amount of
cash equal to the aggregate exercise price payable upon exercise of any Company Warrants and any
Call Option Agreement (as defined in Section 5.2) by such Selling Stockholder at the Closing (the
aggregate such exercise price payable with respect to all Company Warrants with respect to the
vested and exercisable Shares thereunder as of the Closing shall be referred to as the
“Aggregate Exercise Price”), plus (IV) the value of any fractional shares resulting from
the calculation of the number of shares of Acquiror Stock set forth in Section 1.6(c)(ii), based on
the Closing Average Stock Price, and any amount of cash equal to the aggregate exercise price to be
received upon exercise of any Call Option Agreement; and
(ii) a number of shares of Acquiror Stock, rounded to the nearest whole share (with fractional
shares paid in cash as set forth in Section 1.6(c)(i)), equal to (I) the number of Shares being
delivered by such Selling Stockholder at the Closing (which number shall include any Shares
underlying Company Warrants) multiplied by (II) the quotient of (x) the Remaining Stock, less the
stock portion of the Holdback, divided by (y) the aggregate number of Shares (including Shares
underlying Company Warrants) being purchased by the Acquiror from all Selling Stockholders
(including Warrant Holders) at the Closing.
(d) Minority Selling Stockholders Escrow Equivalent. The Minority Selling
Stockholders (i) shall not contribute to the Warranty Escrow Fund and shall be paid directly any
amount which otherwise would have been paid by them into the Warranty Escrow Fund (the
“Minority Selling Stockholders Escrow Equivalent”) and (ii) shall not be required to fund
the Arbiter Costs and shall be paid directly any amount which otherwise would have been paid by
them to fund the Arbiter Costs (the “Minority Selling Stockholders Arbiter Costs
Equivalent”). As a result, in the event any payment from the Purchase Price is to be made to
the Selling Stockholders and 10% of this amount is simultaneously to be paid to the Warranty Escrow
Fund under this Agreement, the Selling Stockholders other than the Minority Selling Stockholders
(the “Escrow Selling Stockholders”) agree that any such amount payable (whether
-7-
in cash or in Acquiror Stock) to them shall be reduced in the aggregate by the Minority
Selling Stockholders Escrow Equivalent which shall be paid to the Warranty Escrow Fund by each
Escrow Selling Stockholder in proportion to its share in the number of Shares delivered by the
Escrow Selling Stockholders to the Acquiror at the Closing. The Escrow Selling Stockholders also
agree that any amount payable to them from the Cash Consideration at the Closing shall be reduced
in the aggregate by the Minority Selling Stockholders Arbiter Costs Equivalent which shall be paid
to the Arbiter Costs Fund by each Escrow Selling Stockholder in proportion to its share in the
number of Shares delivered by the Escrow Selling Stockholders to the Acquiror at the Closing.
(e) Escrow Contribution Cash and Stock Election. Initially, the total property
contributed to the Warranty Escrow Fund shall be a mixture of cash and Acquiror Stock, which, based
on the Closing Average Stock Price, has an aggregate value equal to 10% of the Closing
Consideration. The Acquiror shall contribute property with respect to each Escrow Selling
Stockholder initially having an aggregate value equal to such Escrow Selling Shareholder’s ratable
portion (based on the value of the Closing Consideration such Escrow Selling Shareholder receives
at Closing compared to the total value of the Closing Consideration received by all of the Escrow
Selling Stockholders at Closing) of the total property contributed to the Warranty Escrow Fund.
Certain Selling Stockholders have elected to substitute cash for Acquiror Stock or vice versa in
order to fund its ratable portion of the Warranty Escrow Fund as set forth on Exhibit D,
provided that for Selling Stockholders who have elected to substitute Acquiror Stock for cash, any
fractional share of Acquiror Stock shall be contributed in cash (the “Escrow Contribution
Spreadsheet”). As such, each Escrow Selling Stockholder shall have an ongoing proportionate
interest (their “Escrow Proportionate Interest”) in the property that may be held from time
to time in the Warranty Escrow Fund based on the value of the property such Escrow Selling
Stockholder initially elected to have contributed with respect to it by the Acquiror compared to
the total value of the property initially deposited in the Warranty Escrow Fund by the Acquiror.
Upon any release of escrowed property from the Warranty Escrow Fund to the Escrow Selling
Stockholders, each Escrow Selling Stockholder that elected to have cash contributed with into the
Warranty Escrow Fund with respect to it by the Acquiror shall receive cash first up to the amount
of such Escrow Selling Stockholder’s Escrow Proportionate Interest and then Acquiror Stock for any
balance owed on such Escrow Selling Stockholder’s Escrow Proportionate Interest. Conversely, upon
any release of escrowed property from the Warranty Escrow Fund to the Escrow Selling Stockholders,
each Escrow Selling Stockholder that elected to have Acquiror Stock contributed to the Warranty
Escrow Fund on behalf of it by the Acquiror shall receive Acquiror Stock first up to the amount of
such Escrow Selling Stockholder’s Escrow Proportionate Interest and then cash for any balance owed
on such Escrow Selling Stockholder’s Escrow Proportionate Interest. Upon any release of escrowed
property from the Warranty Escrow Fund to the Escrow Selling Stockholders, the Acquiror Stock in
the Warrant Escrow Fund shall be valued for purposes of determining the foregoing allocations
between cash and Acquiror Stock at average reported closing price for such securities on the NASDAQ
for the ten (10) trading days ending one (1) trading day prior to such release. As a result, the
amount of the Closing Cash Consideration and Closing Stock Consideration shall be appropriately
adjusted for each Escrow Selling Stockholder who elects to substitute cash for stock (or vice
versa) in the Warrant Escrow.
-8-
(f) Liquidation Preference for Top Management. The Selling Stockholders have agreed
to give Xxxxxxx Moustiés, Xxxxxxx Xxxxxxx and Xxxx Xxxxxx (collectively, the “Top
Management”) a certain liquidation preference with respect to their Shares in a recent
amendment to the Shareholders Agreement. This liquidation preference is reflected in the purchase
price allocation spreadsheet attached as Exhibit A (the “Purchase Price Allocation
Spreadsheet”). As a result, the amount of the Closing Cash Consideration and Closing Stock
Consideration shall be appropriately adjusted for each Selling Stockholder to reflect the agreed
upon liquidation preference for the Top Management. Each Selling Stockholder’s proportionate
interest in the cash and proportionate interest in the stock as set forth in the Purchase Price
Allocation Spreadsheet shall be referred to herein as such Selling Stockholder’s “Closing
Consideration Proportionate Interest” of cash or stock, as the case may be.
(g) Estimated Purchase Price and Allocation Spreadsheet. Not later than two business
days prior to the Closing Date, the Selling Stockholders other than FCPI Soge Innovation 3, FCPI
Soge Innovation 5, FCPI Soge Innovation 6 (collectively, “SGAM AI”) shall cause the Company
to provide to the Acquiror its good faith estimates (based on the most current information
available to the Company) of the Closing Balance Sheet, the Net Cash, the Working Capital
Adjustment, the Company Transaction Expenses, the Transfer Taxes and the resulting estimated
Purchase Price Adjustment, together with a spreadsheet showing what portion of the total
consideration each Selling Stockholder is entitled to receive hereunder. The Stockholders’
Representative and the Acquiror shall seek to agree, in good faith, upon an estimate of the
Purchase Price Adjustment (the “Estimated Purchase Price Adjustment”) and the resulting
estimated Purchase Price (the “Estimated Purchase Price”), estimated Closing Cash
Consideration (the “Estimated Cash Consideration”) and estimated Closing Stock
Consideration (the “Estimated Stock Consideration”); provided, however, in the event that
the Stockholders’ Representative and the Acquiror fail or are unable to so agree on the Estimated
Purchase Price Adjustment, the Estimated Purchase Price Adjustment shall be the Estimated Purchase
Price Adjustment furnished by the Company (which shall be deemed to be the Estimated Purchase Price
Adjustment for purposes hereof) and any dispute concerning the amounts thereof after the Closing
shall be resolved in accordance with Section 1.7. Each of the Purchase Price Adjustment and the
Estimated Purchase Price Adjustment shall be calculated applying the currency exchange rate as
quoted by Citibank in New York as of the date of the applicable payment to be made hereunder (the
“Applicable Exchange Rate”).
1.7 Purchase Price True Up.
(a) Following the Closing, the Purchase Price shall be adjusted as provided herein to reflect
the difference between the Estimated Purchase Price Adjustment and the Purchase Price Adjustment,
as finally determined pursuant to this Section 1.7. Within 60 days following the Closing Date, the
Acquiror shall deliver to the Stockholders’ Representative the Closing Balance Sheet, the
calculation of the Working Capital Adjustment, Net Cash, Transfer Taxes and Company Transaction
Expenses together with a calculation of the Purchase Price Adjustment (derived from the Closing
Balance Sheet and/or such other books and records of the Company and its Subsidiaries as are
applicable).
-9-
(b) Subject to the execution of customary auditors’ confidentiality and liability release
undertakings (covering “secret d’affaires”) by the Stockholders’ Representative on its behalf and
on behalf of its representatives (including its auditors), the Acquiror shall provide the
Stockholders’ Representative and its auditors with full and prompt access to the books and records
and relevant personnel of the Acquiror, the Company and its Subsidiaries and their statutory
auditors for the purpose of reviewing the Closing Balance Sheet, the Working Capital Adjustment,
the Net Cash, the Transfer Taxes and the Company Transaction Expenses. Such access shall be (x)
during normal business hours and upon reasonable advance notice, and (y) up until the final
determination of the Purchase Price Adjustment. The Selling Stockholders shall use such access for
the sole purpose of the determination of the Purchase Price Adjustment. In addition, the Selling
Stockholders’ auditors shall have full access to the accounting books and records, work papers,
schedules or additional documents prepared, used or otherwise generated by the statutory auditors
of the Company and its Subsidiaries.
(c) The Closing Balance Sheet and calculation of the Purchase Price Adjustment delivered by
the Acquiror to the Stockholders’ Representative shall be conclusive and binding upon all the
parties to this Agreement unless the Stockholders’ Representative, within sixty (60) days after
delivery thereof, notifies the Acquiror in writing that the Stockholders’ Representative disputes
any of the amounts set forth therein, specifying the nature of the dispute and the basis therefor.
The Stockholders’ Representative and the Acquiror shall in good faith attempt to resolve any
dispute and, if they so resolve all disputes, the Closing Balance Sheet and the Purchase Price
Adjustment, as amended to the extent necessary to reflect the resolution of the dispute, shall be
conclusive and binding on all of the parties to this Agreement. If the Stockholders’
Representative and the Acquiror do not reach agreement in resolving the dispute within twenty (20)
calendar days after notice is given by the Stockholders’ Representative to the Acquiror pursuant to
the second preceding sentence, the parties shall submit the dispute to a mutually satisfactory
partner in the San Xxxx office of the accounting firm of Deloitte & Touche LLP or, if no partner at
such firm will act, to a partner at such other nationally recognized independent accounting firm
which is mutually agreeable to the Stockholders’ Representative and the Acquiror (the
“Arbiter”) for resolution. If the Stockholders’ Representative and the Acquiror cannot
agree on the selection of a partner at an independent accounting firm to act as Arbiter, the
parties shall resolve such dispute through arbitration conducted in accordance with the rules of
the American Arbitration Association with a single arbitrator to act as the Arbiter, who’s decision
shall be conclusive and binding on all of the parties to this Agreement. Promptly, but no later
than twenty (20) calendar days after acceptance of his or her appointment as Arbiter, the Arbiter
shall determine (it being understood that in making such determination, the Arbiter shall be
functioning as an expert and not as an arbitrator), based solely on written submissions by the
Acquiror and the Stockholders’ Representative, and not by independent review, only those issues in
dispute and shall render a written report as to the resolution of the dispute and the resulting
computation of the Purchase Price Adjustment which shall be conclusive and binding on the parties.
All proceedings conducted by the Arbiter shall take place in San Jose, California. In resolving
any disputed item, the Arbiter (x) shall be bound by the provisions of this Section 1.7 and (y) may
not assign a value to any item greater than the greatest value for such items claimed by either
party or less than the smallest value for such items claimed by either party. The fees, costs and
expenses of the Arbiter shall be allocated to and borne by the Acquiror and the Selling
Stockholders based on the inverse of the percentage that the Arbiter’s determination (before such
allocation) bears to the
-10-
total amount of the total items in dispute as originally submitted to the Arbiter. For
example, if the Stockholders’ Representative decides to submit a dispute hereunder to arbitration,
and the Arbiter ultimately awards 70% of the amount disputed by the Stockholders’ Representative,
then the Selling Stockholders will bear 30% of the fees, costs and expenses of the Arbiter (in
addition to their own fees, costs and expenses), and the Acquiror will bear 70% of the Arbiter’s
fees, costs and expenses (in addition to its own fees, costs and expenses).
(d) Upon final determination of the Purchase Price Adjustment, if the Purchase Price as
adjusted by the Purchase Price Adjustment is less than the Purchase Price as adjusted by the
Estimated Purchase Price Adjustment (the “Purchase Price Excess”), the Escrow Selling
Stockholders shall pay to the Acquiror the amount, if any, by which the Purchase Price Excess
exceeds the Holdback, together with interest thereon from the Closing Date to the date of payment
thereof as determined below, by giving the requisite release instructions to the Escrow Agent to
permit the Acquiror to receive such amount of cash out of the Warranty Escrow Fund, Any amounts
payable by the Escrow Selling Stockholders under this clause shall be payable solely out of the
Warranty Escrow Fund. The Selling Stockholders’ Representative, on behalf of the Escrow Selling
Stockholders, shall give the requisite release instructions to the Escrow Agent promptly, but no
later than five (5) business days after such final determination. If the Purchase Price Excess is
less than the Holdback, the Acquiror shall pay to the Selling Stockholders or the Paying Agent, on
behalf of Selling Stockholders, the amount of such difference in cash, together with interest
thereon from the Closing Date to the date of payment thereof as determined below. Any such payment
by the Acquiror shall be made promptly, but no later than five (5) business days after such final
determination; provided that 10% of the cash to otherwise be paid to the Selling Stockholders shall
be deposited into the Warranty Escrow Fund (subject to Section 1.6(d)). Each Selling Stockholder
will receive their Closing Consideration Proportionate Interest in any such remaining cash and
stock payable to them.
(e) Upon final determination of the Purchase Price Adjustment, if the Purchase Price as
adjusted by the Purchase Price Adjustment is more than the Purchase Price as adjusted by the
Estimated Purchase Price Adjustment, the Acquiror shall pay in cash to the Selling Stockholders or
the Paying Agent, on behalf of the Selling Stockholders, the sum of (A) the amount of such
difference and (B) the Holdback, promptly, but no later than five (5) business days after such
final determination, together with interest thereon from the Closing Date to the date of payment
thereof as determined below; provided that 10% of the cash to otherwise be paid to the Selling
Stockholders shall be deposited into the Warranty Escrow Fund (subject to Section 1.6(d)). Each
Selling Stockholder will receive their Closing Consideration Proportionate Interest in any such
remaining cash and stock payable to them.
(f) For the purposes of this Section 1.7, interest will be payable at the “prime” rate, as
announced by The Wall Street Journal, Eastern Edition, from time to time to be in effect,
calculated based on a 365 day year and the actual number of days elapsed.
1.8 Purchase of Common Stock; Net Exercise of Warrants. The Shares to be purchased by
the Acquiror at the Closing shall consist solely of the Company’s common stock, and at such time
there shall be no other outstanding securities of or rights to purchase or otherwise acquire
securities of the Company. Accordingly, each Warrant Holder hereby irrevocably elects to exercise
the entire vested portion of their Company Warrants effective at the
-11-
Closing, with the exercise price to be deemed paid by them on a net exercise basis pursuant to
Section 1.6(c) and hereby confirms that any unvested portion of Company Warrants not so net
exercised at the Closing shall terminate at the Closing in accordance with the terms of the
warrants as modified hereby. As such, all options, warrants or other rights to purchase or acquire
shares of the Company capital stock shall have been exercised or terminated on or prior to the
Closing.
1.9 Securities Act Exemption. The Acquiror Stock to be issued pursuant to this
Agreement shall not be registered under the Securities Act of 1933, as amended (“Securities
Act”), in reliance upon the exemption contained in Section 4(2) of the Securities Act and
Regulation D and Regulation S promulgated thereunder and in reliance upon the representations and
warranties of the Selling Stockholders contained in Article 3 below.
1.10 Stock Restrictions. The certificates representing the shares of Acquiror Stock
issued pursuant to this Agreement shall bear a restrictive legend or legends (and stop transfer
orders shall be placed against the transfer thereof with the Acquiror’s transfer agent), stating
substantially as follows:
(a) “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH,
THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”
(b) Any legend required by the securities laws of any state.
1.11 Withholding. Each of the Acquiror and the Company shall be entitled to deduct
and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement to
any holder or former holder of Company Capital Stock such amounts as may be required to be deducted
or withheld therefrom under the U.S. Internal Revenue Code of 1986, as amended, or any provision of
U.S. state or local law, or any non-U.S. laws or regulations or under any other applicable legal
requirement. To the extent such amounts are so deducted or withheld, such amounts shall be treated
for all purposes under this Agreement as having been paid to the person to whom such amounts would
otherwise have been paid.
SECTION TWO
2. Representations and Warranties Relating to the Company.
In this Agreement, any reference to a “Material Adverse Effect” with respect to any
entity or group of entities means any event, change or effect that is or has a substantial
likelihood to be, materially adverse to the condition (financial or otherwise), properties, assets,
liabilities, business, operations or results of operations of such entity and its subsidiaries,
taken as a whole, or will prevent or materially delay consummation of the Purchase or otherwise
will prevent such entity and its subsidiaries from performing their obligations under this
Agreement,
-12-
except for any event, change or effect that results from or arises in connection with (i) any
changes or events affecting general economic or business conditions, (ii) any changes or events
affecting the industries in which such entity or any of its subsidiaries operates, (iii) the effect
of the public announcement or pendency of this Agreement and the transactions contemplated hereby,
or (iv) the taking of any action required by the terms of this Agreement.
In this Agreement, any reference to a party’s “knowledge” means, (i) for the Acquiror,
such party’s actual knowledge after reasonable inquiry of officers, directors and other employees
of the Acquiror reasonably believed to have knowledge of the matter in question; and (ii) for the
Company or the Selling Stockholders, the Company’s or the Selling Stockholders’ actual knowledge
after reasonable inquiry of the Top Management (as hereinafter defined).
Except as specifically disclosed in a document dated as of the date of this Agreement and
delivered by the Selling Stockholders to the Acquiror prior to the execution and delivery of this
Agreement referencing the appropriate section and subsection numbers to which such exceptions or
disclosure relates (the “Company Disclosure Schedule”) (provided that items disclosed in
one section or subsection of this Agreement shall be deemed disclosed under any other section or
subsection of this Agreement where the applicability of such disclosure should be reasonably
apparent to the Acquiror under the circumstances), the Selling Stockholders, other than SGAM AI and
other than the Minority Selling Stockholders, hereby severally but not jointly represent and
warrant to the Acquiror as of the date hereof and as of the Closing Date as follows:
2.1 Organization; Subsidiaries; Officers, Directors, Members of the Management Board and
Members of the Supervisory Board. Each of the Company and each subsidiary of the Company, if
any (each a “Subsidiary”), is a corporation duly organized, validly existing and in good
standing under the laws of its jurisdiction of organization. Each of the Company and each
Subsidiary has the requisite corporate power and authority and all necessary governmental approvals
to own, lease and operate its properties and to carry on its business as now being conducted and as
proposed to be conducted, except where the failure to have such power, authority and governmental
approvals would not, individually or in the aggregate, have a Material Adverse Effect on Company.
Each of the Company and each Subsidiary is duly qualified or licensed as a foreign corporation to
do business, and is in good standing, in each jurisdiction where the character of the properties
owned, leased or operated by it or the nature of its business makes such qualification or licensing
necessary, except for such failures to be so qualified or licensed and in good standing that would
not, individually or in the aggregate, have a Material Adverse Effect on the Company. A true and
complete list of all the Subsidiaries, together with the jurisdiction of incorporation of each
Subsidiary, is set forth in Section 2.1 of the Company Disclosure Schedule. The Company is the
owner of all outstanding shares of capital stock of each Subsidiary and all such shares are duly
authorized, validly issued, fully paid and nonassessable. All of the outstanding shares of capital
stock of each Subsidiary are owned by the Company free and clear of all liens, charges, claims,
encumbrances or rights of others. There are no outstanding subscriptions, options (including
options de souscription ou d’achat d’actions), warrants, puts, calls, rights, exchangeable or
convertible securities or other commitments or agreements of any character relating to the issued
or unissued capital stock or other securities of any Subsidiary, or otherwise obligating the
Company or any Subsidiary to issue, transfer, sell, purchase, redeem or otherwise acquire any such
securities. Except as set forth in Section 2.1 of the Company Disclosure Schedule, the Company
does not directly or
-13-
indirectly own any equity or similar interest in, or any interest convertible into or
exchangeable or exercisable for, any equity or similar interest in, any corporation, partnership,
limited liability company, joint venture or other business association or entity. Section 2.1 of
the Company Disclosure Schedule sets forth an accurate and complete list of the officers,
directors, members of the Management Board and members of the Supervisory Board of the Company and
each Subsidiary as well as any other person having authority to enter into contracts on behalf of
the Company or the Subsidiaries or having access to the bank accounts of the Company and each
Subsidiary.
2.2 Applicable Organizational Documents. The Company has delivered a true and correct
copy of the bylaws (statuts) or equivalent organizational documents (the “Bylaws”), of the
Company and the Articles of Incorporation or other Charter documents (“Charter”) and Bylaws
of each Subsidiary, as applicable, each as amended to date, to the Acquiror. Neither the Company
nor any Subsidiary is in violation of any of the provisions of its Charter, Bylaws or equivalent
organizational documents, as applicable (the “Applicable Organizational Documents”).
2.3 Capital Structure.
(a) As of the date hereof, the capital stock of the Company consists of 1,885,906 outstanding
shares of Common Stock (the “Company Capital Stock”). As of the date hereof, the
capitalization of the Company is as set forth in Section 2.3(a) of the Company Disclosure Schedule.
The Company Capital Stock is held by the persons with the domicile addresses and in the amounts
set forth in Section 2.3(a) of the Company Disclosure Schedule, which further sets forth for each
such person the number of shares held, class and/or series of such shares and the number of the
applicable stock certificates representing such shares. The Company shall notify the Acquiror in
writing promptly upon becoming aware on or before the Closing Date of any changes arising after the
date hereof in the holders of Company Capital Stock, the number of shares of Company Capital Stock
held by any such holder, and any change in the domicile addresses of any such holder. All
outstanding shares of Company Capital Stock are duly authorized, validly issued, fully paid and
non-assessable and are not subject to preemptive rights created by statute, the Company’s Bylaws,
or any agreement to which the Company is a party or by which it is bound. All shares of Company
Capital Stock and Company Warrants were issued and, if applicable, repurchased (in the case of
shares that were outstanding and repurchased by the Company or any stockholder of the Company) in
compliance with all applicable laws, rules, or regulations, and were issued, transferred and
repurchased (in the case of shares that were outstanding and repurchased by the Company or any
stockholder of the Company) in accordance with any right of first refusal or similar right or
limitation known to the Company or the Selling Stockholders, including those in the Company’s
Bylaws. There are no outstanding shares of Company Capital Stock that constitute unvested
restricted stock or that are otherwise subject to a repurchase or redemption right. There are no
declared or accrued but unpaid dividends with respect to any shares of Company Capital Stock. The
Company has no other capital stock authorized, issued or outstanding.
(b) Except for the Company Warrants (BSPCE) authorized on March 28, 2001, the Company Warrants
(BSPCE A03) for employees and members of the Management Board authorized on March 19, 2003, the
Company Warrants (BSPCE B03) for members of the
-14-
Management Board authorized on March 19, 2003, and the Company Warrant (BSA 03 No. 1)
authorized on March 19, 2003, the Company has never adopted, sponsored or maintained any stock
option plan or any other plan or agreement providing for equity compensation to any person
(including options de souscription ou d’achat d’actions). As of the date hereof and as of the
Closing Date, the Company has reserved 1,000 shares of Company Capital Stock for issuance to one
member of the Supervisory Board of the Company upon the issuance of stock or the exercise of
Company Warrants, which are fully issuable, as of the date hereof, upon the exercise of
outstanding, unexercised Company Warrants. Section 2.3(b) of the Company Disclosure Schedule sets
forth for each outstanding Company Warrant, the name of the holder of such warrant, the type of
entity of such holder, and any ultimate parent entity of such holder, if not an individual, the
domicile address of such holder, the number of shares of Company Capital Stock issuable upon the
exercise of such warrant, the exercise price of such warrant, the date of grant of such warrant,
the vesting schedule for such warrant, including the extent vested to date and whether the vesting
of such warrant is subject to acceleration as a result of the transactions contemplated by this
Agreement or any other events (including a complete description of any such acceleration
provisions). The Company has never granted any Company Warrants to any U.S. residents. True and
complete copies of all agreements and instruments relating to or issued under the Company Warrants
have been provided to the Acquiror and such agreements and instruments have not been amended,
modified or supplemented, and there are no agreements to amend, modify or supplement such
agreements or instruments from the forms thereof provided to the Acquiror.
(c) As of the date hereof, except for the Company Warrants that will be net exercised at the
Closing, there are no options (including options de souscription ou d’achat d’actions), warrants,
calls, rights, convertible securities, commitments or agreements of any character, written or oral,
to which the Company is a party or by which the Company is bound obligating the Company to issue,
deliver, sell, repurchase or redeem, or cause to be issued, delivered, sold, repurchased or
redeemed, any shares of the capital stock of the Company or obligating the Company to grant,
extend, accelerate the vesting of, change the price of, otherwise amend or enter into any such
option, warrant, call, right, commitment or agreement. There are no outstanding or authorized
stock appreciation, phantom stock, profit participation, or other similar rights with respect to
the Company. Except as contemplated hereby, there are no voting trusts, proxies, or other
agreements or understandings with respect to the voting stock of the Company. There are no
agreements to which the Company is a party relating to the registration, sale or transfer
(including agreements relating to rights of first refusal, co-sale rights or “drag-along” rights)
of any Company Capital Stock. As a result of the Purchase, the Acquiror will be the sole record
and beneficial holder of all issued and outstanding Company Capital Stock and all rights to acquire
or receive any shares of Company Capital Stock, whether or not such shares of Company Capital Stock
are outstanding.
2.4 Authority. The execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby have been duly authorized by all necessary corporate action on
the part of the Selling Stockholders. This Agreement has been duly executed and delivered by the
Selling Stockholders and assuming due authorization, execution and delivery by the Acquiror,
constitutes the valid and binding obligation of the Selling Stockholders enforceable against the
Selling Stockholders in accordance with its terms.
-15-
2.5 No Conflicts; Required Filings and Consents.
(a) The execution and delivery of this Agreement by the Selling Stockholders does not, and the
consummation of the transactions contemplated hereby will not, conflict with, or result in any
violation of, or default under (with or without notice or lapse of time, or both), or give rise to
a right of termination, cancellation or acceleration of any material obligation or loss of any
benefit under (i) any provision of the Applicable Organizational Documents of the Company or any of
its Subsidiaries, as amended, or (ii) any material mortgage, indenture, lease, contract or other
agreement or instrument, permit, concession, franchise, license, judgment, order, decree, statute,
law, ordinance, rule or regulation applicable to the Company or any Subsidiary or any of their
properties or assets.
(b) No consent, approval, order or authorization of, or registration, declaration or filing
with, any national or federal, territorial, state, local or foreign government or any agency or
political subdivision of any such government, or any court, administrative agency or commission,
regulatory body or other governmental authority or instrumentality (“Governmental Entity”)
is required by or with respect to the Company or any Subsidiary in connection with the execution
and delivery of this Agreement or the consummation of the transactions contemplated hereby, except
for such consents, approvals, orders, authorizations, registrations, declarations and filings as
may be required under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
the Securities Act, applicable state securities laws and the securities laws of any foreign
country; and (ii) such other consents, authorizations, filings, approvals and registrations which,
if not obtained or made, would not have a Material Adverse Effect on the Company and would not
prevent, or materially alter or delay any of the transactions contemplated by this Agreement; and
(iii) those consents, authorizations, filings, approvals and registrations listed in subsections
(i) through (vi) of Section 4.4(b) with respect to the Acquiror.
2.6 Financial Statements. Section 2.6 of the Company Disclosure Schedule includes a
true, correct and complete copy of the Company’s audited financial statements for the fiscal year
ended December 31, 2005 and its unaudited financial statements (balance sheet, statement of
operations and statement of cash flows) on a consolidated basis as at, and for the six-month period
ended June 30, 2006 (collectively, the “Financial Statements”). The Financial Statements
have been prepared in accordance with French GAAP (except that the unaudited financial statements
do not have notes thereto) applied on a consistent basis throughout the periods indicated and with
each other, and have been properly reconciled to be in accordance with U.S. GAAP. The Financial
Statements accurately set out and describe the financial condition and operating results of the
Company and its consolidated Subsidiaries as of the dates, and for the periods, indicated therein,
subject to normal year-end audit adjustments. As of the date hereof and as of the Closing, the
Company has maintained a standard system of accounting established and administered in accordance
with generally accepted accounting principles.
2.7 Absence of Undisclosed Liabilities. Neither the Company nor any Subsidiary has
material obligations or liabilities of any nature (matured or unmatured, fixed or contingent) other
than (i) those set forth or adequately provided for in the Company’s unaudited consolidated balance
sheet and related schedules as of June 30, 2006 (the “Company Balance Sheet”), (ii) those
incurred in the ordinary course of business and not required to be set forth in the Company Balance
Sheet under generally accepted accounting principles, (iii) those incurred
-16-
in the ordinary course of business since the date of the Company Balance Sheet and consistent
with past practice, and (iv) those incurred in connection with the execution of this Agreement.
2.8 Absence of Certain Changes. Since, but not including, June 30, 2006 (the
“Company Balance Sheet Date”), there has not been, occurred or arisen any:
(a) transaction by the Company or any Subsidiary of material significance except in the
ordinary course of business as conducted on that date and consistent with past practices;
(b) amendments or changes to the Bylaws of the Company;
(c) capital expenditure or capital commitment by the Company or any Subsidiary, in any
individual amount exceeding €50,000, or in the aggregate, exceeding €60,000;
(d) destruction of, damage to, or loss of any assets (including, without limitation,
intangible assets), business or customer of the Company or any Subsidiary (whether or not covered
by insurance) which would constitute a Material Adverse Effect;
(e) strikes, work stoppages, slowdowns, lockouts or arbitrations, or material grievances or
other labor disputes against or involving the Company or any of the Subsidiaries;
(f) unfair labor practice charges, material grievances or complaints (including for wrongful
discharge) by or on behalf of any employee or group of employees;
(g) change in accounting methods or practices (including any change in depreciation or
amortization policies or rates, any change in policies in making or reversing accruals) by the
Company or any revaluation by the Company of any of its or any of its Subsidiaries’ assets;
(h) revaluation by the Company or any Subsidiary of any of their respective material assets;
(i) declaration, setting aside, or payment of a dividend or other distribution in respect to
the capital stock of the Company, or any direct or indirect redemption, purchase or other
acquisition by the Company of any of its capital stock, except repurchases of Company Capital Stock
from terminated Company employees at the original per share purchase price of such shares;
(j) increase in the salary or other compensation payable or to become payable by the Company
to any officers, directors, members of the Management Board, members of the Supervisory Board,
employees or advisors of the Company or any Subsidiary, except in the ordinary course of business
consistent with past practice, or the declaration, payment, or commitment or obligation of any kind
for the payment by the Company of a bonus or other additional salary or compensation to any such
person except as otherwise contemplated by this Agreement, or other than as set forth in Section
2.16 below, the establishment of any bonus, insurance, deferred compensation, pension, retirement,
profit sharing, stock option
-17-
(including without limitation, the granting of stock options, stock appreciation rights,
performance awards), stock purchase or other employee benefit plan;
(k) sale, lease, license of other disposition of any of the assets or properties of the
Company or any Subsidiary, except in the ordinary course of business and not in excess of
€50,000 in the aggregate;
(l) termination or material amendment of any material contract, agreement or license
(including any distribution agreement) to which the Company or any Subsidiary is a party or by
which it is bound;
(m) loan by the Company or any Subsidiary to any person or entity, or guaranty by the Company
or any Subsidiary of any loan, except for (x) travel or similar advances made to employees in
connection with their employment duties in the ordinary course of business, consistent with past
practices and (y) trade payables not in excess of €50,000 in the aggregate and in the ordinary
course of business, consistent with past practices;
(n) waiver or release of any right or claim of the Company or any Subsidiary, including any
write-off or other compromise of any account receivable of the Company or any Subsidiary, in excess
of €50,000 in the aggregate;
(o) the commencement or written notice of, or, to the Company’s or the Selling Stockholders’
knowledge, any threat of commencement of any lawsuit or proceeding against or, to the Company’s or
the Selling Stockholders’ knowledge, investigation of the Company or any Subsidiary or their
respective affairs;
(p) notice of any claim of ownership by a third party of the Company’s or any Subsidiary’s
Intellectual Property (as hereinafter defined) or of infringement by the Company or any Subsidiary
of any third party’s Intellectual Property rights;
(q) issuance or sale by the Company or any Subsidiary of any of its shares of capital stock,
or securities exchangeable, convertible or exercisable therefor, or of any other of its securities;
(r) change in pricing or royalties policies set or charged by the Company or any Subsidiary to
its customers or licensees or in pricing or royalties set or charged by persons who have licensed
Intellectual Property to the Company or any Subsidiary (other than those requested by the
Acquiror);
(s) event or condition of any character that has or could reasonably be expected to have a
Material Adverse Effect on the Company; or
(t) agreement by the Company, any Subsidiary or any officer, director, member of the
Management Board, member of the Supervisory Board or employee of either on behalf of such entity to
do any of the things described in the preceding clauses (a) through (s) (other than negotiations
with the Acquiror and its representatives regarding the transactions contemplated by this
Agreement).
-18-
2.9 Litigation. There is no private or governmental action, suit, proceeding, claim,
arbitration or investigation pending before any agency, court or tribunal, foreign or domestic, or,
to the knowledge of the Company or the Selling Stockholders, threatened (whether orally or in
writing) against the Company or any Subsidiary or any of their respective properties or any of
their respective officers, directors, members of the Management Board or members of the Supervisory
Board (in their capacities as such) that, individually or in the aggregate, could reasonably be
expected to have a Material Adverse Effect on the Company or any Subsidiary. There is no judgment,
decree or order against the Company or any Subsidiary or, to the best knowledge of the Company or
the Selling Stockholders, any of their respective officers, directors, members of the Management
Board or members of the Supervisory Board (in their capacities as such), that could prevent,
enjoin, or materially alter or delay any of the transactions contemplated by this Agreement, or
that would reasonably be expected to have a Material Adverse Effect on the Company. All litigation
to which the Company or any Subsidiary is a party (or, to the knowledge of the Company or the
Selling Stockholders, threatened to become a party) is disclosed in the Company Disclosure
Schedule.
2.10 Restrictions on Business Activities. There is no agreement, judgment,
injunction, order or decree binding upon the Company or any Subsidiary which has or would
reasonably be expected to have the effect of prohibiting or materially impairing any current or
future business practice of the Company or any Subsidiary, any acquisition of property by the
Company or any Subsidiary or the overall conduct of business by the Company or any Subsidiary as
currently conducted or as proposed (as of the date hereof or as of the Closing Date) to be
conducted by the Company or by any Subsidiary. Neither the Company nor any Subsidiary has entered
into any agreement under which the Company or any Subsidiary is restricted from selling, licensing
or otherwise distributing any of its products to any class of customers, in any geographic area,
during any period of time or in any segment of the market.
2.11 Permits; Company Products; Regulation.
(a) Each of the Company and each Subsidiary is in possession of all franchises, grants,
authorizations, licenses, permits, easements, variances, exceptions, consents, certificates,
approvals and orders necessary for the Company or that Subsidiary, to own, lease and operate its
properties or to carry on its business as it is now being conducted (the “Company
Authorizations”) and no suspension or cancellation of any Company Authorization is pending or,
to the best of the Company’s and the Selling Stockholders’ knowledge, threatened, except where the
failure to have, or the suspension or cancellation of, any Company Authorization would not have a
Material Adverse Effect on the Company. Neither the Company nor any Subsidiary is in conflict
with, or in default or violation of, (i) any laws applicable to the Company or any Subsidiary or by
which any property or asset of the Company or any Subsidiary is bound or affected, (ii) any Company
Authorization, or (iii) any note, bond, mortgage, indenture, contract, agreement, lease, license,
permit, franchise or other instrument or obligation to which the Company or any Subsidiary is a
party or by which the Company or any Subsidiary or any property or asset of the Company or any
Subsidiary is bound or affected, except for any such conflict, default or violation that would not,
individually or in the aggregate, have a Material Adverse Effect on the Company or any Subsidiary.
-19-
(b) Except as would not have a Material Adverse Effect on the Company, since the inception of
the Company there have been no written notices, citations or decisions by any Governmental Entity
that any product produced, manufactured, marketed or distributed at any time by the Company or any
Subsidiary (the “Products”) is defective or fails to meet any applicable standards
promulgated by any such Governmental Entity. To the best knowledge of the Company and the Selling
Stockholders, the Company and each Subsidiary has complied in all material respects with the laws,
regulations, policies, procedures and specifications with respect to the design, manufacture,
labeling, testing and inspection of the Products. Except as disclosed in Section 2.11(b) of the
Company Disclosure Schedule, since the inception of the Company, there have been no recalls, field
notifications or seizures ordered or, to the Company’s and the Selling Stockholders’ knowledge,
threatened by any such Governmental Entity with respect to any of the Products.
(c) The Company has obtained, in all countries where either the Company or a Subsidiary is
marketing or has marketed its Products, all applicable licenses, registrations, approvals,
clearances and authorizations required by local, state or federal agencies in such countries
regulating the safety, effectiveness and market clearance of the Products currently or previously
marketed by the Company or any Subsidiary in such countries, except for any such failures as would
not, individually or in the aggregate, have a Material Adverse Effect on the Company. The Company
has identified and made available for examination by the Acquiror all material information relating
to regulation of its Products, including licenses, registrations, approvals, permits, device
listings, inspections, the Company’s recalls and product actions, audits and the Company’s ongoing
field tests. The Company has identified in writing to the Acquiror all international locations
where regulatory information and documents are kept.
2.12 Title to Property.
(a) The Company and each Subsidiary has good and marketable title to all of its respective
properties, interests in properties and assets, real and personal, reflected in the Company Balance
Sheet or acquired after the Company Balance Sheet Date (except properties, interests in properties
and assets sold or otherwise disposed of since the Company Balance Sheet Date in the ordinary
course of business), or with respect to leased properties and assets, valid leasehold interests in,
free and clear of all mortgages, liens, pledges, charges or encumbrances of any kind or character,
except (i) the lien of current taxes not yet due and payable, (ii) such imperfections of title,
liens and easements as do not and will not materially detract from or interfere with the use of the
properties subject thereto or affected thereby, or otherwise materially impair business operations
involving such properties, and (iii) liens securing debt which is reflected on the Company Balance
Sheet. The plants, property and equipment of the Company and Subsidiaries that are used in the
operations of their businesses are in good operating condition and repair. All properties used in
the operations of the Company and its Subsidiaries are reflected in the Company Balance Sheet to
the extent French GAAP reconciled to be in accordance with U.S. GAAP require the same to be
reflected. Section 2.12(a) of the Company Disclosure Schedule sets forth a true, correct and
complete list of all real property owned or leased by the Company and by each Subsidiary, the name
of the lessor, the date of the lease and each amendment thereto and the aggregate annual rental and
other fees payable under such lease. Such leases are in good standing, are valid and effective in
accordance with their
-20-
respective terms, and there is not under any such leases any existing default or event of
default (or event which with notice or lapse of time, or both, would constitute a default).
(b) Section 2.12(b) of the Company Disclosure Schedule also sets forth a true, correct and
complete list of all equipment (the “Equipment”) owned or leased by the Company and its
Subsidiaries, and such Equipment is, taken as a whole, (i) adequate for the conduct of the
Company’s business, consistent with its past practice, and (ii) in good operating condition (except
for ordinary wear and tear).
2.13 Intellectual Property.
(a) The Company and each of its Subsidiaries own, or are licensed or otherwise possess legally
enforceable rights to use all patents, patent rights, trademarks, trademark rights, trade names,
trade name rights, service marks, copyrights, domain names and any applications for any of the
foregoing, maskworks, net lists, schematics, industrial models, inventions, technology, know-how,
trade secrets, ideas, algorithms, processes, computer software programs or applications (in both
source code and object code form), and tangible or intangible proprietary information or material
(“Intellectual Property”) that are used in the business of the Company or any Subsidiary as
currently conducted by the Company or any Subsidiary, except to the extent that the failure to have
such rights could not reasonably be expected to have a Material Adverse Effect on the Company and
the Subsidiary.
(b) Section 2.13 of the Company Disclosure Schedule lists (i) all patents and patent
applications and all registered and material unregistered trademarks, trade names and service
marks, registered and unregistered copyrights, domain names, computer software programs, source
code, object code, data, design tools, user interfaces and maskworks, included in the Intellectual
Property that are owned by the Company or any Subsidiary, including the jurisdictions in which each
such Intellectual Property right has been issued or registered or in which any application for such
issuance and registration has been filed, (ii) all material licenses, sublicenses and other
agreements as to which the Company or any Subsidiary is a party and pursuant to which any person is
authorized to use any Intellectual Property, and (iii) all material licenses, sublicenses and other
agreements as to which the Company or any Subsidiary is a party and pursuant to which the Company
or any Subsidiary is authorized to use any third party patents, trademarks or copyrights, including
software (“Third Party Intellectual Property Rights”) which are used in the manufacture or
development of, are incorporated in, are, or form a part of any Company product that is material to
its business, except in each case for standard, generally commercially available “off the shelf”
products. Neither the Company nor any Subsidiary is in material breach of any license, sublicense
or agreement described in Section 2.13 of the Company Disclosure Schedule. The execution and
delivery of this Agreement by the Company and the consummation of the transactions contemplated
hereby, will neither cause the Company or any Subsidiary to be in material violation or default
under any such license, sublicense or agreement, nor entitle any other party to any such license,
sublicense or agreement to terminate or modify such license, sublicense or agreement. The Company
has paid all maintenance fees, taxes and/or annuities for all issued patents and all pending patent
applications. Except as set forth in Section 2.13 of the Company Disclosure Schedule, there have
been no settlement agreements, consent decrees or judgments relating to the Intellectual Property.
-21-
(c) The Company has delivered to the Acquiror prior to the execution of this Agreement
documentation with respect to any invention, process, design, computer program or other know-how or
trade secret included in such Intellectual Property, including the Company’s and its Subsidiaries’
proprietary software, and reasonably sufficient in detail and content to identify and explain such
invention, process, design, computer program or other know-how or trade secret and to facilitate
its full and proper use without reliance on the special knowledge or memory of any third party. The
materials comprising such software, including the source code and documentation, have been written
in a clear and professional manner so that they may be understood, modified and maintained in an
efficient manner by reasonably competent programmers.
(d) All registered marks, issued patents and registered copyrights identified in Section
2.13(d) of the Company Disclosure Schedules (the “Company Registered IP”) are valid and
subsisting and, to the knowledge of the Selling Stockholders, enforceable, and neither the Company
nor any of its Subsidiaries has received any notice or claim challenging the validity or
enforceability of any Company Registered IP or alleging any misuse of such Company Registered IP.
Neither the Company nor any of its Subsidiaries has taken any action or failed to take any action
that could reasonably be expected to result in the abandonment, cancellation, forfeiture,
relinquishment, invalidation or unenforceability of any of the Company Registered IP (including the
failure to pay any filing, examination, issuance, post registration and maintenance fees, annuities
and the like and the failure to disclose any known material prior art in connection with the
prosecution of patent applications).
(e) No loss or expiration of any Intellectual Property licensed to the Company or any
Subsidiary is pending or reasonably foreseeable or, to the knowledge of the Company, threatened.
There is no outstanding or, the Company’s knowledge, threatened dispute or disagreement with
respect to any license agreement under which the Company or any Subsidiary grants or are licensed
any rights under any Intellectual Property.
(f) No source code of any computer software owned by the Company or any of its Subsidiaries
has been licensed or otherwise provided to another person, and all such source code at all times
has been safeguarded and protected as a trade secret of the Company or one of its Subsidiaries. No
software products of the Company or its Subsidiary (i) contain any code that is owned by any third
party, including any code that is licensed pursuant to the provisions of any “open source” license
agreement or any other license agreement that requires the source code to be distributed or made
available in connection with the distribution of the licensed software in object code form or that
limits the amount of fees that may be charged in connection with sublicensing or distributing such
licensed software (each, an “Open Source License”). None of the Company software products
is, in whole or in part, subject to the provisions of any Open Source License. The Company and the
Subsidiaries have taken commercially reasonable steps to ensure that all software used by them is
free of any disabling codes or instructions, and any virus or other intentionally created,
undocumented contaminant, that may, or may be used to, access, modify, delete, damage or disable
any of internal computer systems (including hardware, software, databases and embedded control
systems) of the Company and the Subsidiaries. The Company and the Subsidiaries have taken
reasonable steps to safeguard such systems and restrict unauthorized access thereto.
-22-
(g) There has been no nor is there any material unauthorized use, disclosure, infringement or
misappropriation of any Intellectual Property rights of the Company or any Subsidiary, any trade
secret material to the Company or any Subsidiary or any Intellectual Property right of any third
party to the extent licensed by or through the Company or any Subsidiary, by any third party,
including any employee or former employee of the Company or any Subsidiary. Neither the Company
nor any Subsidiary has entered into any agreement to indemnify any other person against any charge
of infringement of any Intellectual Property, other than indemnification provisions contained in
purchase orders arising in the ordinary course of business.
(h) The Company has not been sued in any suit, action or proceeding which challenges the
validity of or involves a claim of infringement of any patents, trademarks, service marks,
copyrights or violation of any trade secret or other proprietary right of any third party or which
involved any unfair competition or similar claim. Neither the conduct of the business of the
Company and each Subsidiary as currently conducted or contemplated nor the manufacture, sale,
licensing or use of any of the products of the Company or any Subsidiary as now manufactured, sold
or licensed or used, nor the use in any way of the Intellectual Property in the manufacture, use,
sale or licensing by the Company or any Subsidiary of any products currently existing or proposed
(as of the date hereof and as of the Closing Date), infringes on or conflicts with, in any way, any
license, trademark, trademark right, trade name, trade name right, patent, patent right, industrial
model, invention, service xxxx, trade secret, copyright or other intellectual property right of any
third party. The Company has never received any letters or other communications intended to
suggest that the Company may infringe any third party’s Intellectual Property or unsolicited
letters or other communications offering to license such third party’s Intellectual Property to the
Company. To the Company’s and the Selling Stockholders’ knowledge, no third party is challenging
or reasonably could challenge the ownership by the Company or any Subsidiary, or the validity or
effectiveness of, any of the Intellectual Property. Neither the Company nor any Subsidiary has
brought any action, suit or proceeding for infringement of Intellectual Property or breach of any
license or agreement involving Intellectual Property against any third party. The Company and the
Selling Stockholders are not aware of any infringement of the Company’s Intellectual Property by a
third party and are not aware of any third party action to impair the Company’s rights in the
Intellectual Property, including without limitation, through the filing of patents that could
impair the Company’s ability to practice its current or anticipated business. There are no
pending, or to the best of the Company’s and the Selling Stockholders’ knowledge, threatened
interference, re-examinations, oppositions or nullities involving any patents, patent rights or
applications therefor of the Company or any Subsidiary, except such as may have been commenced by
the Company or any Subsidiary. There is no breach or violation of or threatened or actual loss of
rights under any license agreement to which the Company is a party.
(i) The Company has secured valid written assignments from all consultants and employees who
contributed to the creation or development of Intellectual Property of all the rights to such
contributions that the Company does not already own by operation of law.
(j) The Company has taken all necessary and appropriate steps to protect and preserve the
confidentiality of all Intellectual Property not otherwise protected by
-23-
patents, patent applications or copyright (“Confidential Information”). Each of the
Company and its respective Subsidiaries has a policy requiring each employee, consultant and
independent contractor to execute proprietary information and confidentiality agreements
substantially in the Company’s standard forms and all current and former employees, consultant and
independent contractors of the Company and each Subsidiary have executed such an agreement. All
use, disclosure or appropriation of Confidential Information owned by the Company or a Subsidiary
by or to a third party has been pursuant to the terms of a written agreement between the Company or
the applicable Subsidiary and such third party. All use, disclosure or appropriation of
Confidential Information not owned by the Company or a Subsidiary has been pursuant to the terms of
a written agreement between the Company or a Subsidiary and the owner of such Confidential
Information, or is otherwise lawful.
2.14 Environmental Matters.
(a) The following terms shall be defined as follows:
(i) “Environmental and Safety Laws” shall mean any international, national, state,
regional or local statutes, directives, ordinances, codes, regulations, rules, policies and orders,
as each may be amended from time to time and interpreted by courts, other adjudicatory bodies and
administrative or regulatory agencies, that are intended to assure the protection of the
environment, or that classify, regulate, call for the remediation of, require reporting with
respect to, or list or define hazardous or toxic substances, materials, wastes, pollutants or
contaminants; which regulate the manufacture, handling, transport, use, treatment, storage or
disposal of Hazardous Materials or materials containing Hazardous Materials; or which are intended
to assure the protection, safety and good health of employees, workers or other persons, including
the public.
(ii) “Hazardous Materials” shall mean any toxic or hazardous substance, material or
waste or any pollutant or contaminant, or infectious or radioactive substance or material,
including without limitation, those substances, materials and wastes defined in or regulated under
any Environmental and Safety Laws; petroleum and petroleum products including crude oil and any
fractions thereof; natural gas, synthetic gas, and any liquids, by-products or other mixtures
derived from gas; radon; asbestos; and any other pollutant or contaminant.
(iii) “Property” shall mean all real property leased or owned by the Company or its
Subsidiaries either currently or in the past.
(iv) “Facilities” shall mean all buildings and improvements on the Property of the
Company or its Subsidiaries.
(b) Representations and warranties: (i) no Hazardous Material is contained in or has been
used at or released from the Facilities in a manner that requires reporting to governmental
agencies or that requires monitoring and maintenance to protect public health and worker health and
safety; (ii) all Hazardous Materials and wastes have been generated, handled, transported, used and
disposed of in accordance with all Environmental and Safety Laws; (iii) neither the Company nor its
Subsidiaries has received notice (verbal or
-24-
written) of any noncompliance of the Facilities or of the Company’s or any Subsidiary’s past
or present operations with Environmental and Safety Laws; (iv) no notices, administrative actions
or suits are pending or threatened relating to Hazardous Materials or a violation of any
Environmental and Safety Laws; (v) neither the Company nor its Subsidiaries are a potentially
responsible party under the federal Comprehensive Environmental Response, Compensation and
Liability Act (“CERCLA”), or any similar Environmental and Safety Law; (vi) there has not
been in the past, and are not now, any contamination, disposal, spilling, dumping, incineration,
discharge or treatment of Hazardous Materials on, under or from the Facilities or Property; (vii)
there have not been in the past, and are not now, any underground tanks or underground improvements
at, on or under the Property including without limitation, treatment or storage tanks, sumps, or
water, gas or oil xxxxx; (viii) there are no polychlorinated biphenyls (“PCBs”) deposited,
stored, disposed of or located on the Property or Facilities, or contained in any equipment on the
Property at levels in excess of 50 parts per million; (ix) there is no insulating material
containing urea formaldehyde in the Facilities; (x) the Facilities and the Company’s and its
Subsidiaries uses and activities therein have at all times complied with all Environmental and
Safety Laws; (xi) the Company and its Subsidiaries have all the permits, consents and licenses
required to operate the Facilities and are in full compliance with the terms and conditions of
those permits, consents and licenses; and (xii) neither the Company nor any of its Subsidiaries is
liable for any off-site contamination nor under any Environmental and Safety Laws.
2.15 Taxes.
(a) For purposes of this Section 2.15 and other provisions of this Agreement relating to
Taxes, the following definitions shall apply:
(i) The term “Taxes” shall mean all taxes, however denominated, whether direct or
indirect, tariffs, contributions or charges, fees, duties or levies, including any amount,
interest, fines, penalties or other additions to tax that may become payable in respect thereof or
that may be attributable to any failure to comply with any requirement regarding Tax Returns or Tax
regulations, (A) that are assessed or collected by or under the authority of any Taxing Authority
or imposed by any Governmental Entity, which taxes shall include, without limiting the generality
of the foregoing, all income or profits taxes (including but not limited to, federal, state and
foreign income taxes), payroll and employee withholding taxes, unemployment insurance
contributions, social security taxes, sales and use taxes, ad valorem taxes or value added taxes,
excise taxes, franchise taxes, gross receipts taxes, withholding taxes, business license taxes,
occupation taxes, real and personal property taxes, stamp taxes, environmental taxes, transfer
taxes, registration and transfer duties, customs duties, social contributions, workers’
compensation and other governmental charges, and other obligations of the same or of a similar
nature to any of the foregoing, which are required to be paid, withheld or collected, (B) any
liability for the payment of amounts referred to in (A) as a result of being a member of any
affiliated, consolidated, combined or unitary group, or (C) any liability for amounts referred to
in (A) or (B) as a result of any obligations to indemnify another person or as a result of being a
successor in interest or transferee of another person.
(ii) The term “Taxing Authority” means any Governmental Entity (including, without
limitation, any French or U.S. Governmental Entity) responsible for the administration of any Tax.
-25-
(iii) The term “Returns” shall mean all reports, estimates, declarations, statements
and returns required to be filed in connection with any Taxes including information returns with
respect to such matters as backup withholding and other payments to third parties, claims for
refund, declarations of estimated Tax, capital gain deferral statements, elections, schedules or
attachments thereto and any amendment thereof, and including, where permitted or required,
combined, consolidated or unitary returns for any group of entities that includes the Company, any
of its Subsidiaries, or any of their Affiliates.
(b) All Returns required to be filed by or on behalf of the Company or any Subsidiary and any
affiliated, consolidated, combined or unitary Tax reporting group of which the Company or any
Subsidiary is or was a member have been duly filed on a timely basis with the appropriate Taxing
Authority and such Returns are true, complete and correct. All Taxes shown to be payable on such
Returns or on subsequent assessments with respect thereto, and all payments of estimated Taxes
required to be made by or on behalf of the Company or any Subsidiary sufficient to avoid
underpayment penalties or interest have been paid in full on a timely basis, and no other Taxes are
payable by the Company or any Subsidiary with respect to items or periods covered by such Returns
(whether or not shown on or reportable on such Returns). The Company and each Subsidiary have
withheld and paid over all Taxes required to have been withheld and paid over, and complied with
all information reporting and backup withholding in connection with amounts paid or owing to any
employee, creditor, independent contractor, or other third party. There are no liens on any of the
assets of the Company or any Subsidiary with respect to Taxes, other than liens for Taxes not yet
due and payable. Neither the Company nor any Subsidiary has been at any time a member of an
affiliated group of corporations filing consolidated, combined or unitary income or franchise tax
returns other than as members of a group of which the Company is the ultimate parent for a period
for which the statute of limitations for any Tax potentially applicable as a result of such
membership has not expired.
(c) The amount of the Company’s and any Subsidiary’s liabilities for unpaid Taxes for all
periods through the date of the Company Balance Sheet do not, in the aggregate, exceed the amount
of the liability accruals for Taxes reflected on the Company Balance Sheet, and the Company Balance
Sheet properly accrues, in accordance with French GAAP reconciled to be in accordance with U.S.
GAAP, all liabilities for Taxes of the Company and its Subsidiaries payable after the date of the
Financial Statements attributable to transactions and events occurring prior to such date. No
liability for Taxes of the Company or any Subsidiary has been incurred or material amount of
taxable income has been realized (or prior to and including the Closing will be incurred or
realized) after the date of the Company Balance Sheet other than in the ordinary course of
business.
(d) The Acquiror has been furnished by the Company true and complete copies of (i) all income
tax audit reports, statements of deficiencies, closing or other agreements received by or on behalf
of the Company or any Subsidiary relating to Taxes, and (ii) all federal, state and foreign income
or franchise tax returns and state sales and use tax Returns for or including the Company and its
Subsidiaries for all periods since the Company’s and such Subsidiaries’ inception.
-26-
(e) Neither the Company nor any Subsidiary nor any other person on their behalf has (i)
requested any extension of time with which to file any Tax Return, which Tax Return has since not
been filed, (ii) granted any extension for the assessment or collection of Taxes, which Taxes have
not since been paid, or (iii) granted to any person any power of attorney that is currently in
force with respect to any Tax matter.
(f) No audit of the Returns of or including the Company and its Subsidiaries by a Governmental
Entity or Taxing Authority is in process, threatened or, to the Company’s or the Selling
Stockholders’ knowledge, pending (either in writing or orally, formally or informally). No
deficiencies exist or have been asserted (either in writing or orally, formally or informally) or
are expected to be asserted with respect to Taxes of the Company or any of its Subsidiaries, and
the Company has not received notice (either in writing or orally, formally or informally) nor does
it expect to receive notice that it or any Subsidiary has not filed a Return or paid Taxes required
to be filed or paid. Neither the Company nor any Subsidiary is a party to any action or proceeding
for assessment or collection of Taxes, nor has such event been asserted or threatened (either in
writing or orally, formally or informally) against the Company, any Subsidiary or any of their
respective assets. No waiver or extension of any statute of limitations is in effect with respect
to Taxes or Returns of the Company or any Subsidiary.
(g) The Company and its Subsidiaries are not (nor have they ever been) parties to any tax
sharing agreement.
(h) No Subsidiary of the Company is or has been a United States real property holding
corporation within the meaning of Section 897(c)(2) of the U.S. Internal Revenue Code of 1986, as
amended (the “Code”) during the applicable period specified in Section 897(c)(1)(A)(ii) of
the Code. Neither the Company nor any Subsidiary has agreed to, nor is it required to make, other
than by reason of the Purchase, any adjustment by reason of, a change in accounting method.
(i) Neither the Company nor any Subsidiary (i) is subject to any rulings of any Taxing
Authority, or has entered into any written and legally binding agreement or is currently under
negotiations to enter into any such agreements with any Taxing Authority, that would affect the
situation of any of the Company or the Subsidiaries in any time period ending after the Closing
Date; (ii) has made any commitment or entered into any agreement or taken any action resulting in a
Tax deferral or Tax deferral liability (including any agreement (e.g., an installment sale
agreement) that will result in Tax liability after the Closing Date attributable to a transaction
occurring prior to the Closing Date); (iii) benefits from a specific Tax regime subordinated to the
respect of any undertaking whatsoever; (iv) has waived any statute of limitations in respect of
Taxes, or agreed to any extension of time with respect to a Tax assessment or deficiency.
(j) The Tax credits (including the French research tax credit) and Tax losses reported in the
Tax returns of the Company and of the Subsidiaries are valid and will not be affected by the
transactions contemplated by this Agreement.
(k) All transactions and agreements between the Company and the Subsidiaries have been entered
into and have been or are being performed at arm’s length and
-27-
any cash disbursement related thereto were paid (x) in accordance with French Tax law, (y) in
consideration of true and actual services, and (z) no tax reassessment might occur or penalties
might be paid in this respect. The Company and the Subsidiaries have adopted an appropriate
transfer pricing policy in compliance with French and U.S. Tax Laws, where applicable, and have all
the necessary documents to evidence such compliance.
(l) The Company Disclosure Schedule contains accurate and complete information regarding the
Company’s and its Subsidiaries’ net operating losses for Tax purposes. The Company and its
Subsidiaries have no net operating losses and credit carryovers or other tax attributes currently
subject to limitation under applicable Tax laws.
(m) Neither the Company nor any Subsidiary will recognize or become responsible for any Tax or
social contribution amount with respect to the net exercise of the Company Warrants and sale of the
Company Capital Stock by the Selling Stockholders or otherwise in connection with the consummation
of the transactions contemplated by this Agreement.
2.16 Employee Benefit Plans.
(a) Section 2.16 of the Company Disclosure Schedule lists, with respect to the Company and
each Subsidiary, where applicable (i) all employee benefit plans, programs, agreements and
policies, (ii) each loan to a non-officer employee in excess of €10,000 and each loan to an
officer, director, member of the Management Board or member of the Supervisory Board, (iii) all
stock option, stock purchase, phantom stock, stock appreciation right and other equity based plans,
programs, arrangements or agreements, (iv) all supplemental retirement, severance, sabbatical,
medical, dental, vision care, disability, employee relocation, cafeteria benefit, time savings
accounts or dependent care, life insurance or accident insurance plans, programs, arrangements or
agreements, (v) all leave or other time off plans, programs, policies, arrangements or agreements,
(vi) all alternative work schedules (including those deviating from the 35 hour work week for
French employees), plans, programs, policies, arrangements or agreements (vii) all contracts and
agreements relating to employment, consulting or other compensation arrangements that provide for
annual compensation in excess of €100,000, all collective bargaining employment agreements, and
all change in control, termination and severance plans, programs, arrangements and agreements with
any of the officers, directors, members of the Management Board or members of the Supervisory Board
or employees of the Company or its Subsidiaries (other than, in each case, any such contract or
agreement that is terminable by the Company or its Subsidiary at will or without penalty or other
adverse consequence), (viii) all bonus, pension, profit sharing, savings (including salary savings
accounts), deferred compensation and other incentive plans, programs, arrangements and agreements,
(ix) all sick leave, vacation pay, salary continuation for disability, hospitalization, medical
insurance, life insurance and scholarship plans and programs maintained by the Company or any
Subsidiary or to which the Company or any Subsidiary contributed or is obligated to contribute for
current or former employees of the Company or any Subsidiary, (x) other fringe or employee benefit
plans, programs, arrangements or agreements that apply to senior management of the Company or any
Subsidiary and that do not generally apply to all employees, and (xi) any current or former
employment or executive compensation or severance agreements, written or otherwise, as to which
unsatisfied obligations of the Company or any
-28-
Subsidiary of greater than €10,000 remain for the benefit of, or relating to, any present
or former employee, consultant, officer, director, member of the Management Board or member of the
Supervisory Board of the Company or any Subsidiary (collectively, the “Company Plans”).
(b) Correct and complete copies of the following documents, with respect to each of the
Company Plans, have been made available or delivered to the Acquiror by the Company, to the extent
applicable: (i) any plans, all amendments thereto and related trust documents, insurance contracts
or other funding arrangements, and amendments thereto; (ii) summary plan descriptions; (iii)
written communications to employees relating to the Company Plans.
(c) The Company Plans have been maintained in all material respects in accordance with their
terms and with all provisions of applicable law and regulations. No fiduciary has any liability
for breach of fiduciary duty or any other failure to act or comply in connection with the
administration or investment of the assets of any Company Plan.
(d) The consummation of the transactions contemplated by this Agreement will not in themselves
(i) entitle any current or former employee or other service provider of the Company or any
Subsidiary to severance benefits or any other similar payment (including, without limitation,
unemployment compensation, golden parachute or bonus), except as expressly provided in this
Agreement, or (ii) accelerate the time of payment or vesting of any such benefits, or increase the
amount of compensation due any such employee or service provider.
(e) There has been no amendment to, written interpretation or announcement (whether or not
written) by the Company or any Subsidiary relating to, or change in participation or coverage
under, any Company Plan which would materially increase the expense of maintaining such Plan above
the level of expense incurred with respect to that Plan for the most recent fiscal year included in
the Company’s financial statements.
2.17 Certain Agreements Affected by the Purchase. Neither the execution and delivery
of this Agreement nor the consummation of the transactions contemplated hereby will in themselves
(i) result in any payment (including, without limitation, severance, unemployment compensation,
golden parachute, bonus or otherwise) becoming due to any officer, director, member of the
Management Board or member of the Supervisory Board or employee of the Company or any of its
Subsidiaries, (ii) materially increase any employee benefits otherwise payable by the Company, or
(iii) result in the acceleration of the time of payment or vesting of any such employee benefits.
2.18 Employee Matters.
(a) Disclosure Schedule Section 2.18(a) sets forth a complete and accurate list of all labor
or collective bargaining agreements to which the Company or any Subsidiary is a party or that
pertain to any employees of the Company or any of the Subsidiaries and sets forth the name of the
current employee representative or members of the works council, as applicable, as well as a
description of the process for electing such representative or works council members, as
applicable. The Company has delivered or otherwise made available to the
-29-
Acquiror true, correct and complete copies of any labor or collective bargaining agreements
listed in Section 2.18(a) of the Company Disclosure Schedule, together with all amendments,
modifications or supplements thereto.
(b) No employees are represented by any labor organization and no trade union has designated
any employee of the Company or any Subsidiary as its delegate. No labor organization or group of
employees has made a pending demand for recognition, and there are no representation proceedings or
petitions seeking a representation proceeding presently pending or, to the knowledge of the Company
and the Selling Stockholders, threatened to be brought or filed. There is no activity intended to
result in the appointment of a union delegate involving the Company or any of the Subsidiaries
pending, or to the knowledge of the Company and the Selling Stockholders, threatened by any labor
organization or group of employees.
(c) There are no (i) strikes, work stoppages, slowdowns, lockouts or arbitrations, or (ii)
material grievances or other labor disputes pending or, to the knowledge of the Company and the
Selling Stockholders, threatened against or involving the Company or any of the Subsidiaries.
There are no unfair labor practice charges, grievances or complaints pending or, to the knowledge
of the Company and the Selling Stockholders, threatened by or on behalf of any employee or group of
employees.
(d) There are no complaints, charges or claims against the Company or any of the Subsidiaries
pending or, to the knowledge of the Company and the Selling Stockholders, threatened that could be
brought or filed with any Governmental Entity based on, arising out of, in connection with or
otherwise relating to the employment or termination of employment of or failure to employ, any
individual. There are no pending claims against the Company or any of its Subsidiaries under any
workers compensation plan or policy or for long term disability. Each of the Company and the
Subsidiaries is in material compliance with all laws and the applicable collective bargaining
agreement(s) relating to the employment of labor, including all such laws relating to terms and
conditions of employment, employment practices, wages, hours, collective bargaining, works council,
security and work condition council, personal delegates, elections of employee representatives,
discrimination, civil rights, safety and health, workers’ compensation, the collection and payment
of withholding and/or social security taxes and any similar tax, and the collection, use and
confidentiality of their employees’ personal information except for immaterial non-compliance, and
is otherwise not engaged in any unfair labor practice. The French DADS forms for the calendar
years 2003, 2004 and 2005 were prepared and filed in accordance with all legal requirements.
(e) All employment contracts to which the Company is a party or by which it is bound were
entered into under ordinary and customary conditions, and no special benefits or entitlements have
been agreed to which are in excess of the mandatory requirements of law or the applicable
collective bargaining agreements, unilateral commitments or established custom or usage that create
any obligations in excess of the mandatory requirements of law or the applicable collective
bargaining agreements. There are no contracts, plans or arrangements covering directors or
employees or former directors or employees of the Company which contain any “change of control” or
similar provisions.
-30-
(f) All payments due to employees have been made or properly recorded as a liability on the
books of the Company, including, if applicable, those with respect to employees’ profit sharing
(participation des salariés). Since, but not including, June 30, 2006, the Company has not (i)
paid or agreed to pay any bonuses or made or agreed to make any increase in the rate of wages,
salaries or other remuneration of any of its directors or its employees generally or any specific
group or category of its employees, other than in the ordinary course of business and in a manner
consistent with past practices or as dictated by the mandatory requirements of law or the
applicable collective bargaining agreements, or pursuant to existing contractual requirements, or
(ii) changed its hiring or termination policies or practices in any material respect. The Company
is not liable for any payment to any of its former employees in respect of salaries, indemnity of
any nature whatsoever or any other sum which may be due in respect of the termination of any
employment contract.
(g) Section 2.18(g) of the Company Disclosure Schedule sets forth an accurate and complete
list of the entire workforce of the Company and the Subsidiaries, including the names, duration of
employment agreement, salary, benefits and dates of hire of all employees of the Company and the
Subsidiaries, and sets forth a list of all employees who are currently on a leave of absence
(whether paid or unpaid), the reasons therefor, the expected return date, and whether reemployment
of such employee is guaranteed by contract or statute, and a list of all employees who have
requested a leave of absence to commence at any time after the date of this Agreement, the reason
therefor, the expected length of such leave, and whether reemployment of such employee is
guaranteed by contract or statute. Such list also sets forth a list of all employees that are on a
non-standard work schedule and the reasons therefore and a description of such schedule. The
Company has no knowledge of any plans by any employee to go on a leave of absence. There are no
claims pending or threatened against the Company or any Subsidiary with respect to such leaves of
absence or non-standard work schedules. None of the Company’s or its Subsidiaries’ employees have
given notice of resignation, or have indicated any opposition to the legal devolution to the
Company or its Subsidiary of such employee’s rights to all or part of the Company’s and its
Subsidiaries’ Intellectual Property. The employees identified as key employees on a confidential
attachment to Section 2.18(g) of the Company Disclosure Schedule (the “Key Employees”) are
the key employees of the Company and the Company and the Selling Stockholders have no knowledge
that such Key Employees do not wish to become employees of the Acquiror and continue working in the
Company’s business following the Closing Date.
(h) No employee or former employee of the Company or any Subsidiary has suffered, is suffering, or may reasonably be expected to suffer from any chronic injury or illness resulting from
exposure to any hazardous processes used in connection with the business of the Company or its
Subsidiaries or present at the place of such business, and the Company has not received written
notice from any Governmental Entity that any such employee or former employee has filed a claim for
compensation or indemnity in respect of such exposure.
(i) All settlement agreements entered into by the Company or any Subsidiary with former
employees are valid and constitute valid waivers by both the Company or such Subsidiary and the
former employee as to potential disputes with respect to the subject matter of such settlement
agreements.
-31-
2.19 Material Contracts.
(a) Subsections (i) through and including (ix) of Section 2.19(a) of the Company Disclosure
Schedule contain a list of all contracts and agreements to which the Company or any Subsidiary is a
party and that are material to the business, results of operations, or condition (financial or
otherwise), of the Company and the Subsidiaries taken as a whole (such contracts, agreements and
arrangements as are required to be set forth in Section 2.19(a) of the Company Disclosure Schedule
being referred to herein collectively as the “Material Contracts”). Material Contracts
shall include, without limitation, the following and shall be categorized in the Company Disclosure
Schedule as follows:
(i) each contract and agreement (other than routine purchase orders and pricing quotes in the
ordinary course of business covering a period of less than 1 year) for the purchase of inventory,
spare parts, other materials or personal property with any supplier or for the furnishing of
services to the Company or any Subsidiary under the terms of which the Company or any Subsidiary:
(A) paid or otherwise gave consideration of more than €50,000 in the aggregate during the most
recently completed calendar year, (B) is likely to pay or otherwise give consideration of more than
€50,000 in the aggregate during the current calendar year, (C) is likely to pay or otherwise
give consideration of more than €50,000 in the aggregate over the remaining term of such
contract, or (D) cannot be cancelled by the Company or such Subsidiary without penalty or further
payment of less than €5,000;
(ii) each customer contract and agreement (other than routine purchase orders, pricing quotes
with open acceptance and other tender bids, in each case, entered into in the ordinary course of
business and covering a period of less than one year) to which the Company or any Subsidiary is a
party which (A) involved consideration of more than €50,000 in the aggregate during the most
recently completed calendar year, (B) is likely to involve consideration of more than €50,000 in
the aggregate during the current calendar year, (C) is likely to involve consideration of more than
€50,000 in the aggregate over the remaining term of the contract, or (D) cannot be cancelled by
the Company or such Subsidiary without penalty or further payment of less than €5,000;
(iii) (A) all distributor, manufacturer’s representative, broker, franchise, agency and dealer
contracts and agreements to which the Company or any Subsidiary is a party (specifying on a matrix,
in the case of distributor agreements, the name of the distributor, product, territory, termination
date and exclusivity provisions) and (B) all sales promotion, market research, marketing and
advertising contracts and agreements to which the Company or any Subsidiary is a party which: (1)
involved consideration of more than €50,000 in the aggregate during the most recently completed
calendar year, (2) are likely to involve consideration of more than €50,000 in the aggregate
during the current calendar year, or (3) are likely to involve consideration of more than
€50,000 in the aggregate over the remaining term of the contract;
(iv) all management contracts with independent contractors or consultants (or similar
arrangements) to which the Company or any Subsidiary is a party;
-32-
(v) all contracts and agreements (excluding routine checking account overdraft agreements
involving xxxxx cash amounts) under which the Company or any Subsidiary has created, incurred,
assumed or guaranteed (or may create, incur, assume or guarantee) indebtedness or under which the
Company or any Subsidiary has imposed (or may impose) a security interest or lien on any of their
respective assets, whether tangible or intangible, to secure indebtedness;
(vi) all contracts and agreements that limit the ability of the Company or any Subsidiary or,
after the Closing, the Acquiror or any of its affiliates, to compete in any line of business or
with any person or in any geographic area or during any period of time, or to solicit any customer
or client;
(vii) all contracts and agreements between or among the Company or any Subsidiary, on the one
hand, and any affiliate of the Company (other than a wholly owned subsidiary), on the other hand:
(viii) all contracts and agreements to which the Company or any Subsidiary is a party under
which it has agreed to supply products to a customer at specified prices, whether directly or
through a specific distributor, manufacturer’s representative or dealer; and
(ix) all other contracts or agreements (A) which are material to the Company and its
Subsidiaries or the conduct of their respective businesses, (B) the absence of which would have a
Material Adverse Effect on the Company, (C) which are believed by the Company to be of unique value
even though not material to the business of the Company, or (D) which contain material obligations
remaining to be performed by the Company or any Subsidiary, or which contain material liabilities
of the Company or any Subsidiary that remain unsatisfied (including any material contracts or
agreements that have no limitation on liability of the Company or any Subsidiary).
(b) Except as would not, individually or in the aggregate, have a Material Adverse Effect on
the Company, each Company license and each Material Contract is a legal, valid and binding
agreement, and none of the Company licenses or Material Contracts is in default by its terms or has
been cancelled by the other party; the Company and the Subsidiaries are not in receipt of any claim
of default under any such agreement; and none of the Company or any of the Subsidiaries anticipates
any termination or change to, or receipt of a proposal with respect to, any such agreement as a
result of the Purchase or otherwise. The Company has furnished the Acquiror with true and complete
copies of all such agreements together with all amendments, waivers or other changes thereto.
There are no material commitments or obligations to the Company’s customers that are not expressly
set forth in the written contracts furnished by the Company for review by the Acquiror.
2.20 Interested Party Transactions. Neither the Company nor any Subsidiary is
indebted to any officer, director, member of the Management Board, member of the Supervisory Board,
employee or agent of the Company or any Subsidiary (except for amounts due as normal salaries and
bonuses and in reimbursement of ordinary expenses), and no such person is indebted to the Company
or any Subsidiary. To the Company’s and the Selling
-33-
Stockholders’ knowledge, none of the Company or any Subsidiary’s officers, directors, members
of the Management Board or members of the Supervisory Board, or any members of their immediate
families, are, directly or indirectly, indebted to the Company or any Subsidiary (other than in
connection with purchases of the Company or Subsidiary’s stock) or have any direct or indirect
ownership interest in any firm or corporation with which the Company or any Subsidiary is
affiliated or with which the Company or any Subsidiary has a business relationship, or any firm or
corporation which competes with the Company or any Subsidiary except that officers, directors,
members of the Management Board and members of the Supervisory Board and/or stockholders of the
Company or any Subsidiary may own stock in (but not exceeding two percent of the outstanding
capital stock of) any publicly traded companies that may compete with the Company or any
Subsidiary. To the Company’s and the Selling Stockholders’ knowledge, none of the Company or any
Subsidiary’s officers, directors, members of the Management Board or members of the Supervisory
Board or any members of their immediate families are, directly or indirectly, interested in any
material contract with the Company or any Subsidiary. Neither the Company nor any Subsidiary is a
guarantor or indemnitor of any indebtedness of any other person, firm or corporation.
2.21 Insurance. The Company and each of its Subsidiaries have policies of insurance
and bonds of the type and in amounts customarily carried by persons conducting businesses or owning
assets similar to those of the Company and its Subsidiaries. There is no material claim pending
under any of such policies or bonds as to which coverage has been questioned, denied or disputed by
the underwriters of such policies or bonds. All premiums due and payable under all such policies
and bonds have been paid and the Company and its Subsidiaries are otherwise in compliance with the
terms of such policies and bonds. The Company and the Selling Stockholders have no knowledge of
any threatened termination of, or material premium increase with respect to, any of such policies.
2.22 Compliance With Laws. Each of the Company and its Subsidiaries has complied
with, are not in violation of, and have not received any notices of violation with respect to, any
applicable statute, law or regulation with respect to the conduct of its business, or the ownership
or operation of its business, except for such violations or failures to comply as would not
reasonably be expected to have a Material Adverse Effect on the Company.
2.23 Minute Books. The minute books of the Company and its Subsidiaries provided to
the Acquiror contain a complete summary of all meetings of members of the supervisory board and
stockholders or actions by written consent, when applicable, since the time of incorporation of the
Company and the respective Subsidiaries through the date of this Agreement, and all the reports of
the Management Board with respect to the stockholder meetings reflect all transactions referred to
in the minutes of such stockholders’ meetings accurately in all material respects.
2.24 Complete Copies of Materials. The Company has delivered or made available true
and copies of each document which has been requested in writing by the Acquiror or its counsel in
connection with their legal and accounting review of the Company and its Subsidiaries.
-34-
2.25 Brokers’ and Finders’ Fees. The Company has not incurred, nor will it incur,
directly or indirectly, any liability for brokerage or finders’ fees or agents’ commissions or
investment bankers’ fees or any similar charges in connection with this Agreement or any
transaction contemplated hereby.
2.26 Inventory. The inventories shown on the Financial Statements or thereafter
acquired by the Company, consisted of items of a quantity and quality usable or salable in the
ordinary course of business. Since the Company Balance Sheet Date, the Company has continued to
replenish inventories in a normal and customary manner consistent with past practices. The Company
has not received written or oral notice that it will experience in the foreseeable future any
difficulty in obtaining, in the desired quantity and quality and at a reasonable price and upon
reasonable terms and conditions, the raw materials, supplies or component products required for the
manufacture, assembly or production of its products. The values at which inventories are carried
reflect the inventory valuation policy of the Company, which is consistent with its past practice
and in accordance with generally accepted accounting principles applied on a consistent basis.
Since the Company Balance Sheet Date, due provision was made on the books of the Company in the
ordinary course of business consistent with past practices to provide for all slow-moving,
obsolete, or unusable inventories to their estimated useful scrap values and such inventory
reserves are adequate to provide for such slow-moving, obsolete or unusable inventory and inventory
shrinkage. The Company does not currently have any inventory held by its distributors.
2.27 Accounts Receivable.
(a) The Company has made available to the Acquiror a list of all accounts receivable of the
Company and each Subsidiary reflected on the Financial Statements (“Accounts Receivable”)
along with a range of days elapsed since invoice.
(b) All Accounts Receivable of the Company and its Subsidiaries arose in the ordinary course
of business, are carried at values determined in accordance with French GAAP consistently applied
and reconciled to be in accordance with U.S. GAAP. No person has any lien on any of such Accounts
Receivable and no request or agreement for deduction or discount has been made with respect to any
of such Accounts Receivable.
2.28 Customers and Suppliers. As of the date hereof and as of the Closing Date, no
customer which individually accounted for more than 5% of the Company’s gross revenues during the
12-month period preceding the date hereof, and no supplier of the Company, has cancelled or
otherwise terminated, or made any written threat to the Company to cancel or otherwise terminate
its relationship with the Company, or has at any time on or after the Company Balance Sheet Date
decreased materially its services or supplies to the Company in the case of any such supplier, or
its usage of the services or products of the Company in the case of such customer, and to the
Company’s and the Selling Stockholders’ knowledge, no such supplier or customer intends to cancel
or otherwise terminate its relationship with the Company or to decrease materially its services or
supplies to the Company or its usage of the services or products of the Company, as the case may
be. As of the date hereof and as of the Closing Date, no customer which individually accounted for
more than 5% of the Company’s gross revenues during the 12 month period preceding the Closing Date,
has cancelled or otherwise terminated,
-35-
or made any written threat to the Company to cancel or otherwise terminate, for any reason,
including without limitation the consummation of the transactions contemplated hereby, its
relationship with the Company, and to the Company’s and the Selling Stockholders’ knowledge, no
such customer intends to cancel or otherwise terminate its relationship with the Company or to
decrease materially its usage of the services or products of the Company. The Company has not
knowingly breached, so as to provide a benefit to the Company that was not intended by the parties,
any agreement with, or engaged in any fraudulent conduct with respect to, any customer or supplier
of the Company. To the Company’s and the Selling Stockholders’ knowledge, STMicroelectronics has
not been eligible for or received the benefit of any Tax credit (including research and development
credits) or other subsidy or rebate from a Governmental Entity or other third party with respect to
any of the amounts paid by STMicroelectronics to the Company and its Subsidiaries since January 1,
2005. To the Company’s and the Selling Stockholders’ knowledge, STMicroelectronics has not been
eligible for or received the benefit of any Tax credit (including research and development credits)
or other subsidy or rebate from a Governmental Entity or other third party with respect to more
than 5% of the amounts paid by STMicroelectronics to the Company and its Subsidiaries during the
period from January 1, 2002 through December 31, 2004.
2.29 No Commitments Regarding Future Products. The Company has made no sales to
customers that are contingent upon providing future enhancements of existing products, to add
features not presently available on existing products or to otherwise enhance the performance of
its existing products other than beta or similar arrangements pursuant to which the Company’s
customers from time to time test or evaluate products. The products the Company has delivered to
customers substantially comply with published specifications for such products and the Company has
not received material complaints from customers about its products that remain unresolved. Section
2.29 of the Company Disclosure Schedule accurately sets forth a complete list of products in
development.
2.30 Forecasts. The estimates, projections, forecasts or plans delivered by the
Selling Stockholders, the Company or any of their respective advisors to the Acquiror during its
due diligence of the Company and its Subsidiaries were prepared in good faith, but there is no
assurance given that they will turn out to have been accurate predictions of future events.
2.31 Representations Complete. None of the representations or warranties made by the
Selling Stockholders herein or in any Schedule hereto, including the Company Disclosure Schedule,
or certificate furnished by the Selling Stockholders pursuant to this Agreement, when all such
documents are read together in their entirety, contains or will contain at the Closing any untrue
statement of a material fact, or omits or will omit at the Closing to state any material fact
necessary in order to make the statements contained herein or therein, in the light of the
circumstances under which made, not misleading.
2.32 No Other Representations and Warranties Relating to the Company. Except as set
forth herein or in any Schedule hereto, including the Company Disclosure Schedule, or certificate
furnished by the Selling Stockholders pursuant to this Agreement, the Selling Stockholders make no
other representation or warranty.
-36-
2.33 Fraud and Intentional Misrepresentation. To the knowledge of each Selling
Stockholder, none of the Selling Stockholders has engaged in fraud or made any intentional
misrepresentation in connection with the transactions contemplated by this Agreement.
SECTION THREE
3. Representations and Warranties of Selling Stockholders.
Each Selling Stockholder hereby represents and warrants to the Acquiror, as to himself,
herself or itself, as the case may be, as follows:
3.1 Power, Authorization and Validity. The Selling Stockholder has all requisite
legal and, to the extent applicable, corporate power, and authority to enter into and perform its
obligations under this Agreement and to consummate the transactions contemplated hereby. The
execution, delivery and performance of this Agreement and the consummation of the transactions
contemplated hereby have been duly and validly approved and authorized by all necessary action,
including, if applicable, corporate action, by or on behalf of such Selling Stockholder. This
Agreement has been duly executed and delivered by such Selling Stockholder or its attorney-in-fact
pursuant to a valid power of attorney and constitutes a valid and binding obligation of the Selling
Stockholder, subject to the laws of general application relating to bankruptcy, insolvency and the
relief of debtors and rules of law governing specific performance, injunctive relief and equitable
remedies. No consent, approval, order or authorization of, or registration, declaration or filing
with, any Governmental Entity, is required by or with respect to the Selling Stockholder in
connection with the execution and delivery of this Agreement by the Selling Stockholder or the
consummation by the Selling Stockholder of the transactions contemplated hereby.
3.2 Title to Stock. The Selling Stockholder is the sole owner of the Shares reflected
next to such Selling Stockholder’s name on Exhibit A and has or will have, as of the
Closing, good, valid and marketable title to such Stock free and clear of all restrictions, claims,
liens, charges, encumbrances and equities whatsoever. The Selling Stockholder represents that he,
she or it has or will have, as of the Closing, full right, power and authority to sell, transfer
and deliver such Stock to the Acquiror, and, upon delivery of the certificate or certificates
therefor duly endorsed for transfer to the Acquiror and the Acquiror’s payment for and acceptance
thereof, will transfer to the Acquiror good, valid and marketable title thereto free and clear of
any restriction, claim, lien, charge, encumbrance or equity whatsoever. The Selling Stockholder is
not party to any voting trust, agreement or arrangement affecting the exercise of the voting rights
of the Shares, other than the Company Shareholders Agreements (as defined below), all of which
agreements terminate by their terms at the Closing. There is no action, proceeding, claim or, to
the Selling Stockholder’s knowledge, investigation against the Selling Stockholder or the Selling
Stockholder’s assets, properties or, as applicable, any of the Selling Stockholder’s respective
officers, directors, members of the Management Board or members of the Supervisory Board, pending
or, to the Selling Stockholder’s knowledge, threatened, at law or in equity, or before any court,
arbitrator or other tribunal, or before any administrative law judge, hearing officer or
administrative agency relating to or in any other manner impacting upon the Shares held by such
Selling Stockholder.
-37-
3.3 No Violation. Other than those rights waived pursuant to Section 6.15, the
execution, delivery and performance of this Agreement, and the consummation of the Purchase and the
other transactions contemplated by this Agreement do not and will not conflict with or result in a
violation of the Applicable Organizational Documents, the shareholders agreement among the Company
and certain of its shareholders dated as of March 19, 2003 (the “Shareholders Agreement”),
the shareholders agreement among the Company and certain of its shareholders dated as of May 20,
2003 (the “First Warrant Shareholders Agreement”), the shareholders agreement among the
Company and four of its employee-shareholders dated as of April 30, 2001 (the “Special
Employee-Shareholders Agreement”), the shareholders agreement among the Company and certain of
its employee-shareholders dated as of March 28, 2001 (the “Main Employee-Shareholders
Agreement” and collectively, with the Shareholders Agreement, the First Warrant Shareholders
Agreement, the Special Employee-Shareholders Agreement and the Main Employee- Shareholders
Agreement, the “Company Shareholders Agreements”), or partnership agreement of the Selling
Stockholder, or conflict with, or (with or without notice or lapse of time, or both) result in a
termination, breach, impairment or violation of, or constitute a default or result in the creation
or imposition of any lien, charge or encumbrance upon any of the Selling Stockholder’s Shares
under, (a) any instrument, indenture, lease, mortgage or other agreement or contract to which the
Selling Stockholder is a party or to which such Selling Stockholder or any of such Selling
Stockholder’s assets or properties may be subject or (b) any federal, state, local or foreign
judgment, writ, decree, order, ordinance, statute, rule or regulation applicable to the Selling
Stockholder or the Selling Stockholder’s assets or properties. The consummation of the Purchase
and the other transactions contemplated by this Agreement will not require the consent of any third
person with respect to the rights, licenses, franchises, leases or agreements of the Selling
Stockholder.
3.4 Acknowledgment. The Selling Stockholder hereby acknowledges that the Selling
Stockholder has read this Agreement, the Escrow Agreement and the other documents to be delivered
in connection with the consummation of the transactions contemplated hereby and has made an
independent examination of the transactions contemplated hereby (including the tax consequences
thereof). The Selling Stockholder acknowledges that the Selling Stockholder has had an opportunity
to consult with and has relied solely upon the advice, if any, of the Selling Stockholder’s legal
counsel, financial advisors, or accountants with respect to the transactions contemplated hereby to
the extent the Selling Stockholder has deemed necessary, and has not been advised or directed by
the Acquiror, the Company or their respective legal counsel or other advisors in respect of any
such matters and has not relied on any such parties in connection with this Agreement and the
transactions contemplated hereby.
3.5 Investment Representations. Either Selling Stockholder is located outside the
United States at the time such Selling Stockholder enters into this Agreement or otherwise
committed itself to do so and shall not sell, transfer or otherwise dispose of the Acquiror Stock
it receives in this transaction for a period of at least one year following the Closing Date, or:
(a) Selling Stockholder is sophisticated in transactions of this type and capable of
evaluating the merits and risks of the transactions described herein and has the capacity to
protect its own interests. Selling Stockholder has not been formed solely for the purpose of
entering into the transactions described herein and is acquiring the Acquiror Stock for
-38-
investment for its own account, not as a nominee or agent, and not with the view to, or for
resale, distribution thereof, in whole or in part.
(b) Selling Stockholder has not and does not presently intend to enter into any contract,
undertaking, agreement or arrangement with any person or entity to sell, transfer or pledge the
Acquiror Stock, other than to an affiliate, partner or former partner of such Selling Stockholder
in compliance with the Securities Act.
(c) Selling Stockholder acknowledges its understanding that the Acquiror intends to distribute
the Acquiror Stock pursuant to a private placement exempt from registration under the Securities
Act. In furtherance thereof, Selling Stockholder represents and warrants that it is an “accredited
investor” as that term is defined in Rule 501 of Regulation D under the Securities Act, has the
financial ability to bear the economic risk of its investment and has adequate means for providing
for its current needs and personal contingencies.
(d) Selling Stockholder agrees that it shall not sell or otherwise transfer any of the
Acquiror Stock unless (i) pursuant to registration under the Securities Act, as contemplated by
Section 6.17, (ii) pursuant to Rule 144 (or any successor rule) under the Securities Act, (iii) to
an affiliate, partner or former partner of such Selling Stockholder in compliance with the
Securities Act, or (iv) pursuant to an opinion of counsel reasonably satisfactory to the Acquiror
that no violation of the Securities Act will be involved in such transfer. Selling Stockholder
fully understands that none of the Acquiror Stock issued in connection with the Purchase has been
registered under the Securities Act or under the securities laws of any applicable state or other
jurisdiction and, therefore, cannot be resold, pledged, assigned or otherwise disposed of unless
subsequently registered under the Securities Act and under the applicable securities laws of such
states or jurisdictions or an exemption from such registration is available. Selling Stockholder
understands the lack of liquidity and restrictions on transfer of the Acquiror Stock and that this
investment is suitable only for a person or entity of adequate financial means that has no need for
immediate liquidity of this investment and that can afford a total loss of its investment.
SECTION FOUR
4. Representations and Warranties of Acquiror.
Except as disclosed in a document dated as of the date of this Agreement and delivered by the
Acquiror to the Company prior to the execution and delivery of this Agreement (the “Acquiror
Disclosure Schedule”), the Acquiror hereby represents and warrants to the Selling Stockholders
as follows:
4.1 Organization, Standing and Power. The Acquiror is a corporation duly organized,
validly existing and in good standing under the laws of its jurisdiction of organization. The
Acquiror has the corporate power to own its properties and to carry on its business as now being
conducted and as proposed to be conducted and is duly qualified to do business and is in good
standing in each jurisdiction in which the failure to be so qualified and in good standing would,
individually or in the aggregate, have a Material Adverse Effect on the Acquiror. The Acquiror has
delivered or made available a true and correct copy of its Charter and Bylaws each
-39-
as amended to date, to the Company or its counsel. Neither the Acquiror nor any of its
subsidiaries is in violation of any material provisions of its Charter or Bylaws or equivalent
organizational documents.
4.2 Capital Structure. The authorized capital stock of the Acquiror consists of
75,000,000 shares of Acquiror Common Stock, US$0.00015 par value, and 5,000,000 shares of Acquiror
Preferred Stock, US$0.00015 par value, of which 26,889,628 shares of Acquiror Common Stock and no
shares of Acquiror Preferred Stock were issued and outstanding as of the close of business on
October 20, 2006. All outstanding shares of capital stock of the Acquiror have been duly
authorized and validly issued, are fully paid and nonassessable. The Acquiror Common Stock
constitutes the only class of equity securities of the Acquiror or any of its subsidiaries
registered or required to be registered under the Exchange Act. The shares of Acquiror Stock to be
issued in the Purchase have been duly authorized and reserved for issuance and, when issued in
accordance with the terms of this Agreement, will be validly issued, fully paid, nonassessable and
free of any preemptive right created by statute, the Charter or Bylaws of the Acquiror or any
agreement to which the Acquiror is a party or by which it is bound.
4.3 Authority. The Acquiror has all requisite corporate power and authority to enter
into this Agreement and to consummate the transactions contemplated hereby. The execution and
delivery of this Agreement and the consummation of the transactions contemplated hereby have been
duly authorized by all necessary corporate action on the part of the Acquiror. This Agreement has
been duly executed and delivered by the Acquiror and constitutes the valid and binding obligations
of the Acquiror, subject to (i) laws of general application relating to bankruptcy, insolvency and
the relief of debtors; and (ii) rules of law governing specific performance, injunctive relief and
other equitable remedies.
4.4 No Conflict; Required Filings and Consents.
(a) The execution and delivery of this Agreement does not, and the consummation of the
transactions contemplated hereby will not, conflict with, or result in any violation of, or default
under (with or without notice or lapse of time, or both), or give rise to a right of termination,
cancellation or acceleration of any obligation or loss of a benefit under (i) any provision of the
Charter or Bylaws or other organizational documents of the Acquiror, or (ii) any material mortgage,
indenture, lease, contract or other agreement or instrument, permit, concession, franchise,
license, judgment, order, decree, statute, law, ordinance, rule or regulation applicable to the
Acquiror or its properties or assets, except where such conflicts, violations and defaults would
not, individually or in the aggregate, have a Material Adverse Effect on the Acquiror.
(b) No consent, approval, order or authorization of, or registration, declaration or filing
with, any Governmental Entity, is required by or with respect to the Acquiror, in connection with
the execution and delivery of this Agreement by the Acquiror, or the consummation by the Acquiror,
of the transactions contemplated hereby, except for (i) the filing of a Form 8-K with the U.S.
Securities Exchange Commission (the “SEC”) and National Association of Securities Dealers
(“NASD”) within 4 business days after the execution and delivery of this Agreement and
within 4 business days after the Closing Date, (ii) such consents, approvals, orders,
authorizations, registrations, declarations and filings as may be required under
-40-
the Exchange Act or the Securities Act, (iii) any filings as may be required under applicable
state securities laws and the securities laws of any foreign country, (iv) the filing with the
NASDAQ of a Notification Form for Listing of Additional Shares with respect to the shares of
Acquiror Stock issuable under the Purchase, (v) foreign investments in France, (vi) competition
law, and (vii) such other consents, authorizations, filings, approvals and registrations which, if
not obtained or made, would not, individually or in the aggregate, have a Material Adverse Effect
on the Acquiror and would not prevent, materially alter or delay any of the transactions
contemplated by this Agreement.
4.5 SEC Documents. The Acquiror has timely filed all required reports, statements and
documents with the SEC, all of which have, to the best of the Acquiror’s knowledge, complied in all
material respects with all applicable requirements of the Securities Act and the Exchange Act. The
Acquiror has made available to the Company true and complete copies of all forms, reports,
statements and documents filed with the SEC and all reports, statements and other information
provided by the Acquiror to its stockholders (collectively, the “SEC Reports”). As of
their respective dates, the SEC Reports did not contain any untrue statement of any material fact
or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.
4.6 Brokers’ and Finders’ Fees. Acquiror has not incurred, nor will it incur,
directly or indirectly, any liability for brokerage or finders’ fees or agents’ commissions or
investment bankers’ fees or any similar charges in connection with this Agreement or any
transaction contemplated hereby, other than those of RBC Capital Markets Corporation.
4.7 Financial Statements. The consolidated financial statements (including any notes
thereto) contained in the SEC Reports (i) complied as to form in all material respects with the
published rules and regulations of the SEC with respect thereto, (ii) were prepared in accordance
with U.S. GAAP applied on a consistent basis throughout the periods indicated (except as may be
indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q
or 8-K promulgated by the SEC) and (iii) each presented fairly, in all material respects, the
consolidated financial position of the Acquiror and its consolidated subsidiaries as of the
respective dates thereof and for the respective periods indicated therein, except as otherwise
noted therein (subject, in the case of unaudited statements, to normal and recurring year-end
adjustments which were not and are not expected, individually or in the aggregate, to have a
material adverse effect on the business, properties, financial condition or operating results of
the Acquiror, as such business is presently conducted). The Acquiror does not intend to correct or
restate, nor, to the Acquiror’s knowledge, is there any basis for any correction or restatement of,
any aspect of any of the consolidated financial statements contained in the SEC Reports. The
Acquiror has not had any material disagreement with any of its auditors regarding accounting
matters or policies during any of its past three full years or during the current fiscal
year-to-date which disagreements would require disclosure to the Acquiror’s Board of Directors.
The books and records of the Acquiror and each of its subsidiaries have been, and are being
maintained in all material respects in accordance with applicable legal and accounting requirements
and the consolidated financial statements contained in the SEC Reports are consistent with such
books and records.
-41-
4.8 Internal Controls. The Acquiror and each of its subsidiaries has established and
maintains, adheres to and enforces a system of internal accounting controls which are effective in
providing assurance regarding the reliability of financial reporting and the preparation of
financial statements in accordance with U.S. GAAP (including the consolidated financial statements
contained in the SEC Reports), including policies and procedures that (i) require the maintenance
of records that in reasonable detail accurately and fairly reflect in all material respects the
transactions and dispositions of the assets of the Acquiror and its subsidiaries, (ii) provide
assurance that transactions are recorded as necessary to permit preparation of financial statements
in accordance with U.S. GAAP, and that receipts and expenditures of the Acquiror and its
subsidiaries are being made only in accordance with appropriate authorizations of management and
the Board of Directors of the Acquiror and (iii) provide assurance regarding prevention or timely
detection of unauthorized acquisition, use or disposition of the material assets of the Acquiror
and its subsidiaries. Neither the Acquiror nor any of its subsidiaries (including any employee
thereof) nor, to the Acquiror’s knowledge, the Acquiror’s independent auditors, has identified or
been made aware of (i) any significant deficiency or material weakness in the system of internal
accounting controls utilized by the Acquiror and its subsidiaries, (ii) any fraud, whether or not
material, that involves the Acquiror’s management or other employees who have a role in the
preparation of financial statements or the internal accounting controls utilized by the Acquiror
and its subsidiaries or (iii) any claim or allegation regarding any of the foregoing.
4.9 Changes. Since the date of the Acquiror’s most recent quarterly report on Form
10-Q or most recent periodic report on Form 8-K filed with the SEC, (i) there has not been any
Acquiror development that has not otherwise been publicly disclosed that would have a material
adverse effect on the business, properties, financial condition or operating results of the
Acquiror, as such business is presently conducted, (ii) the Acquiror and its subsidiaries have not
incurred any debts or liabilities except for debts or liabilities incurred in the ordinary course
of business and except in connection with obligations under contracts and commitments incurred in
the ordinary course of business, (iii) the Acquiror and its subsidiaries have not entered into or
terminated any of its material contracts and (iv) there has not been any change in the assets,
liabilities, financial condition or operating results of the Acquiror and its subsidiaries from
that reflected in the consolidated financial statements included with the most recent quarterly
report on Form 10-Q, except changes in the ordinary course of business that have not been, in the
aggregate, materially adverse.
4.10 Registration Rights. Except as contemplated hereby, the Acquiror has not granted
or agreed to grant any registration rights, including piggy-back rights, to any person or entity.
4.11 Registration of Common Stock. Acquiror Common Stock is registered pursuant to
Section 12(g) of the Exchange Act and is listed on NASDAQ, and the Acquiror has taken no action
with the intention of, or likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act or delisting the Acquiror Common Stock from NASDAQ. The Acquiror has
not been notified by NASDAQ of any action or potential action by NASDAQ or of any violation of any
NASDAQ Rules that could result in the delisting of Acquiror Common Stock from NASDAQ.
-42-
SECTION FIVE
5. Conduct Prior to the Closing. Throughout this Section 5, each of the covenants of
the Selling Stockholders shall be made on a several but not joint basis, except as specifically
identified herein.
5.1 Conduct of Business of Company. During the period from the date of this Agreement
and continuing until the earlier of the termination of this Agreement or the Closing, the Selling
Stockholders other than SGAM AI, shall cause the Company (except to the extent expressly
contemplated by this Agreement or as consented to in writing by the Acquiror, such consent not to
be unreasonably withheld or delayed), to carry on its and its Subsidiaries’ business in the usual,
regular and ordinary course in substantially the same manner as heretofore conducted, to pay and to
cause its Subsidiaries to pay debts and Taxes when due, subject to the Acquiror’s consent (such
consent not to be unreasonably withheld or delayed) to the filing of material Tax Returns, to pay
or perform other obligations when due, and to use all reasonable efforts consistent with past
practice and policies to preserve intact its and its Subsidiaries’ present business organization,
keep available the services of its and its Subsidiaries’ present officers and Key Employees and
preserve its and its Subsidiaries’ relationships with customers, suppliers, distributors,
licensors, licensees, and others having business dealings with it or its Subsidiaries, to the end
that its and its Subsidiaries’ goodwill and ongoing businesses shall be unimpaired at the Closing.
The Selling Stockholders shall promptly notify the Acquiror of any event or occurrence not in the
ordinary course of the Company or its Subsidiaries’ business, and of any event which could have a
Material Adverse Effect. Without limiting the foregoing, except as expressly contemplated by this
Agreement, the Selling Stockholders other than SGAM AI shall cause the Company not to do, cause or
permit any of the following, or allow, cause or permit any of its Subsidiaries to do, cause or
permit any of the following, without the prior written consent of the Acquiror (such consent not to
be unreasonably withheld or delayed):
(a) Material Contracts. Enter into any material contract or commitment, or violate,
amend or otherwise modify or waive any of the terms of any of its Material Contracts, other than in
the ordinary course of business consistent with past practice;
(b) Issuance of Securities. Issue, deliver or sell or authorize or propose the
issuance, delivery or sale of, or purchase or propose the purchase of, any shares of its capital
stock or securities convertible into, or subscriptions, rights, warrants or options to acquire, or
other agreements or commitments of any character obligating it to issue any such shares or other
convertible securities, other than the issuance of shares of its Common Stock pursuant to the
exercise of stock options, warrants or other rights therefor outstanding as of the date of this
Agreement;
(c) Intellectual Property. Transfer to any person or entity any rights to its
Intellectual Property other than in the ordinary course of business;
(d) Exclusive Rights. Enter into or amend any agreements pursuant to which any other
party is granted exclusive marketing or other exclusive rights of any type or scope with respect to
any of its products or technology;
-43-
(e) Dispositions. Sell, lease, license or otherwise dispose of or encumber any of its
properties or assets which are material, individually or in the aggregate, to its and its
Subsidiaries’ business, taken as a whole, except in the ordinary course of business consistent with
past practice;
(f) Indebtedness. Incur any indebtedness for borrowed money or guarantee any such
indebtedness or issue or sell any debt securities or guarantee any debt securities of others;
(g) Leases. Enter into operating lease in excess of €10,000;
(h) Payment of Obligations. Pay, discharge or satisfy in an amount in excess of
€10,000 in any one case or €100,000 in the aggregate, any claim, liability or obligation
(absolute, accrued, asserted or unasserted, contingent or otherwise) arising other than in the
ordinary course of business, other than the payment, discharge or satisfaction of liabilities
reflected or reserved against in the Company Financial Statements;
(i) Capital Expenditures. Make any capital expenditures, capital additions or capital
improvements except in the ordinary course of business and consistent with past practice;
(j) Insurance. Materially reduce the amount of any material insurance coverage
provided by existing insurance policies;
(k) Termination or Waiver. Terminate or waive any right of substantial value, other
than in the ordinary course of business;
(l) Employee Benefit Plans; New Hires; Pay Increases. Adopt or amend any employee
benefit or stock purchase or option plan, or hire any new officer level employee, director level
employee, or employee at the level of a member of the Management Board or Supervisory Board (except
that it may hire a replacement for any current such level employee if it first provides the
Acquiror advance notice regarding such hiring decision), pay any special bonus or special
remuneration to any employee or officer, director, member of the Management Board or member of the
Supervisory Board, or increase the salaries or wage rates of its employees;
(m) Severance Arrangement. Grant any severance or termination pay (i) to any officer,
director, member of the Management Board or member of the Supervisory Board or (ii) to any other
employee except (A) payments made pursuant to standard written agreements outstanding on the date
of this Agreement or (B) grants which are made in the ordinary course of business in accordance
with its standard past practice;
(n) Lawsuits. Commence a lawsuit other than (i) for the routine collection of bills,
(ii) in such cases where it in good faith determines that failure to commence suit would result in
the material impairment of a valuable aspect of its business, provided that it consults with the
Acquiror prior to the filing of such a suit, or (iii) for a breach of this Agreement;
-44-
(o) Acquisitions. Acquire or agree to acquire by merging or consolidating with, or by
purchasing a substantial portion of the assets of, or by any other manner, any business or any
corporation, partnership, association or other business organization or division thereof, or
otherwise acquire or agree to acquire any assets which are material, individually or in the
aggregate, to its and its Subsidiaries’ business, taken as a whole;
(p) Taxes. Other than in the ordinary course of business, make or change any material
election in respect of Taxes, adopt or change any accounting method in respect of Taxes, file any
material Tax Return or any amendment to a material Tax Return, enter into any closing agreement
with any Taxing Authority in respect of Taxes of the Company or any Subsidiary, settle any claim or
assessment in respect of Taxes, or consent to any extension or waiver of the limitation period
applicable to any claim or assessment in respect of Taxes;
(q) Revaluation. Revalue any of its assets, including without limitation writing down
the value of inventory or writing off notes or accounts receivable other than in the ordinary
course of business;
(r) Applicable Organizational Documents. Cause or permit any amendments to its or its
Subsidiaries’ Applicable Organizational Documents, other than the changes required as a result of
the exercise of the Company Warrants;
(s) Dividends; Changes in Capital Stock. Declare or pay any dividends on or make any
other distributions (whether in cash, stock or property) in respect of any of its capital stock, or
split, combine or reclassify any of its capital stock or issue or authorize the issuance of any
other securities in respect of, in lieu of or in substitution for shares of its capital stock, or
repurchase or otherwise acquire, directly or indirectly, any shares of its capital stock except
from former employees, officers, directors, members of the Management Board, members of the
Supervisory Board and consultants in accordance with agreements providing for the repurchase of
shares in connection with any termination of service to it or its Subsidiaries;
(t) Stock Warrants, Etc. Accelerate, amend or change the period of exercisability or
vesting of options, warrants or other rights to purchase Company Capital Stock or authorize cash
payments in exchange for any options, warrants or other such rights; or
(u) Other. Take or agree in writing or otherwise to take, any of the actions
described in Sections 5.1(a) through and including (t) above, or any action which would make any of
its representations or warranties contained in this Agreement untrue or incorrect or prevent it
from performing or cause it not to perform its covenants hereunder.
5.2 No Shop.
(a) Other than in connection with (i) the exercise (if any) of the drag along right contained
in the Company Shareholders Agreements and (ii) the call option rights contained in the call option
agreements (promesses de vente) entered into prior to the date of this Agreement between certain
Selling Stockholders, as described in Section 2.8(b)(1) of the Company Disclosure Schedule (the
“Call Option Agreements”), the Selling Stockholders shall not, and the Selling Stockholders
other than SGAM AI shall cause the Company, its
-45-
Subsidiaries, all of its and their Affiliates, officers, directors, members of the Management
Board, members of the Supervisory Board, employees, representatives or agents of the Selling
Stockholders, the Company or any of the Subsidiaries (collectively, the “Representatives”)
not to, directly or indirectly, (i) discuss, knowingly encourage, negotiate, undertake, initiate,
authorize, recommend, propose or enter into, whether as the proposed surviving, merged, acquiring
or acquired corporation or otherwise, any transaction involving a merger, consolidation, business
combination, purchase or disposition of any material amount of the assets of the Company or any of
its Subsidiaries or any capital stock or other ownership interests of the Company or any of its
Subsidiaries (including, without limitation, any public offering or registration of shares of the
Company) other than the transactions contemplated by this Agreement (an “Acquisition
Transaction”), (ii) facilitate, encourage, solicit or initiate discussions, negotiations or
submissions of proposals or offers in respect of an Acquisition Transaction, (iii) furnish or cause
to be furnished, to any person, any information concerning the business, operations, properties or
assets of the Company or its Subsidiaries in connection with an Acquisition Transaction, or (iv)
otherwise cooperate in any way with, or assist or participate in, facilitate or encourage, any
effort or attempt by any other person to do or seek any of the foregoing, including without
limitation, in connection with the exercise of preemptive rights under the Company Shareholders
Agreements.
(b) The Selling Stockholders shall, and the Selling Stockholders other than SGAM AI shall
cause the Company to, notify the Acquiror orally and in writing promptly (but in no event later
than 24 hours) after receipt by any of the Selling Stockholders or the Company of any proposal or
offer from any person other than the Acquiror to effect an Acquisition Transaction or any request
for non-public information relating to the Company or any of its Subsidiaries or for access to the
properties, books or records of the Company or any of its Subsidiary by any person other than the
Acquiror in a view to complete an Acquisition Transaction. Such notice shall indicate the identity
of the person making the proposal or offer, or intending to make a proposal or offer or requesting
non-public information or access to the books and records of the Company, the material terms of any
such proposal or offer, or modification or amendment to such proposal or offer and copies of any
written proposals or offers or amendments or supplements thereto. The Selling Stockholders shall
keep the Acquiror informed, on a current basis, of any material changes in the status and any
material changes or modifications in the material terms of any such proposal, offer, indication or
request.
(c) The Selling Stockholders shall, and the Selling Stockholders other than SGAM AI shall
cause the Company, its Subsidiaries and their Representatives to, immediately cease and cause to be
terminated any existing discussions or negotiations with any persons (other than the Acquiror)
conducted heretofore with respect to any Acquisition Transaction. The Selling Stockholders shall
not (and the Selling Stockholders other than SGAM AI shall cause the Company and its Subsidiaries
not to) release any third party from the confidentiality and standstill provisions of any agreement
to which the Company or any of its Subsidiaries is a party.
-46-
SECTION SIX
6. Additional Agreements. Throughout this Section 6, each of the covenants of the
Selling Stockholders shall be made on a several and not joint basis, except as specifically
identified herein.
6.1 Commercially Reasonable Efforts and Further Assurances. Subject to the terms and
conditions of this Agreement and the requirements of applicable law, each of the parties to this
Agreement shall use its commercially reasonable efforts to effectuate the transactions contemplated
hereby and to fulfill and cause to be fulfilled the conditions to closing under this Agreement.
Each party hereto, at the reasonable request of another party hereto, shall execute and deliver
such other instruments and do and perform such other acts and things as may be necessary or
desirable for effecting completely the consummation of this Agreement and the transactions
contemplated hereby.
6.2 Consents; Cooperation.
(a) Each of the parties shall use its reasonable efforts to promptly (i) obtain from any
Governmental Entity any material consents, licenses, permits, waivers, approvals, authorizations or
orders required to be obtained or made by the parties or the Company or any of their subsidiaries
in connection with the authorization, execution and delivery of this Agreement and the consummation
of the transactions contemplated hereunder and (ii) make all necessary filings, and thereafter make
any other required submissions, with respect to this Agreement and the Purchase required under the
Securities Act and the Exchange Act and any other applicable federal or state securities laws.
(b) From the date of this Agreement until the earlier of the Closing or the termination of
this Agreement in accordance with Section 8, each party shall promptly notify the other party in
writing of any pending or, to the knowledge of such party, threatened action, proceeding or
investigation by any Governmental Entity or any other person (i) challenging or seeking material
damages in connection with this Agreement or the transactions contemplated hereunder or (ii)
seeking to restrain or prohibit the consummation of the Purchases or the transactions contemplated
hereunder or otherwise limit the right of the Acquiror or its subsidiaries to own or operate all or
any portion of the businesses or assets of the Company.
(c) Each of the parties shall give or cause to be given any required material notices to third
parties identified on Schedule 6.2(c), and use its reasonable efforts to obtain all
material consents, waivers and approvals from third parties (i) necessary, proper or advisable to
consummate the transactions contemplated hereunder, (ii) disclosed or required to be disclosed in
the Company Disclosure Schedule or the Acquiror Disclosure Schedule, or (iii) required to prevent a
Material Adverse Effect on the Company or the Acquiror from occurring prior to or after the
Closing, each as identified on Schedule 6.2(c). In the event that the Acquiror or the
Company shall fail to obtain any third party consent, waiver or approval described in this Section
6.2(c), it shall use its reasonable efforts, and shall take any such actions reasonably requested
by the other party, to minimize any adverse effect upon the Acquiror and the Company, their
respective subsidiaries and their respective businesses resulting (or which could reasonably be
expected to result after the Closing) from the failure to obtain such consent, waiver
-47-
or approval, provided that no party hereto or the Company shall be required to make payments
to any third parties to induce their consent, waiver or approval.
(d) Each of the parties will, and (save for the Selling Stockholders incorporated as
investment funds, fonds communs de placements à risques, fonds communs de placement dans
l’innovation and societé de capital risque) will cause their respective subsidiaries to, take all
reasonable actions necessary to comply promptly with all legal requirements which may be imposed on
them with respect to the consummation of the transactions contemplated by this Agreement and will
promptly cooperate with and furnish information to any party hereto necessary in connection with
any such requirements imposed upon such other party in connection with the consummation of the
transactions contemplated by this Agreement and will take all reasonable actions necessary to
obtain (and will cooperate with the other parties hereto in obtaining) any consent, approval, order
or authorization of, or any registration, declaration or filing with, any Governmental Entity or
other person, required to be obtained or made in connection with the taking of any action and
contemplated by this Agreement.
6.3 Access to Information.
(a) The Selling Stockholders other than SGAM AI shall cause the Company to afford the Acquiror
and its accountants, counsel and other representatives, reasonable access during normal business
hours upon reasonable notice during the period prior to the earlier of the termination of this
Agreement in accordance with Section 8 or the Closing to (i) all of the Company’s properties,
books, contracts, commitments and records, and (ii) all other information concerning the business,
properties and personnel, Taxes and Tax Returns of the Company as the Acquiror may reasonably
request provided that such access shall not unduly disrupt the Company’s normal business
activities. The Selling Stockholders other than SGAM AI shall cause the Company to provide to the
Acquiror and its accountants, counsel and other representatives copies of internal financial
statements promptly upon request. The Acquiror shall afford the Company and its accountants,
counsel and other representatives, reasonable access during normal business hours upon reasonable
notice during the period prior to the earlier of the termination of this Agreement in accordance
with Section 8 or the Closing to (i) all of the Acquiror’s and its subsidiaries’ properties, books,
contracts, commitments and records, and (ii) all other information concerning the business,
properties and personnel of the Acquiror and its subsidiaries as the Company may reasonably request
provided that such access shall not unduly disrupt the Acquiror’s normal business activities. The
Acquiror agrees to provide to the Company and its accountants, counsel and other representatives
copies of internal financial statements promptly upon request.
(b) Subject to compliance with applicable law, from the date hereof until the earlier of the
termination of this Agreement in accordance with Section 8 or the Closing, each of the Acquiror and
the Company shall confer on a regular and frequent basis with one or more representatives of the
other party to report operational matters of materiality and the general status of ongoing
operations.
-48-
(c) No information or knowledge obtained in any investigation pursuant to this Section 6.3
shall affect or be deemed to modify any representation or warranty contained herein or the
conditions to the obligations of the parties to consummate the Purchase.
6.4 Confidentiality. The parties acknowledge that the Acquiror and the Company have
previously executed a non-disclosure agreement dated October 4, 2005 as amended by the letter
agreement between the Acquiror and the Company dated March 31, 2006 (the “Confidentiality
Agreement”), which Confidentiality Agreement shall continue in full force and effect in
accordance with its terms.
6.5 Public Disclosure. Unless otherwise permitted by this Agreement, the Selling
Stockholders other than SGAM AI shall cause the Company to consult with the Acquiror before issuing
any press release or otherwise making any public statement or making any other public (or
non-confidential) disclosure (whether or not in response to an inquiry) regarding the terms of this
Agreement and the transactions contemplated hereby, and neither shall issue any such press release
or make any such statement or disclosure without the prior approval of the other (which approval
shall not be unreasonably withheld, conditioned or delayed), except as may be required by law or to
obtain necessary third party consents or by obligations pursuant to any listing agreement with any
national securities exchange or with the NASD.
6.6 Escrow Agreement. On or before the Closing, the Escrow Agent and the
Stockholders’ Representative (each as hereinafter defined) will execute the Escrow Agreement
contemplated by Section 9 in the form attached hereto as Exhibit D (“Escrow
Agreement”).
6.7 Blue Sky Laws. The Acquiror shall take such steps as may be necessary to comply
with the securities and blue sky laws of all jurisdictions which are applicable to the issuance of
the Acquiror Stock in connection with the Purchase. The Company shall use its reasonable best
efforts to assist the Acquiror as may be necessary to comply with the securities and blue sky laws
of all jurisdictions which are applicable in connection with the issuance of the Acquiror Stock in
connection with the Purchase.
6.8 Employment Agreements. On the Closing Date, the Selling Stockholders other than
SGAM AI will use their reasonable best efforts to cause the Designated Employees to execute and
deliver to the Acquiror the Employment Agreements.
6.9 Spreadsheet. The Company shall deliver to the Acquiror a spreadsheet (the
“Spreadsheet”) in a form reasonably acceptable to the Acquiror, which spreadsheet shall be
certified as complete and correct by the Chief Executive Officer and Chief Financial Officer of the
Company as of the Closing and which shall include, among other things, as of the Closing, (i) all
Selling Stockholders and their respective addresses, (ii) the number of Shares held by such persons
(including the respective certificate numbers), the date of acquisition of such Shares, (iii) the
cash portion of the Remaining Amount to be paid to each Selling Stockholder, (iv) the number of
shares of the Remaining Amount to be delivered to each Selling Stockholder (v) the amount of cash
and Acquiror Stock to be deposited into the Escrow Fund on behalf of each Selling Stockholder, and
such other information relevant thereto or which the Acquiror may reasonably request. The Company
shall deliver the Spreadsheet two (2) Business Days prior to the Closing Date.
-49-
6.10 Non-Competition; Non-Solicitation; Confidentiality.
(a) For a period of three (3) years from and after the Closing Date, the Designated Employees
shall not, directly or indirectly, own, manage, engage in, operate, control, work for, consult
with, render services for, do business with, maintain any interest in (proprietary, financial or
otherwise) or participate in the ownership, management, operation or control of, any business,
whether in corporate, proprietorship or partnership form or otherwise, engaged in developing
software that enables voice or video internet protocol communications and/or services or that
otherwise competes with the Company or any of the Subsidiaries (a “Restricted Business”);
provided, however, that the restrictions contained in this Section 6.10(a) shall not restrict the
acquisition by such Designated Employees, directly or indirectly, of less than 5% of the
outstanding capital stock of any company engaged in a Restricted Business.
(b) For a period of three (3) years from and after the Closing Date, the Designated Employees
shall not, directly or indirectly: (i) cause, solicit, induce or encourage any employees of the
Company or its Subsidiaries to leave such employment or hire, employ or otherwise engage any such
individual; or (ii) cause, induce or encourage any material client, customer, supplier, or licensor
of the Company or any of its Subsidiaries (including any existing or former customer of the Company
or its Subsidiaries) or any other person who has a material business relationship with the Company
or any of its Subsidiaries, to terminate or adversely modify any such actual relationship.
(c) From and after the Closing Date, each Selling Stockholder shall not and, where applicable,
shall cause their officers, directors, members of the Management Board, members of the Supervisory
Board, employees and Affiliates not to, directly or indirectly, disclose, reveal, divulge or
communicate to any person other than authorized officers, directors, members of the Management
Board, members of the Supervisory Board and employees of the Acquiror or use or otherwise exploit
for its own benefit or for the benefit of anyone other than the Acquiror, any Confidential
Information (as defined below). Each Selling Stockholder shall not have any obligation to keep
confidential (or cause its officers, directors, members of the Management Board, members of the
Supervisory Board or Affiliates to keep confidential) any Confidential Information if and to the
extent disclosure thereof is specifically required by applicable law; provided, however, that in
the event disclosure is required by applicable law, the Selling Stockholder shall, to the extent
reasonably possible, provide the Acquiror with prompt notice of such requirement prior to making
any disclosure so that the Acquiror may seek an appropriate protective order. For purposes of this
Section 6.10(c), “Confidential Information” means any information with respect to the
Company or any of its Subsidiaries, including methods of operation, customer lists, products,
prices, fees, costs, technology, inventions, trade secrets, know-how, software, marketing methods,
plans, personnel, suppliers, competitors, markets or other specialized information or proprietary
matters. “Confidential Information” does not include, and there shall be no obligation
hereunder with respect to, information that (i) is generally available to the public on the date of
this Agreement or (ii) becomes generally available to the public other than as a result of a
disclosure not otherwise permissible hereunder.
(d) The covenants and undertakings contained in this Section 6.10 relate to matters which are
of a special, unique and extraordinary character and a violation of any of the terms of this
Section 6.10 will cause irreparable injury to the Acquiror, the amount of
-50-
which will be impossible to estimate or determine and which cannot be adequately compensated.
Accordingly, the remedy at law for any breach of this Section 6.10 will be inadequate. Therefore,
the Acquiror will be entitled to a temporary and permanent injunction, restraining order or other
equitable relief from any court of competent jurisdiction in the event of any breach of this
Section 6.10 without the necessity of proving actual damage. The rights and remedies provided by
this Section 6.10 are cumulative and in addition to any other rights and remedies which the
Acquiror may have hereunder or at law or in equity.
6.11 Company Transaction Expenses. The Company Transaction Expenses, the Company’s
Accounting Fees, the Independent Accountant Fees and the Independent Accountant Fees Excess shall
be paid as follows:
(a) The Acquiror shall be entitled to reimbursement for such Company Transaction Expenses (to
the extent not reflected in the Purchase Price Adjustment) solely out of the Warranty Escrow Fund.
No later than three business days prior to the Closing Date, the Selling Stockholders shall deliver
to the Acquiror (i) final invoices in respect of the Company Transaction Expenses from third-party
service providers to whom payments are required to be made by the Company or any of the
Subsidiaries, and (ii) a statement of the Company setting forth an estimate of the aggregate amount
of Company Transaction Expenses (whether or not paid as of such date) as of the Closing Date. On
the Closing Date prior to the Closing, the Selling Stockholders shall deliver to the Acquiror a
statement of the Company setting forth the aggregate amount of Company Transaction Expenses as of
the Closing Date (whether or not paid as of such date). The Selling Stockholders other than SGAM
AI shall cause the Company to pay and discharge all such Company Transaction Expenses at or prior
to the Closing. All final invoices shall provide that the amounts set forth therein represent
payment in full for all fees and expenses payable by the Company in connection with the
transactions contemplated by this Agreement.
(b) In the event the Purchase is not consummated:
(i) 50% of the Company’s Accounting Fees (and any VAT payable on it), up to a maximum amount
of €200,000, shall be invoiced by the Company to the Acquiror and promptly paid by the Acquiror
to the Company.
(ii) The Independent Accountant Fees and the Independent Accountant Fees Excess (and any VAT
payable on them as the case may be) shall be borne directly by the Acquiror and shall not be
invoiced to the Company.
(c) The “Company Transaction Expenses” shall mean any brokers, bankers, finders,
legal, auditing or other third party service provider fees and expenses incurred by the Company in
connection with the preparation and review of the transactions set forth herein; provided that
“Company Transaction Expenses” shall not include(i) the entire amount of the Company’s Accounting
Fees (plus any VAT payable on it) up to a maximum amount of $300,000 and (ii) 50% of the
Independent Accountant Fees (plus any VAT payable on it), which amounts set forth in clauses (i)
and (ii) shall be credited to the Net Cash to the extent such amounts were paid, recorded as a
liability or accrued by the Company prior to Closing.
-51-
(d) The “Company’s Accounting Fees” shall mean KPMG’s and SOFIRA’s fees and expenses
(VAT excluded) incurred with respect to the preparation of the Company’s audited financial
statements for 2005 and reviewed financial statements for the first two quarters of 2006.
(e) The “Independent Accountant Fees” shall mean the fees and expenses (VAT excluded)
up to a maximum of $60,000 of Xx. Xxxxx Xxxxxxx or any of its affiliates incurred with respect to
the preparation of the Company’s audited financial statements for 2005 and reviewed financial
statements for the first two quarters of 2006.
(f) The “Independent Accountant Fees Excess” shall mean the fees and expenses (VAT
excluded) above the amount of $60,000 of Xx. Xxxxx Xxxxxxx or any of its affiliates incurred with
respect to the preparation of the Company’s audited financial statements for 2005 and reviewed
financial statements for the first two quarters of 2006.
(g) The “Accountant Fees” shall mean the Company’s Accounting Fees, the Independent
Accountant Fees and the Independent Accountant Fees Excess.
6.12 Notification of Certain Matters. On or before the Closing Date, the Selling
Stockholders shall give notice to the Acquiror and the Acquiror shall give notice to the Selling
Stockholders, as promptly as reasonably practicable upon becoming aware of (a) any fact, change,
condition, circumstance, event, occurrence or non-occurrence that has caused or is reasonably
likely to cause any representation or warranty in this Agreement made by it to be untrue or
inaccurate in any material respect at any time after the date hereof and prior to the Closing, (b)
any material failure on its part to comply with or satisfy any covenant, condition or agreement to
be complied with or satisfied by it hereunder or (c) the institution of or the threat of
institution of any legal proceeding against any of the Acquiror, the Selling Stockholders, the
Company or any of its Subsidiaries related to this Agreement or the transactions contemplated
hereby; provided that the delivery of any notice pursuant to this Section 6.12 shall not limit or
otherwise affect the remedies available hereunder to the party receiving such notice, or the
representations or warranties of, or the conditions to the obligations of, the parties hereto.
6.13 Release. Each Selling Stockholder hereby unconditionally releases and forever
discharges the Acquiror, its affiliates and the respective affiliates, officers and directors of
the Acquiror and its affiliates, effective as of the Closing, from (a) any and all obligations or
duties the Company might have to such Selling Stockholder and (b) any and all claims of liability,
whether legal or equitable, of every kind and nature, which such Selling Stockholder ever had, now
has or may claim against the Company in relation to events, facts or circumstances that occurred or
existed prior to the Closing Date; provided, however, that this release shall exclude (i) those
liabilities of the Acquiror under this Agreement, (ii) if such Selling Stockholder is an officer,
director, member of the Management Board, member of the Supervisory Board or employee of the
Company or any Subsidiary of the Company, this release shall exclude, to the extent applicable, (A)
compensation (including bonuses), if any, for the current pay period not yet paid, (B)
reimbursement for expenses incurred by such Selling Stockholder in the ordinary course of his or
her employment which are reimbursable under the expense reimbursement policies of the Company or
any Subsidiary (C) accrued vacation, subject to the policies on accrual and carryforward of the
Company or any Subsidiary and (D) any other claims that such
-52-
Selling Stockholder may have due to his or her status as a member of the Management Board or
employee of the Company and (iii) any claims against any officer, director, member of the
Management Board or member of the Supervisory Board of the Company or any Subsidiary based on fraud
(but not including any claim for which such officer, director, member of the Management Board or
member of the Supervisory Board is entitled to indemnification from the Company or such
Subsidiary). This Section 6.13 shall be for the benefit of, and shall be enforceable by, the
Company, the Acquiror, any other subsidiary of the Acquiror, and their respective affiliates,
officers and directors.
6.14 Resignation of Officers, Directors, Members of the Management Board and Members of
the Supervisory Board. The Selling Stockholders other than SGAM AI shall cause each of the
members of the Existing Supervisory Board to submit a letter of resignation as a member of the
Supervisory Board of the Company, effective on or before the Closing Date or shall otherwise cause
the removal of such member of the Supervisory Board prior to the Closing Date.
6.15 Preemptive Right. Each Selling Stockholder waives to the fullest extent possible
the benefit of the preemptive right accruing to the benefit of such Selling Stockholder provided
for in the Company Shareholders Agreements (the “Preemptive Right”) and acknowledges that
the execution and delivery of this Agreement, shall be deemed notification by and to such Selling
Stockholder as required in such agreements; provided, however, that, vis-à-vis the relevant third
parties concerned by the Preemptive Right but not party to this Agreement, each Selling Stockholder
shall provide due notification of such contemplated transfer of the Shares held by such Selling
Stockholder in accordance with the terms and conditions of such agreements.
6.16 Transfer Restrictions for Top Management. In addition to all other transfer
restrictions and legend requirements set forth herein, each member of the Top Management (Xxxxxxx
Moustiés, Xxxxxxx Xxxxxxx and Xxxx Xxxxxx) hereby agrees not to sell, transfer, pledge or otherwise
dispose of 80% of the Acquiror Stock each such person shall receive pursuant to this Agreement,
including any shares of Acquiror Stock deposited in the Escrow Fund on behalf of any of the Top
Management (the “Lockup Shares”), for a period of two years following the Closing Date;
provided that 1/6th of each such person’s Lockup Shares may be sold, transferred, pledged or
otherwise disposed of by such person beginning on the first anniversary of the Closing Date;
provided however, that all Lockup Shares may be sold to the acquiring party in a Change of Control
(as hereinafter defined) of the Acquiror; provided further that such restrictions on Lockup Shares
shall continue in full force and effect immediately following such Change of Control with respect
to any shares of equity securities received in exchange or as consideration for the Lockup Shares
in such Change of Control transaction. For purposes of this Section 6.16, a “Change of
Control” shall mean: the acquisition of the Acquiror by another entity by means of any
transaction or series of related transactions to which the Acquiror is party (including, without
limitation, any stock acquisition, reorganization, merger or consolidation but excluding any sale
of stock for capital raising purposes), that results in the voting securities of the Acquiror
outstanding immediately prior thereto failing to represent immediately after such transaction or
series of transactions (either by remaining outstanding or by being converted into voting
securities of the surviving entity or the entity that controls such surviving entity) a majority of
the total voting power represented by the outstanding voting
-53-
securities of the Acquiror, such surviving entity or the entity that controls such surviving
entity; or (b) a sale, lease or other conveyance of all or substantially all of the assets of the
Acquiror.
6.17 Registration Statement on Form S-3. The Acquiror will use its commercially
reasonable efforts to file a Registration Statement on Form S-3 (so long as the Acquiror is then
eligible to use such form) with respect to the resale of the shares of Stock Consideration within
10 days following the filing of the Acquiror’s Item 2.01 8-K/A with respect to the Purchase that
contains all financial statements required to be filed as exhibits thereto, and will use its
commercially reasonable efforts to (i) cause such Registration Statement to be declared effective
by the SEC as soon as practicable thereafter and (ii) keep such registration statement effective
for a period of up to one hundred eighty (180) days following the termination of the Escrow Fund
pursuant to Section Nine or, if earlier, until the distribution contemplated in the registration
statement has been completed. The Acquiror shall pay the legal fees for its own counsel, as well
as the filing fees associated with such registration statement but the Selling Stockholders shall
pay their own legal fees as well as any underwriting discounts or commissions associated with sales
of shares pursuant to the registration statement. The Acquiror’s obligations pursuant to this
Section 6.17 shall be conditioned upon receipt from each Selling Stockholder of such information
concerning such Selling Stockholder as is required to be set forth in the Registration Statement
under the Securities Act and applicable rules and regulations thereunder. The Acquiror may by
written notice to the Selling Stockholders, require that the Selling Stockholders immediately cease
the sale of shares pursuant to such Registration Statement if the Acquiror’s Board of Directors
determines in good faith that, due to pending material corporate developments, it is in the best
interests of the stockholders of the Acquiror to suspend the use of the Registration Statement.
Upon receipt of such notice, the Selling Stockholders shall immediately discontinue any sales under
the Registration Statement until advised in writing by the Acquiror that such Registration
Statement may again be used. The Selling Stockholders severally, and not jointly, shall indemnify
and hold harmless the Acquiror, each of its directors, each of its officers who sign the
Registration Statement and each person, if any, who controls the Acquiror within the meaning of the
Securities Act, against any Damages (as hereinafter defined) to which such indemnified persons
become subject under the Securities Act or the Exchange Act or any other federal or state statutory
law or regulation insofar as such Damages arise out of or are based upon (i) any failure on the
part of the Selling Stockholder to comply with the covenants or agreements herein or (ii) any
untrue or alleged untrue statement of any material fact contained in the Registration Statement or
the prospectus contained therein or any amendment or supplement thereto, or the omission or alleged
omission to state therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent such untrue statement or alleged
untrue statement or omission or alleged omission was made in reliance upon and in conformity with
the written information furnished to the Acquiror by or on behalf of such Selling Stockholder for
the express purpose of inclusion in such Registration Statement or the prospectus contained therein
or any amendment or supplement thereto. In addition to the foregoing, the Acquiror shall, as
expeditiously as reasonably possible:
(a) prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be
necessary to comply with the provisions of the Securities Act with respect to the disposition of
all securities covered by such registration statement;
-54-
(b) furnish to the Selling Stockholders such number of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other
documents as they may reasonably request in order to facilitate the disposition of Stock
Consideration owned by them;
(c) use all commercially reasonable efforts to register and qualify the securities covered by
such registration statement under such other securities or Blue Sky laws of such jurisdictions as
shall be reasonably requested by the Selling Stockholders, provided that the Acquiror shall not be
required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions;
(d) notify each Selling Stockholder at any time when a prospectus relating thereto is required
to be delivered under the Securities Act of the happening of any event as a result of which the
prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing;
(e) cause all such Stock Consideration registered pursuant to this Section 6.17 to be listed
on a national exchange or trading system and on each securities exchange and trading system on
which similar securities issued by the Acquiror are then listed; and
(f) provide a transfer agent and registrar for all Stock Consideration registered pursuant to
this Agreement and a CUSIP number for all such Stock Consideration, in each case not later than the
effective date of such registration.
6.18 Registration with French Tax Authority. The Acquiror shall be responsible for
registration of each Share transferred under this Agreement with French tax authorities and all
stamp duties payable upon such registration (which amounts paid by the Acquiror shall be credited
toward the Purchase Price as set forth in Section 1).
6.19 Selling Stockholders Advisors Fees. The fees of Xxxxxxxx Xxxxxx LLP
(“Xxxxxxxx Xxxxxx”), Sardis Capital Limited (“Sardis”) and Xxxxxxxxx Xxxxxxx Xxxxxx
Xxxxxxxxxx Xxxxxxxx & Xxxxxxxxx, LLP (“Xxxxxxxxx”) in connection with the negotiation,
preparation and delivery of this Agreement and the transactions contemplated hereby (the
“Selling Stockholders Advisors Fees”) shall be paid in cash as follows:
(a) The fees of Xxxxxxxx Xxxxxx in connection with the negotiation, preparation and delivering
of this Agreement and the transactions contemplated hereby (the “Xxxxxxxx Xxxxxx Fees”)
shall be paid in cash in Euros as follows:
(i) Upon Closing, upon request of the Xxxxxxxx Xxxxxx Clients (as defined below) made hereby
under Article 1277 of the French Civil Code, the Acquiror shall pay the Xxxxxxxx Xxxxxx Fees on
behalf of the Xxxxxxxx Xxxxxx Clients in cash by wire transfer to an account designated by Xxxxxxxx
Xxxxxx, by deducting the Xxxxxxxx Xxxxxx Fees pro rata to the portion of the Remaining Cash payable
to the Xxxxxxxx Xxxxxx Clients, and proceed to payment of the Selling Stockholders’ contributions
to the Xxxxxxxx Xxxxxx Fees as set out below.
-55-
(ii) Each of the Selling Stockholders other than the Xxxxxxxx Xxxxxx Clients hereby
acknowledges to have benefited from Xxxxxxxx Xxxxxx’x services in relation to this transaction. As
a result, each of these Selling Stockholders agrees to reduce the portion of the Remaining Cash it
is entitled to receive on Closing by its ratable portion of the Xxxxxxxx Xxxxxx Fees based on its
Closing Consideration Proportionate Interest.
(iii) For the purpose of this Section 6.19, the “Xxxxxxxx Xxxxxx Clients” shall be
SGAM AI, FCPR Banexi Ventures 2, Banexi Ventures Partners SA, Credit Lyonnais Venture Capital and
SORIDEC.
(b) The fees of Sardis Capital Limited (“Sardis”) in connection with the negotiation,
preparation and delivering of this Agreement and the transactions contemplated hereby (the
“Sardis Fees”) shall be paid in cash in U.S. Dollars as follows:
(i) Upon Closing and upon payment of any amounts out of the Holdback to the Selling
Stockholders, upon request of the Sardis Clients (as defined below), the Acquiror shall pay the
Sardis Fees on behalf of the Sardis Clients, in cash by wire transfer to an account designated by
Sardis, by deducting the Sardis Fees pro rata to the portion of the Remaining Cash payable to the
Sardis Clients, and proceed to payment of the Selling Stockholders’ contributions to the Sardis
Fees as set out below.
(ii) Each of the Selling Stockholders other than the Sardis Clients hereby acknowledges to
have benefited from Sardis’ services in relation to this transaction. As a result, each of these
Selling Stockholders agrees to reduce the portion of the Remaining Cash it is entitled to receive
on Closing by its ratable portion of the Sardis Fees based on its Closing Consideration
Proportionate Interest.
(iii) For the purpose of this Section 6.19, the “Sardis Clients” shall be the Xxxxxxxx
Xxxxxx Clients plus the Top Management.
(c) The fees of Xxxxxxxxx Xxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx & Xxxxxxxxx, LLP
(“Xxxxxxxxx”) in connection with the negotiation, preparation and delivering of this
Agreement and the transactions contemplated hereby (the “Xxxxxxxxx Fees”) shall be paid in
cash in U.S. Dollars as follows:
(i) Upon Closing, upon request of the Xxxxxxxxx Clients (as defined below), the Acquiror shall
pay the Xxxxxxxxx Fees on behalf of the Xxxxxxxxx Clients in cash by wire transfer to an account
designated by Xxxxxxxxx, by deducting the Xxxxxxxxx Fees pro rata to the portion of the Remaining
Cash payable to the Xxxxxxxxx Clients, and proceed to payment of the Selling Stockholders’
contributions to the Xxxxxxxxx Fees as set out below.
(ii) Each of the Selling Stockholders other than the Xxxxxxxxx Clients hereby acknowledges to
have benefited from Xxxxxxxxx’x services in relation to this transaction. As a result, each of
these Selling Stockholders agrees to reduce the portion of the Remaining Cash it is entitled to
receive on Closing by its ratable portion of the Xxxxxxxxx Fees based on its Closing Consideration
Proportionate Interest.
-56-
(iii) For the purpose of this Section 6.19, the “Xxxxxxxxx Clients” shall be the
Xxxxxxxx Xxxxxx Clients.
SECTION SEVEN
7. Conditions to the Purchase.
7.1 Conditions to Obligations of Each Party to Effect the Purchase. The respective
obligations of each party to this Agreement to consummate and effect this Agreement and the
transactions contemplated hereby shall be subject to the satisfaction on or prior to the Closing of
each of the following conditions, any of which may be waived, in writing, by agreement of all the
parties hereto:
(a) No Injunctions or Restraints on Purchase and Conduct of Business; Illegality. No
temporary restraining order, preliminary or permanent injunction or other order issued by any court
of competent jurisdiction or other legal or regulatory restraint or prohibition preventing the
consummation of the Purchase or the Acquiror’s conduct or operation of the business of the Company
following the Purchase shall be in effect, nor shall any proceeding brought by any Governmental
Entity, seeking any of the foregoing be pending; nor shall there be any action taken, or any
statute, rule, regulation or order enacted, entered, enforced or deemed applicable to the Purchase,
which makes the consummation of the Purchase or the Acquiror’s conduct or operation of the business
of the Company following the Purchase, illegal. In the event an injunction or other order shall
have been issued, each party agrees to use its reasonable best efforts to have such injunction or
other order lifted.
(b) Governmental Approval. The Acquiror and the Company and their respective
subsidiaries shall have timely obtained from each Governmental Entity all approvals, waivers and
consents, if any, necessary for consummation of or in connection with the Purchase, including,
without limitation, such approvals, waivers and consents as may be required under HSR, under the
Securities Act and under any state securities laws.
7.2 Additional Conditions to Obligations of Selling Stockholders. The obligations of
the Selling Stockholders to consummate and effect this Agreement and the transactions contemplated
hereby shall be subject to the satisfaction at or prior to the Closing of each of the following
conditions, any of which may be waived, in writing, by the Selling Stockholders:
(a) Representations, Warranties and Covenants. (i) Each of the representations and
warranties of the Acquiror, in this Agreement that is expressly qualified by a reference to
materiality shall be true in all respects as so qualified, and each of the representations and
warranties of the Acquiror, in this Agreement that is not so qualified shall be true and correct in
all material respects, on and as of the Closing as though such representation or warranty had been
made on and as of such time (except that those representations and warranties which address matters
only as of a particular date shall remain true and correct as of such date), and (ii) the Acquiror,
shall have performed and complied in all material respects with all covenants, obligations and
conditions of this Agreement required to be performed and complied with by it as of the Closing.
-57-
(b) Certificates of Acquiror.
(i) Compliance Certificate of Acquiror. The Selling Stockholders shall have been
provided with a certificate executed on behalf of the Acquiror by its President or its Chief
Financial Officer to the effect that, as of the Closing, each of the conditions set forth in
Section 7.2(a) has been satisfied with respect to the Acquiror.
(ii) Certificate of Secretary of Acquiror. The Selling Stockholders shall have been
provided with a certificate executed by the Secretary or Assistant Secretary of the Acquiror
certifying:
(A) resolutions duly adopted by the Board of Directors of the Acquiror authorizing the
execution of this Agreement and the execution, performance and delivery of all agreements,
documents and transactions contemplated hereby; and
(B) the incumbency of the officers of the Acquiror executing this Agreement and all agreements
and documents contemplated hereby.
(c) Good Standing. The Company shall have received a certificate or certificates of
the Secretary of State of the State of Delaware and any applicable franchise tax authority of such
state, certifying as of a date no more than three (3) business days prior to the Closing that the
Acquiror, has filed all required reports, paid all required fees and taxes and is, as of such date,
in good standing and authorized to transact business in such state.
(d) Escrow Agreement. The Acquiror and Escrow Agent shall have entered into an Escrow
Agreement substantially in the form attached hereto as Exhibit D.
7.3 Additional Conditions to the Obligations of Acquiror. The obligations of the
Acquiror to consummate and effect this Agreement and the transactions contemplated hereby shall be
subject to the satisfaction at or prior to the Closing of each of the following conditions, any of
which may be waived, in writing, by the Acquiror:
(a) Representations, Warranties and Covenants. (i) Each of the representations and
warranties of the Selling Stockholders in this Agreement that is expressly qualified by a reference
to materiality shall be true in all respects as so qualified, and each of the representations and
warranties of the Selling Stockholders in this Agreement that is not so qualified shall be true and
correct in all material respects, on and as of the Closing (except that those representations and
warranties which address matters only as of a particular date shall remain true and correct as of
such date), and (ii) the Selling Stockholders shall have performed and complied in all material
respects with all covenants, obligations and conditions of this Agreement required to be performed
and complied with by them as of the Closing.
(b) No Material Adverse Effect. There shall not have occurred any Material Adverse
Effect on the Company between the date hereof and the Closing.
-58-
(c) Certificates of Selling Stockholders and Company.
(i) Compliance Certificate of Selling Stockholders. The Acquiror shall have been
provided with a certificate executed on behalf of the Selling Stockholders by the Stockholders’
Representative to the effect that, as of the Closing, each of the conditions set forth in Section
7.3(a)and (b) has been satisfied.
(ii) Certificate of President of Company. The Acquiror shall have been provided with
a certificate executed by the President of the Company certifying the Bylaws of the Company, as in
effect immediately prior to the Closing, including all amendments thereto.
(d) Third Party Consents. The Acquiror shall have been furnished with evidence
satisfactory to it that the Company has obtained those consents, waivers, approvals or
authorizations of those Governmental Entities and third parties whose consent or approval are
required in connection with the Purchase as set forth in Section 6.2.
(e) Legal Opinion. The Acquiror shall have received a legal opinion from the Selling
Stockholders’ legal counsel in a form reasonably acceptable to the Acquiror and substantially in
the form attached hereto as Exhibit E.
(f) Resignation of Members of the Supervisory Board. The Acquiror shall have received
letters of resignation from each of the members of the Existing Supervisory Board resigning as
members of the Supervisory Board of the Company, effective as of Closing.
(g) Certain Information Required by the Code. Each holder of Company capital stock or
Company Warrants who holds ten percent (10%) or more (by value) of the interests in the Company,
within the meaning of Section 1060(e)(2) of the Code, immediately prior to the Purchase, and who,
in connection with the Acquiror, enters into an agreement that is subject to Section 1060(e)(1) of
the Code with the Company or (or is related to any person who enters into any such agreement,
within the meaning of Section 267(b) or Section 707(b)(1) of the Code) shall furnish the Acquiror
with any information required pursuant to Section 1060(e) of the Code at such time and in such
manner as the Acquiror may reasonably request in order to comply with Section 1060(e) and any
regulations promulgated thereunder.
(h) Repayment of Loans. All loans made by the Company to any of its holders of
Company Capital Stock shall have been repaid to the Company in full.
(i) Employment Agreement. The Acquiror shall have received from each of the
Designated Employees an executed Employment Agreement in substantially the form attached hereto as
Exhibit B.
(j) Escrow Agreement. The Acquiror shall have received from the Escrow Agent and the
Stockholders’ Representative an executed Escrow Agreement substantially in the form attached hereto
as Exhibit D.
-59-
(k) All Shares Tendered. All of the Shares (representing 100% of the issued and
outstanding capital stock of the Company) shall have been tendered or sold to the Acquiror by the
Selling Stockholders at Closing pursuant to this Agreement (none of which shall have repudiated
their obligations hereunder prior to Closing). Without limiting the generality of the foregoing,
all Company Warrants shall be have been exercised prior to or shall be net exercised in connection
with the Closing.
(l) FIRPTA. The Company shall have provided the Acquiror, as of the Closing Date,
with a properly executed Foreign Investment and Real Property Tax Act of 1980 (“FIRPTA”)
Notification Letter, which shall state that shares of capital stock of the Subsidiary do not
constitute “United States real property interests” under Section 897(c) of the Code. In addition,
simultaneously with delivery of such Notification Letter, the Company shall have provided to the
Acquiror a form of notice to the Internal Revenue Service in accordance with the requirements of
Treasury Regulation Section 1.897 2(h)(2) along with written authorization for the Acquiror to
deliver such notice form to the Internal Revenue Service.
(m) Stock Collar. The reported closing price per share of the Acquiror Stock on the
NASDAQ on any given trading day following the date of this Agreement shall not be less than 80% of
the closing price on the date of this Agreement (in the event such closing price is lower than 80%
of the closing price on the date of this Agreement, the “Stock Collar Condition” shall be
deemed to have occurred).
(n) Fairness Opinion. The fairness opinion of RBC Xxxx Xxxxxxxx Inc. received by the
Acquiror as of the date of this Agreement shall have been reissued to the Acquiror and its Board of
Directors and otherwise confirmed to the Acquiror’s satisfaction as of the Closing Date.
SECTION EIGHT
8. Termination, Amendment and Waiver.
8.1 Termination.
(a) Mutual Consent. This Agreement may be terminated at any time prior to the Closing
by the mutual written consent of the Acquiror and the Selling Stockholders.
(b) Unilateral Termination.
(i) Either the Acquiror or the Selling Stockholders, by giving written notice to the other,
may terminate this Agreement if a court of competent jurisdiction or other Governmental Entity
shall have issued a nonappealable final order, decree or ruling or taken any other action, in each
case having the effect of permanently restraining, enjoining or otherwise prohibiting the Purchase.
(ii) Either the Acquiror or the Selling Stockholders, by giving written notice to the other,
may terminate this Agreement if the Purchase shall not have been consummated on or by November 30,
2006 which date may be extended by the mutual written consent of the parties hereto (the
“Termination Date”); provided, however, that the right to
-60-
terminate this Agreement pursuant to this Section 8.1(b)(ii) shall not be available to any
party whose failure to perform in any material respect any of its obligations or covenants under
this Agreement results in the failure of any condition set forth in Sections 7.2 or 7.3, as
applicable, or if the failure of such condition results from facts or circumstances that constitute
a material breach of a representation or warranty or covenant made under this Agreement by such
party.
(c) Termination for Breach. Either the Acquiror or the Selling Stockholders may
terminate this Agreement at any time prior to the Closing if the other has committed a material
breach of (a) any of its material representations and warranties set forth in Section 2, Section 3
and Section 4, as applicable, such that the conditions in Section 7 would not be satisfied or (b)
any of its material covenants in this Agreement such that the conditions in Section 7 would not be
satisfied, and has not cured such material breach within thirty (30) days after the party seeking
to terminate this Agreement has given the other party written notice of the material breach and its
intention to terminate this Agreement pursuant to this Section 8.1; provided that notwithstanding
the foregoing, no cure period shall be required for a breach which by its nature cannot be cured.
(d) Stock Collar Termination. The Acquiror may terminate this Agreement at any time
prior to the Closing if the Stock Collar Condition has occurred.
8.2 Effect of Termination. In the event of termination of this Agreement as provided
in Section 8.1, this Agreement shall forthwith become void and there shall be no liability or
obligation on the part of the Acquiror, or the Selling Stockholders or their respective officers,
directors, members of the Management Board, members of the Supervisory Board, stockholders or
affiliates; provided that, the provisions of Section 6.4, Section 6.10(c), Section 6.10(d), Section
6.11(b) and this Section 8 shall remain in full force and effect and survive any termination of
this Agreement.
8.3 Fees and Expenses. Except as otherwise expressly set forth in this Agreement,
whether or not the Purchase is consummated, all costs and expenses incurred in connection with this
Agreement and the transactions contemplated including, without limitation, filing fees and the fees
and expenses of brokers, bankers, advisors, accountants, legal counsel and financial printers,
shall be paid by the party incurring such expense subject to the terms hereof.
8.4 Amendment. The parties may cause this Agreement to be amended at any time by
execution of an instrument in writing signed on behalf of each of the parties.
8.5 Extension; Waiver. At any time prior to the Closing any party may, to the extent
legally allowed, (i) extend the time for the performance of any of the obligations or other acts of
the other parties, (ii) waive any inaccuracies in the representations and warranties made to such
party contained herein or in any document delivered pursuant hereto, and (iii) waive compliance
with any of the agreements or conditions for the benefit of such party contained herein. Any
agreement on the part of a party to any such extension or waiver shall be valid only if set forth
in an instrument in writing signed on behalf of such party.
-61-
SECTION NINE
9. Escrow and Indemnification.
9.1 Survival of Representations and Warranties. All covenants and agreements to be
performed prior to the Closing (except as otherwise contemplated herein), and all representations
and warranties in this Agreement, as well as the Special Indemnity Matters shall survive the
consummation of the Purchase and continue until the same day of the month as the Closing Date in
the 18th month following the Closing Date (the “Initial Escrow Termination Date”); provided
that (i) if any bona fide claims for indemnification have been timely asserted with respect to any
such representations, warranties, covenants and agreements prior to the Initial Escrow Termination
Date, the representations, warranties, covenants and agreements on which any such claims are based
shall continue in effect with respect to such claims until final resolution of such claims, (ii)
the representations and warranties with respect to Taxes set forth in Section 2.15 shall survive
until the earliest of (the “Final Escrow Termination Date”) (a) thirty (30) days after
expiration of all applicable statutes of limitations relating to such Taxes and (b) the third
anniversary of the Closing Date and (iii) the representations and warranties set forth in Sections
3.1, 3.2, 3.3, 4.1, 4.2, 4.3 and 4.4 shall survive until the tenth anniversary of the Closing Date.
All covenants and agreements to be performed after the Closing shall continue in accordance with
their terms.
9.2 Warranty Escrow Fund. As soon as practicable after the Closing, without any act
of any Selling Stockholder, 10% of the Closing Consideration to be paid to Selling Stockholders
pursuant to Section 1.2 in the amounts of cash (the “Warranty Escrow Cash”) and shares of
Acquiror Stock (the “Warranty Escrow Shares” and, together with the Warranty Escrow Cash,
the “Warranty Escrow Property”) as specified on Exhibit C shall be registered in
the name of, and be deposited into the Escrow Fund with Bank of the West, a California bank (or
such other institution approved by the Acquiror and the Selling Stockholders) as escrow agent (the
“Escrow Agent”), such deposit to constitute the Warranty Escrow Fund and to be governed by
the terms set forth herein and in the Escrow Agreement attached hereto as Exhibit D. In
the event that any Damages (as defined below) arise, the Warranty Escrow Fund shall be available
(i) to return the SGAM AI Special Earnout (as hereinafter defined) to the Acquiror pursuant to
Section 9.4 and (ii) as recourse to compensate the Acquiror Indemnified Persons (as hereinafter
defined) pursuant to the indemnification obligations of the Escrow Selling Stockholders other than
SGAM AI pursuant to Section 9.3 and in accordance with the Escrow Agreement. At least two (2) days
prior to the Closing, the Selling Stockholders shall deliver a schedule listing each Escrow Selling
Stockholder and such Escrow Selling Stockholder’s initial interest in the Warranty Escrow Fund (and
showing such Escrow Selling Stockholder’s interest in the Warranty Escrow Shares and Warranty
Escrow Cash, based on the number of Warranty Escrow Shares and amount Warranty Escrow Cash
delivered to the Escrow Agent at the Closing on behalf of such Escrow Selling Stockholder).
9.3 Indemnification.
(a) Indemnification by Selling Stockholders. Subject to the limitations set forth in
this Section 9, from and after the Closing, the Escrow Selling Stockholders other than SGAM AI
shall protect, defend, indemnify and hold harmless the
-62-
Acquiror and the Company and their respective affiliates, officers, directors, managers,
members, employees, representatives and agents (the Acquiror, the Company and each of the foregoing
persons or entities is hereinafter referred to individually as an “Acquiror Indemnified
Person” and collectively as “Acquiror Indemnified Persons”) from and against any and
all actual losses, amounts paid in settlement, costs, damages, liabilities, fees (including without
limitation reasonable attorneys’ fees) and expenses (collectively, the “Damages”), that any
of the Acquiror Indemnified Persons incurs by reason of or in connection with (i) any
misrepresentation, breach of, or default in connection with, any of the representations,
warranties, covenants or agreements of the Selling Stockholders contained in this Agreement or any
closing certificates furnished by the Selling Stockholders or the Company at the Closing, or (ii)
the matters disclosed in Section 2.8(b)(1) of the Company Disclosure Schedule (such matters
identified in clause (ii) above are referred to as the “Special Indemnity Matters”).
(b) Indemnification by Acquiror. Subject to the limitations set forth in this Section
9, from and after the Closing, the Acquiror shall protect, defend, indemnify and hold harmless the
Selling Stockholders and their respective affiliates, officers, directors, members of the
Management Board, members of the Supervisory Board, managers, members, employees, representatives
and agents (the Selling Stockholders and each of the foregoing persons or entities is hereinafter
referred to individually as a “Selling Stockholder Indemnified Person” and collectively as
“Selling Stockholder Indemnified Persons” and together with the Acquiror Indemnified
Persons, the “Indemnified Persons”) from and against any and all Damages, that any of the
Selling Stockholder Indemnified Persons incurs by reason of or in connection with any
misrepresentation, breach of, or default in connection with, any of the representations,
warranties, covenants or agreements of the Acquiror contained in this Agreement or any closing
certificates furnished by the Acquiror at the Closing.
(c) Materiality. For purposes of this Section 9.3 only, solely in determining the
amount of any Damages related to, resulting from, arising out of, or caused by any breach of the
representations and warranties herein, such representations and warranties shall be read without
regard to any materiality or “Material Adverse Effect” qualifier contained therein, with the intent
that any breach of such representation or warranty so read which gives rise to Damages shall be
subject to indemnification under this Section 9.3. For clarity, the foregoing shall not apply when
reading the representations and warranties for purposes of determining whether a breach of such
representations and warranties has occurred.
(d) Exclusive Remedy and Limitations. In the event the Purchase is consummated,
except in the event of actual fraud or intentional misrepresentation (which is further addressed
below in this paragraph), resort to the Warranty Escrow Fund shall be the sole and exclusive remedy
of the Acquiror Indemnified Persons for any Damages resulting from breaches of representations and
warranties and Special Indemnity Matters other than the representations and warranties in Section
3. The maximum amount of each Selling Stockholder’s liability for any misrepresentation, breach of
or default in connection with any of the representations and warranties of such Selling Stockholder
contained in Section 3 shall be limited to an amount equal to the value of the total consideration
received by such Selling Stockholder pursuant to this Agreement (with any Acquiror Stock received
valued at the average reported closing price for such securities on the NASDAQ for the ten (10)
trading days ending one (1) trading day prior to such release of escrowed property). The maximum
amount of the
-63-
Acquiror’s liability for any misrepresentation, breach of, or default in connection with, any
of the representations and warranties of the Acquiror contained in this Agreement or any closing
certificates furnished by the Acquiror at the Closing, shall be limited to an amount equal to the
value of the Escrow Property as of the Closing Date, based on the Closing Average Stock Price. The
foregoing shall not be deemed a limitation on any remedy for Damages associated with a breach of a
covenant or other agreement of the parties. Each Selling Stockholder shall be responsible for its
own covenants and its own actual fraud and intentional misrepresentation without limitation and no
Selling Stockholder shall be liable for a breach of another Selling Stockholder’s covenants or the
actual fraud or intentional misrepresentation of another Selling Stockholder in excess of its
Escrow Proportionate Interest in the Escrow Fund Property.
(e) Indemnity Threshold; Subrogation. Notwithstanding anything to the contrary
contained in this Agreement:
(i) Neither the Acquiror Indemnified Persons nor the Selling Stockholder Indemnified Persons
shall be entitled to indemnification for any Damages unless such Damages shall in the aggregate
exceed €150,000, in which case such indemnified person shall be entitled to the entire amount of
such Damages from dollar one.
(ii) Upon making any payment to an Indemnified Person hereunder for any indemnification claim
pursuant to this Section Nine, the indemnifying person shall be subrogated, to the extent of such
payment, to any rights which such Indemnified Person may have against any third-person with respect
to the subject matter underlying such indemnification claim and all of the Indemnified Persons with
respect to such claim shall assign any such rights to the indemnifying person with respect to such
claim.
9.4 SGAM AI Special Earnout. In the event there are no Damages suffered by the
Acquiror Indemnified Persons incurred by reason of or in connection with (i) any misrepresentation,
breach of, or default in connection with, any of the representations, warranties, covenants or
agreements of the Selling Stockholders contained in this Agreement or any closing certificates
furnished by the Selling Stockholders or the Company at the Closing, or (ii) the matters disclosed
in Section 2.8(b)(1) of the Company Disclosure Schedule, then SGAM AI shall receive as additional
earnout consideration hereunder the amount deposited on its behalf into the Warranty Escrow Fund
(the “SGAM AI Special Earnout”) as and at the same time as the other Selling Stockholders’
portions of the Warranty Escrow Fund shall be released to them pursuant to the Escrow Agreement.
To the extent there are any such Damages, the amount of the SGAM AI Special Earnout to be paid to
SGAM AI shall be reduced by the amount equal to the total amount payable to the Acquiror
Indemnified Persons from the Warranty Escrow Fund under this Agreement and the Escrow Agreement
with respect to such Damages multiplied by the quotient of (x) the value of the Closing
Consideration received by SGAM AI at the Closing divided by (y) the aggregate value of the Closing
Consideration received by the Escrow Selling Stockholders at the Closing. The amount of such
reduction in the SGAM AI Special Earnout shall be returned to the Acquiror out of the Warranty
Escrow Fund as and at the same time as the other Selling Stockholders’ portions of the Warranty
Escrow Fund are distributed to the Acquiror pursuant to the Escrow Agreement. The balance of any
SGAM AI Special Earnout, if any, shall be paid to SGAM AI as additional earnout consideration as
and at the same time as the other
-64-
Escrow Selling Stockholders’ portions of the Warranty Escrow Fund shall be released to them
pursuant to the Escrow Agreement.
9.5 Escrow Period. The Warranty Escrow Fund shall remain in existence until the
Initial Escrow Termination Date. The Warranty Escrow Property remaining in the Warranty Escrow
Fund at the Initial Escrow Termination Date shall be paid to the Escrow Selling Stockholders,
except for (i) the amount of any bona fide claim for Damages outstanding as of such date, 70% of
which amount shall be cash in U.S. dollars based on the Applicable Exchange Rate as of the Initial
Escrow Termination Date and 30% of which amount shall be shares of Acquiror Stock based on the
Closing Average Stock Price (the “Outstanding Claims Reserve”) and (ii) an amount of cash
equal to US$100,000 for potential Tax Damages arising during the indemnification period for Taxes
remaining after the Initial Escrow Termination Date (the “Tax Escrow Fund” and together
with the Outstanding Claims Reserve, the “Special Reserve Escrow Fund”). Any balance of
the Special Reserve Escrow Fund remaining at the expiration of the Final Escrow Termination Date
shall be paid to the Escrow Selling Stockholders, except for the amount of any bona fide claim for
Damages outstanding as of such date, 70% of which amount shall be cash in U.S. dollars based on the
Applicable Exchange Rate as of the Final Escrow Termination Date and 30% of which amount shall be
shares of Acquiror Stock based on the Closing Average Stock Price, which amount shall not be
released until final resolution of such claims (the “Escrow Period”). As soon as all such
claims have been resolved, the Escrow Agent shall deliver to the Escrow Selling Stockholders all
property remaining in the Warranty Escrow Fund and not required to satisfy such claims. Deliveries
of Warranty Escrow Property to the Escrow Selling Stockholders pursuant to this Section 9.5 and the
Escrow Agreement shall be made in proportionate amounts of cash and share as described in Section
1.6(e). In the event that there is not sufficient cash remaining in the Warranty Escrow Fund to
satisfy the foregoing requirements of this Section 9.5, then such remaining cash will be applied
first and the balance shall be in shares of Acquiror Stock.
9.6 Distributions; Voting.
(a) Any cash or shares of the Acquiror Stock or other equity securities issued or distributed
by the Acquiror (including shares issued upon a stock split) (“New Property”) in respect of
the Warranty Escrow Shares that have not been released from the Warranty Escrow Fund shall be added
to the Warranty Escrow Fund and become a part thereof.
(b) Each Escrow Selling Stockholder shall have voting rights with respect to that number of
Warranty Escrow Shares contributed to the Warranty Escrow Fund on behalf of such Escrow Selling
Stockholder (and on any voting securities added to the Warranty Escrow Fund in respect of such
Warranty Escrow Shares) so long as such Warranty Escrow Shares or other voting securities are held
in the Warranty Escrow Fund. As the record holder of such shares, the Escrow Agent shall vote such
shares in accordance with the instructions of the Escrow Selling Stockholders having the beneficial
interest therein and shall promptly deliver copies of all proxy solicitation materials to such
Escrow Selling Stockholders. The Acquiror shall show the Acquiror Stock contributed to the
Warranty Escrow Fund as issued and outstanding on its balance sheet.
-65-
9.7 Method of Asserting Claims. All claims for indemnification by the Acquiror, or
any other Indemnified Person pursuant to this Section 9 shall be made in accordance with the
provisions of the Escrow Agreement. The Acquiror Indemnified Persons shall be entitled to receive
the amount of any Damages as follows: 70% out of the Escrow Cash and 30% out of the Escrow Shares.
For purposes of determining the value of the Escrow Shares to be used to reimburse any claim for
Damages, the Escrow Shares shall be valued at the average reported closing price for such
securities on the NASDAQ for the ten (10) trading days ending one (1) trading day prior to the date
such claim is finally resolved and determined to be payable out of the Warranty Escrow Fund.
9.8 Tax Characterization of Indemnification Payments. All indemnity payments made by
the Selling Stockholders to an Acquiror Indemnified Person shall be treated for all tax purposes as
adjustments to the consideration paid with respect to the Shares.
9.9 Representative of the Stockholders; Power of Attorney.
(a) Upon the Closing, and without further act of any stockholder, each Selling Stockholder
hereby appoints Société Générale Asset Management Alternative Investments as its agent and
attorney-in-fact to act for and on behalf of the Selling Stockholders, to act in the capacity of
the Stockholders’ Representative hereunder, to give and receive notices and communications on
behalf of the Selling Stockholders, to enter into the Reiterative Deed of Sale, to enter into and
perform the Escrow Agreement, to authorize delivery to the Acquiror of Escrow Property or other
property from the Warranty Escrow Fund in satisfaction of claims by the Acquiror or any other
Indemnified Person, to object to such deliveries, to agree to, negotiate, enter into settlements
and compromises of, and demand arbitration and comply with orders of courts and awards of
arbitrators with respect to such claims, and to take all actions necessary or appropriate in the
judgment of the Stockholders’ Representative for the accomplishment of the foregoing in its
absolute discretion.
(b) The Stockholders’ Representative shall not be liable or responsible for any act he may do
or omit to do hereunder save in the event of gross negligence or willful misconduct of the
Stockholders’ Representative. Without limiting the generality of the foregoing, the Stockholders’
Representative shall not incur any liability with respect to any action taken or suffered by him in
reliance upon any note, direction, instruction (including instructions of all or part of the
Selling Stockholders), consent, statement or other document believed by him to be genuinely and
duly authorized, nor for any action or inaction in reliance in good faith upon advice of legal
counsel. The Stockholders’ Representative will not be required to make any verification in order
to assess the authenticity or the accuracy of the documents transmitted to the Stockholders’
Representative under this mandate.
(c) Each of the Selling Stockholders, the Acquiror and the Stockholders’ Representative hereby
agrees that (i) the assignment of the Stockholders’ Representative under this Agreement shall
terminate on the Final Escrow Termination Date, (ii) the assignment of the Stockholders’
Representative under this Agreement may be terminated at any time by the Stockholders’
Representative prior to the expiry of Final Escrow Termination Date by giving written notice of
such termination to the other Parties; provided, however, that the Stockholders’ Representative
appoints another stockholders’ representative who shall
-66-
substitute for him and who shall comply with the full requirements of such mandate. Such
right to termination shall not give rise to damages to the parties hereof. If the Stockholders’
Representative shall die, become disabled or otherwise be unable to fulfill his responsibilities
hereunder, former Selling Stockholders whose aggregate pro-rata share in the Company share capital
immediately prior to Closing exceeds 50% shall, within twenty (20) business days after such death
or disability, appoint a successor to the Stockholders’ Representative and immediately thereafter
notify the Acquiror of the identity of such successor. Any such successor shall succeed the
Stockholders’ Representative as Stockholders’ Representative hereunder.
(d) Each of the Selling Stockholders other than the Stockholders’ Representative hereby
irrevocably agrees:
(i) to contribute (pro-rata its number of Shares delivered on Closing) on first written demand
of the Stockholders’ Representative to any and all out of pocket expenses, cost or disbursements
reasonably incurred by the Stockholders’ Representative in connection with its appointment and
agrees that such contribution may be paid to the Stockholders’ Representative directly out of any
amount to be paid from the Escrow Fund to the Selling Stockholders;
(ii) to appoint and instruct legal advisers, as proposed by the Stockholders’ Representative,
to advise and represent the Stockholders’ Representative in any legal and/or administrative
proceedings brought against the Selling Stockholders or any of them;
(iii) jointly and severally with each other Selling Stockholder to indemnify and hold harmless
the Stockholders’ Representative upon first written demand from and against any Damages incurred or
suffered by the Stockholders’ Representative in connection with its appointment (save for any such
Damages which arises from gross negligence or willful misconduct on the part of the Stockholders’
Representative);
(iv) to inform immediately the Stockholders’ Representative of any change in his address; and
(v) to transfer (pro-rata based on its Closing Consideration Proportionate Interest) a total
amount of $95,000 from the Closing Cash Consideration to an escrow account opened with the Escrow
Agent in the name of the Acquiror pursuant to the Escrow Agreement in order to finance the costs,
disbursements and out-of-pocket expenses which may be incurred by the Stockholders’ Representative
under its assignment (the “Stockholders’ Representative Expenses Reserve”) and enter into
any escrow agreement with the Escrow Agent, on behalf of the Selling Stockholders to that extent.
The escrow account shall be U.S. dollar denominated, interest bearing and located in the United
States (the “Stockholders’ Representative Escrow Account”). The Escrow Agent shall release
any amount from the Stockholders’ Representative Expenses Reserve to the Stockholders’
Representative upon simple request from the Stockholders’ Representative accompanied with the
relevant invoice. The Stockholders’ Representative Escrow Account shall be held by the Escrow
Agent until the Final Escrow Termination Date. After this period, any balance of the Stockholders’
Representative Expenses Reserve remaining on the Stockholders’ Representative Escrow Account shall
be repaid by the Escrow Agent to Selling Stockholders, save for any outstanding amount necessary
-67-
to finance reasonable future costs, disbursements and out-of-pocket expenses which may be
incurred by the Stockholders’ Representative in relation with any claim outstanding at such date,
which shall be paid to the Stockholders’ Representative directly and shall not be refundable.
(e) The Stockholders’ Representative hereby agrees:
(i) to forward to each other Seller a copy of each notification received by it of a claim by
the Acquiror hereunder, within twenty (20) business days of the Stockholders’ Representative’s
receipt of the same;
(ii) during such time as one or more claims by the Acquiror remains outstanding, to provide
each Selling Stockholder, on a quarterly basis, with a summary written report describing the
progress of each such outstanding claim; and
(iii) to comply with any written request of Selling Stockholders whose aggregate pro-rata
number of Shares delivered at Closing exceeds 50% regarding the conduct of any claim, provided
always that the Stockholders’ Representative shall not be obliged to comply with any such request
unless it has received pre-payment, or security reasonably satisfactory to it for the payment, of
any out of pocket expenses, costs or disbursements which it reasonably estimates are likely to
arise in connection with such compliance.
SECTION TEN
10. General Provisions.
10.1 Notices. All notices, requests, instructions or other documents to be given
under this Agreement shall be in writing and shall be deemed given (i) five (5) Business Days
following sending by registered or certified mail, postage prepaid, (ii) when sent if sent by
facsimile; provided, however, that the facsimile is promptly confirmed by telephone confirmation
thereof, (iii) when sent if attached in “portable document format” to an electronic mail address
(with evidence of confirmation of receipt), (iv) when delivered, if delivered personally to the
intended recipient, and (v) one (1) Business Day following sending by overnight delivery via an
international courier service, and in each case, addressed to a party at the following address for
such party:
(a) | If to the Acquiror, to: | |||
PDF Solutions, Inc. | ||||
000 Xxxx Xxx Xxxxxx Xxxxxx, Xxxxx 000 | ||||
Xxx Xxxx, XX 00000 | ||||
Attention: Xxxx Xxxxxx | ||||
Facsimile No: 000-000-0000 | ||||
Telephone No.: 000-000-0000 |
-68-
With a copy to: | ||||
Xxxxxx, Xxxxxxxxxx & Xxxxxxxxx LLP | ||||
0000 Xxxxx Xxxx | ||||
Xxxxx Xxxx, XX 00000 | ||||
Attention: Xxxxx Xxxx | ||||
Facsimile No.: (000) 000-0000 | ||||
Telephone No.: (000) 000-0000 | ||||
(b) | If to the Selling Stockholders, to: | |||
Société Générale Asset Management Alternative Investments | ||||
000 Xxxxx Xxxxx Xxxxxx | ||||
00000 Xxxxxxxxxx, Xxxxxx | ||||
Attention: Xxxx Xxxxxxxx | ||||
Telephone No.: 00 (0) 000 000 000 | ||||
With a copy to: | ||||
Xxxxxxxx Xxxxxx LLP | ||||
00 xxxxxx Xxxxxxx Xxxxxxxx | ||||
00000 Xxxxx, Xxxxxx | ||||
Attention: Xxxxx d’Orgeval | ||||
Facsimile No: +33 (0) 1 44 34 80 50 | ||||
Telephone No.: x00 (0) 0 00 00 00 45 | ||||
Xxxxxxxxx Xxxxxxx Xxxxxx Xxxxxxxxxx Xxxxxxxx & Xxxxxxxxx, LLP | ||||
000 Xxxxxxxxxxxx Xxxxx | ||||
Xxxxx Xxxx, XX 00000 | ||||
Attention: Xxxxxxxxxxx X. Xxxxxx | ||||
Facsimile No. (000) 000-0000 | ||||
Telephone No. (000) 000-0000 |
10.2 Interpretation. When a reference is made in this Agreement to Exhibits or
Schedules, such reference shall be to an Exhibit or Schedule to this Agreement unless otherwise
indicated. The words “include,” “includes” and “including” when used
herein shall be deemed in each case to be followed by the words “without limitation.” The
phrase “made available” in this Agreement shall mean that the information referred to has
been made available if requested by the party to whom such information is to be made available.
The phrases “the date of this Agreement,” “the date hereof,” and terms of similar
import, unless the context
-69-
otherwise requires, shall be deemed to refer to October 25, 2006. The table of contents and
headings contained in this Agreement are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement.
10.3 Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original and all of which together shall constitute one instrument.
10.4 Entire Agreement; Nonassignability; Parties in Interest. This Agreement and the
documents and instruments and other agreements specifically referred to herein or delivered
pursuant hereto, including the Exhibits, the Schedules, including the Company Disclosure Schedule
and the Acquiror Disclosure Schedule (a) constitute the entire agreement among the parties with
respect to the subject matter hereof and supersede all prior agreements and understandings, both
written and oral, among the parties with respect to the subject matter hereof, except for the
Confidentiality Agreement, which shall continue in full force and effect, and shall survive any
termination of this Agreement or the Closing, in accordance with its terms, (b) are not intended to
confer upon any other person any rights or remedies hereunder and (c) shall not be assigned by
operation of law or otherwise except as otherwise specifically provided.
10.5 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, the parties agree to renegotiate such provision in good faith,
in order to maintain the economic position enjoyed by each party as close as possible to that under
the provision rendered unenforceable. In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded
from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision
were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its
terms.
10.6 Remedies Cumulative. Except as otherwise provided herein, any and all remedies
herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any
other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of
any one remedy will not preclude the exercise of any other remedy.
10.7 Governing Law; Venue; English Language. This Agreement and all acts and
transactions pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of California, without
giving effect to principles of conflicts of law. Each of the parties to this Agreement consents to
the exclusive jurisdiction and venue of the courts of the state and federal courts of Santa Xxxxx
County, California. All disputes concerning this Agreement shall be conducted exclusively in the
English language and this English language version of this Agreement shall supersede and take
precedence over any translation of this Agreement into another language to the extent such
translation is inconsistent with this English language version of this Agreement.
10.8 Rules of Construction. The parties hereto agree that they have been represented
by counsel during the negotiation, preparation and execution of this Agreement.
-70-
10.9 Amendments and Waivers. Any term of this Agreement may be amended or waived only
with the written consent of the parties or their respective successors and assigns. Any amendment
or waiver effected in accordance with this Section 10.9 shall be binding upon the parties and their
respective successors and assigns.
10.10 Attorneys’ Fees. If any action or proceeding relating to this Agreement or the
enforcement of any provision of this Agreement is brought against any party hereto, each party
shall bear responsibility for its respective attorneys’ fees, costs and disbursements.
[Signature Page Follows]
-71-
IN WITNESS WHEREOF, the parties have duly executed this Stock Purchase Agreement as of the
date first above written.
THE ACQUIROR: | ||||
PDF SOLUTIONS, INC. | ||||
By: | /s/ Xxxx X. Xxxxxxxx | |||
Signature | ||||
Name: | Xxxx X. Xxxxxxxx | |||
Title: | Chief Executive Officer | |||
THE STOCKHOLDERS’ REPRESENTATIVE: | ||||
SOCIÉTÉ GÉNÉRALE ASSET MANAGEMENT ALTERNATIVE INVESTMENTS |
||||
By: | /s/ Xxxx Xxxxxxxx | |||
Signature | ||||
Name: | Xxxx Xxxxxxxx | |||
Title: | Principal | |||
[SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT]
THE SELLING STOCKHOLDERS: | ||||
/s/ XXXXXXX XXXXXXX
|
/s/ XXX XXXXXX
|
|
/s/ SOCIETE CIVILE TR INVESTISSEMENTS
|
/s/ SORIDEC SA
|
|
/s/ XXXXXXXXX XXXXXXXX-XXXXXXX
|
/s/ BANEXI VENTURES 2
|
|
/s/ XXXXXX XXXXXXX
|
/s/ CREDIT LYONNAIS VENTURES CAPITAL
|
|
/s/ XXXXXXX XXXXXXX
|
/s/ FCPI SOGE INNOVATION 3 / SGAM
|
|
/s/ XXXXXXXX XXXX XXXXXXXX
|
/s/ FCPI SOGE INNOVATION 5 / SGAM
|
|
/s/ XXXXXXX MOUSTIES
|
/s/ FCPI SOGE INNOVATION 6 / SGAM
|
|
/s/ SOCIETE CIVILE MOUSTIES INVEST
|
/s/ XXXXXXX XXXXXX
|
|
/s/ XXXXXXX CREISSENT-MOUSTIES
|
/s/ XXXXXX XXXXXX-DOURLENT
|
|
/s/ XXXXXX MOUSTIES
|
/s/ DIDIER CUVILLEZ
|
|
/s/ XXXX MOUSTIES
|
/s/ XXXX XXXXXX HUGUES
|
|
/s/ ANDRE MOUSTIES
|
/s/ DIDIER VIEUX
|
|
/s/ XXXX XXXXXX
|
/s/ XXXX XXXXXX
|
|
/s/ SOCIETE CIVILE MIKATI
|
/s/ XXXXXX BERGOGNE
|
|
/s/ XXXXXXXX XXXXXX
|
/s/ XXXXXX XXXXXX
|
|
/s/ XXXXXXX XXXXXX
|
/s/ XXX XXXXXXXX
|
|
/s/ XXXXXX HURON
|
/s/ XXXXXXX XXXXXXX
|
|
/s/ XXXXXX MEGA
|
/s/ XXXXXXX XXXXXX
|
|
/s/ XXXXXXX XXXXXXX
|
/s/ XXXXXX XXXXXXX
|
|
/s/ XXXX VERNEDE
|
/s/ XXXXXXXX XXXXXXXX
|
|
/s/ XXXXXXXX XXXXX
|
||
/s/ XXXXXXXX XXXXXXXXX
|
||
/s/ XXXXXXX XXXXXXXXX
|
||
/s/ XXXXXXX XXXXXXX
|
||
/s/ XXXXXXXX XXXXXX
|
||
/s/ XXXXXXXXXX XXXXXXX
|
||
/s/ XXXXXXXX XXXXXX DE XXXXXXXX
|
||
/s/ XXXXX XXX
|
||
/s/ XXXXXXX XXXXXX
|
||
/s/ XXXXXXXX XXXXXXXXX
|
||
/s/ FLORENT COURREN
|
||
/s/ PRISCA RAVELOJOANA
|
||
/s/ XXXXXXXX XXXXXX DOCTEUR
|
EXHIBITS
Exhibit A – | Selling Stockholders, Warrant Holders and Holders of Invalid
Warrants (Purchase Price Allocation Spreadsheet) |
|
Exhibit B – | Form of Employment Agreement |
|
Exhibit C – | Warranty Escrow Fund Contribution Spreadsheet |
|
Exhibit D – | Form of Escrow Agreement |
|
Exhibit E – | Form of Legal Opinion from Selling Stockholders’ Counsel |